Dosing regimen for BCMA-CD3 bispecific antibodies
The dosing scheme for anti-BCMA x anti-CD3 antibody constructs in BCMA-positive neoplasms addresses safety and tolerability issues by cycling doses and periods of administration, ensuring rapid therapeutic efficacy through T cell activation.
Patent Information
- Application Number
- JP2024125698
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-07-31
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-26
AI Technical Summary
Current treatments for BCMA-positive neoplasms, such as multiple myeloma, lack favorable safety and tolerability profiles while requiring a prolonged time to reach a therapeutically effective dose, thereby reducing efficacy.
A dosing scheme for anti-BCMA x anti-CD3 antibody constructs administered in cycles, with doses ranging from 6.5 μg/day to 650 μg/day for at least 7 consecutive days, followed by periods without administration, to achieve a favorable safety and tolerability profile while ensuring rapid therapeutic efficacy.
This dosing regimen allows for quicker attainment of the target dose, enhancing the onset of response in BCMA-positive neoplasms by promoting T cell activation and reducing adverse events.
Abstract
Description
[Technical field]
[0001] The present invention relates to an antibody construct comprising a first domain that binds BCMA and a second domain that binds CD3 for use in the treatment or amelioration of a BCMA positive neoplasm, the antibody construct being administered at a specified dose in at least one cycle, the cycle comprising a specified period of administration of the antibody construct.Further, the present invention relates to a method of treatment of a BCMA positive neoplasm comprising administering a specified amount of such an antibody construct and the use of such an antibody construct for the manufacture of a medicament for the treatment of a BCMA positive neoplasm. [Background technology]
[0002] Multiple myeloma (MM) is a malignant tumor of plasma cells that proliferates in the bone marrow and releases paraproteins. Acquired laboratory conditions include infection, bone destruction, bone marrow failure, renal failure, and hypercalcemia. The age-adjusted annual incidence is increasing, with approximately 6 new cases per 100,000 people. The incidence is twice as high in the black population of the United States as in the white population. The 5-year survival rate for MM has increased from approximately 25% of newly diagnosed patients in 1975 to approximately 45% in 2006. This improvement is mainly due to new drugs such as proteasome inhibitors and immunomodulators. However, MM is not considered curable with current approaches. Patients who are unresponsive to proteasome inhibitors and immunomodulators have an unfavorable outcome with a median overall survival of 9 months.
[0003] Outcomes are particularly poor in high-risk populations, such as the subgroup of del17p13-positive MM. Although many agents are in clinical development for MM, new treatment options remain needed. Patients who present with symptomatic disease are initially treated with first-line induction therapy, followed by high-dose chemotherapy with autologous stem cell support in eligible patients. Patients eligible for intensive treatment are determined by age (upper limit 65-75 years), absence of comorbidities, and intact renal function. This regimen has improved survival in young, healthy patients, but the median duration of response did not exceed 3 years, and few patients remained disease-free for more than 10 years.
[0004] Consolidation and maintenance approaches have been tested to increase the depth and duration of remission. As maintenance therapy is difficult due to lack of efficacy or tolerability, there remains the option to improve survival outcomes in the transplant setting by adding new therapies to induction, consolidation or maintenance regimens. Patients who are not candidates for high-dose therapy usually receive induction regimens similar to transplant candidates. These regimens include combinations with the proteasome inhibitor bortezomib or melphalan-based thalidomide. The median overall survival (OS) of melphalan-thalidomide-prednisone (MPT) in elderly patients is 40 months. Lenalidomide in combination with dexamethasone is the standard regimen for relapsed / refractory MM, but may transition to the first-line setting in transplant-ineligible patients.
[0005] Other established regimens in the relapsed setting are repeated induction regimens or immunomodulator-based salvage combinations with bortezomib or alkylating agents. Patients with relapsed disease need improved outcomes (progression-free survival (PFS) and OS). Patients who do not respond to established therapies and progress on treatment have dismal outcomes with OS of 9 months on treatment and 3 months off treatment. Unmet needs are highest in these patients.
[0006] Bispecific molecules such as BiTE® (bispecific T cell engager) antibody constructs are recombinant protein constructs with one binding domain specific for a selected tumor-associated surface antigen on target cells and a second binding domain specific for CD3, a subunit of the T cell receptor complex on T cells. Due to their special design, BiTE® antibody constructs are uniquely suited to transiently bind T cells to target cells and simultaneously potently activate the intrinsic cytolytic capacity of T cells against target cells. First generation BiTE® antibody constructs (see WO 99 / 54440 and WO 2005 / 040220) have entered clinical use as AMG103 (blinatumomab, anti-CD19×anti-CD3) and AMG110 (solitomab, anti-EpCAM×anti-CD3). Blinatumomab, approved for patients with ALL, is administered by continuous intravenous infusion with a low initial dose during the first dosing period and a higher dose during the first and all subsequent cycles for the remainder of the treatment. In a comparison of stepwise dosing with flat dosing as a means to reach the target dose of blinatumomab, stepwise dosing was found to be more effective in reducing adverse events. Thus, in view of the positive efficacy signals and favorable safety profile, a similar dosing scheme has been used for solitomab, administered at increasing doses in each cycle. An important further development of the first generation BiTE antibody constructs provided bispecific antibody constructs that bind to context-independent epitopes at the N-terminus of the CD3ε chain of humans and common marmosets (Callithrix jacchus), cotton-top tamarins (Saguinus oedipus) or common squirrel monkeys (Saimiri sciureus) (WO 2008 / 119567). The first BiTE® molecule containing this new CD3ε binding domain to be clinically tested was AMG 330. In line with previously used dosing schemes, initiating treatment at a lower dose before escalating to the target dose reduced the magnitude of cytokine elevation, and AMG 330 was also administered in an escalating dosing regimen.The administration of a low dose of the anti-target x anti-CD3 antibody construct in the first administration step is understood as a pre-observation or adaptation phase to avoid or limit side effects resulting from the patient's first contact with the antibody construct.
[0007] B-cell maturation antigen (BCMA, TNFRSF17, CD269) is a transmembrane protein that belongs to the TNF receptor superfamily. BCMA expression is selectively induced during late plasma cell differentiation and is absent in naive and memory B cells. BCMA binding to its ligands, B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL), promotes the survival of bone marrow plasma cells and plasmablasts. BCMA does not maintain normal B-cell homeostasis, but is required for the survival of long-lived plasma cells. Studies in BCMA- / - mice showed that the survival of long-lived bone marrow plasma cells was impaired, but B-cell development and early humoral immune responses were indistinguishable from wild-type mice. BCMA mRNA expression is highly elevated in malignant plasma cell disorders. In contrast, mRNA expression in normal tissues is very low and restricted to lymphoid tissues where normal long-lived plasma cells reside. BCMA protein expression has been reported to be restricted exclusively to plasma cells. BCMA expression is restricted to plasmablasts and long-lived plasma cells and is undetectable in other normal human tissues. BCMA is ubiquitously expressed on the cell surface of MM cells and is expressed on malignant plasma cells at relatively higher levels than those observed on normal plasma cells. There is no correlation between BCMA expression and MM stage, response to last treatment, and time since diagnosis. Neither T cells, myeloid cells, nor CD34+ hematopoietic stem cells express BCMA. The selective expression of BCMA makes it a very attractive target for antibody- and chimeric antigen receptor (CAR)-based therapies.
[0008] AMG420 (formerly BI836909) is a bispecific T cell engager that binds to BCMA on target cells and CD3ε on T cells. It acts as a bridge between MM cells and cytotoxic T lymphocytes (CTLs) by directing the cytolytic activity of CTLs to MM cells. AMG420 consists of two single chain variable fragments (scFv), one directed against BCMA and the other against CD3. Each of the scFv fragments consists of a VH and a VL domain connected by a glycine / serine linker. The two scFv fragments are also connected by a glycine / serine linker.
[0009] The inventors have surprisingly found that for anti-BCMA x anti-CD3 antibody constructs, it is most beneficial for MM patients to reach the target dose in the patient's serum without delay. The sooner the patient's target dose is reached, the faster the onset of response is likely to be. This is shown by the rapid onset of CR of ALL, a tumor in the bone marrow, which can more easily reach T cells (Stackelberg et al. JCO 2016). On the other hand, if the antibody construct takes a long time to reach a therapeutically effective dose in the patient's body (e.g., due to stepwise administration), the efficiency of the antibody construct appears to be poor. Without being bound by theory, the inventors believe that this phenomenon is related to T cell proliferation and T cell redistribution. [Prior art documents] [Patent documents]
[0010] [Patent Document 1] WO 99 / 54440 [Patent Document 2] International Publication No. 2005 / 040220 [Patent Document 3] International Publication No. 2008 / 119567 [Non-patent literature]
[0011] [Non-Patent Document 1] Stackelberg et al. JCO 2016 Summary of the Invention [Problem to be solved by the invention]
[0012] It is therefore an object of the present invention to provide a dosing scheme for anti-BCMA x anti-CD3 antibody constructs that provides a favorable safety and tolerability profile while yielding positive efficacy signals. [Means for solving the problem]
[0013] Accordingly, the present invention relates to an antibody construct comprising a first domain that binds BCMA and a second domain that binds CD3 for use in the treatment or amelioration of a BCMA positive neoplasm, wherein the antibody construct is administered at a dose of from 6.5 μg / day to a maximum of 650 μg / day in at least one cycle, wherein one cycle comprises a period of administration of the antibody construct of at least 7 consecutive days.
[0014] The present invention further relates to a method for the treatment or amelioration of a BCMA positive neoplasm, comprising administering to a subject in need thereof an antibody construct comprising a first domain that binds to BCMA and a second domain that binds to CD3, wherein the antibody construct is administered at a dose of 6.5 μg / day to a maximum of 650 μg / day in at least one cycle, wherein one cycle comprises a period of administration of the antibody construct of at least 7 consecutive days.
[0015] The present invention further relates to the use of an antibody construct comprising a first domain that binds BCMA and a second domain that binds CD3, for the manufacture of a medicament for the treatment of a BCMA positive neoplasm, wherein the antibody construct is administered at a dose of 6.5 μg / day to a maximum of 650 μg / day, in at least one cycle, one cycle comprising a period of administration of the antibody construct of at least 7 consecutive days.
[0016] The present invention also relates to the use of an antibody construct comprising a first domain that binds to BCMA and a second domain that binds to CD3, for the treatment or amelioration of a BCMA positive neoplasm, wherein the antibody construct is administered at a dose of 6.5 μg / day to a maximum of 650 μg / day in at least one cycle, wherein one cycle comprises an administration period of the antibody construct of at least 7 consecutive days. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] A "neoplasm" is an abnormal growth of tissue that usually, but not necessarily, forms a mass. When it also forms a mass, it is commonly referred to as a "tumor". In brain tumors, uncontrolled division of cells means that the neoplastic mass increases in size, which in closed spaces such as the intracranial cavity quickly becomes problematic as the mass invades and displaces the brain space, leading to compression of brain tissue and increased intracranial pressure and destruction of the parenchyma. According to the present invention, the term "neoplasm" or "tumor" also refers to conditions that would benefit from treatment with the antibody constructs described herein. This includes chronic and acute disorders or diseases, including pathological conditions that predispose a mammal to the condition of interest (neoplasm or tumor).
[0018] Neoplasms or tumors can be benign, potentially malignant (precancerous) or malignant (cancerous). A malignant neoplasm / tumor is commonly referred to as a cancer. It usually invades and destroys surrounding tissues and may also form metastases, i.e., spread to other parts, tissues or organs of the body. A "primary tumor" is a tumor that grows at the anatomical site where tumor progression begins and progresses to result in a cancerous mass. For example, a brain tumor occurs when abnormal cells form in the brain. Many cancers develop at their primary site, but then form metastases or spread to other parts (e.g., tissues and organs) of the body. These additional tumors are "secondary tumors." Many cancers continue to be named after their primary site even after they have spread to other parts of the body.
[0019] Lymphomas and leukemias are hematopoietic or lymphoid neoplasms. For the purposes of this invention, lymphomas and leukemias are also encompassed by the terms "tumor," "cancer," or "neoplasm." Lymphomas are a group of blood cancers that arise from lymphocytes (a type of white blood cell). Leukemias are a group of cancers that usually begin in the bone marrow and result in large numbers of abnormal white blood cells. These white blood cells are not fully developed and are called blasts or leukemia cells. Lymphomas and leukemias are part of a broader group of tumors of the hematopoietic and lymphatic tissues.
[0020] For purposes of the present invention, the terms "neoplasm," "tumor," and "cancer" may be used interchangeably and include both primary tumors / cancers and secondary tumors / cancers (or "metastases") as well as mass-forming neoplasms (tumors) and lymphoid neoplasms (such as lymphomas and leukemias) and also MRD.
[0021] The term "minimal residual disease" (MRD) refers to evidence of the presence of a small number of residual cancer cells remaining in a patient after cancer treatment, for example when the patient is in remission (the patient has no symptoms or signs of the disease). If only a small number of cancer cells remain, they are usually not detectable by conventional means, as standard tests used to assess or detect cancer are not sensitive enough to detect MRD. Recently, highly sensitive molecular biological MRD tests have become available, such as flow cytometry, PCR and next generation sequencing. These tests can measure minimal levels of cancer cells in tissue samples, sometimes as little as one cancer cell in a million normal cells. In the context of the present invention, the terms "prevention," "treatment," or "amelioration" of a neoplasm are also envisioned to encompass "prevention, treatment, or amelioration of MRD," regardless of whether MRD has been detected or not.
[0022] BCMA-positive neoplasms are assumed to be B-cell or plasma cell neoplasms. B cells, also called B lymphocytes, are a type of white blood cell of the lymphocyte subtype. They function in the humoral immune component of the adaptive immune system by secreting antibodies. In addition, B cells present antigens (also classified as professional antigen-presenting cells) and secrete cytokines. In mammals, B cells mature in the bone marrow, which is located in the center of most bones. B cells differ from the other two classes of lymphocytes - T cells and natural killer (NK) cells - in that they express a B-cell receptor (BCR) on the cell membrane. The BCR allows B cells to bind to specific antigens and initiate an antibody response against them. Plasma cells, also called plasma B cells, plasma cells, or effector B cells, are white blood cells that secrete large amounts of antibodies. They are usually transported by the plasma and lymphatic system. Plasma cells originate from the bone marrow. B cells differentiate into plasma cells that produce antibody molecules closely modeled on the receptors of precursor B cells. Once released into the blood and lymph, these antibody molecules bind to target antigens and begin to neutralize or destroy them.
[0023] The expression level of BCMA on the cell surface can be determined, for example, by flow cytometry analysis. The subpopulation of cells selected for analysis of BCMA expression (e.g., B cells, plasma cells, MM cells, CD138+ cells) can be stained, for example, with an anti-BCMA antibody followed by a secondary antibody and then analyzed in a FACS assay. BCMA-negative cell lines (K562, A549, TC71, CCRF-CEM, etc.) can be used as controls. A shift in the FACS assay (BCMA-negative cell lines define 0% BCMA expression) indicates that the cells being analyzed are BCMA positive. Different levels of BCMA expression can be present on the surface cells, such as low, medium, or high expression. See also Quinn et al., Blood (2011) 117:890-901 and Sanchez et al, Br J Heamatol 2012 Jul 18.
[0024] A "BCMA positive neoplasm" or a "(BCMA positive) B cell or plasma cell neoplasm" may be selected from the group including, but not limited to, multiple myeloma, relapsed and / or refractory multiple myeloma, heavy chain multiple myeloma, light chain multiple myeloma, extramedullary myeloma (extramedullary plasmacytoma, extramedullary multiple myeloma), plasmacytoma, plasma cell leukemia, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma) and smoldering myeloma (smoldering multiple myeloma). Thus, the present disclosure also relates to the antibody constructs for use in the treatment or amelioration of multiple myeloma (MM), plasmacytoma, plasma cell leukemia and Waldenstrom's macroglobulinemia as described herein. The MM may be selected from the group consisting of or including relapsed and / or refractory multiple myeloma, heavy chain multiple myeloma, light chain multiple myeloma, extramedullary multiple myeloma and smoldering multiple myeloma.
[0025] The antibody constructs of the present invention (and pharmaceutical compositions comprising such antibody constructs) are useful in the treatment, amelioration and / or prevention of a BCMA positive neoplasm as described herein in a subject in need thereof. The term "treatment" refers to both therapeutic treatment and prophylactic or preventative measures. Treatment includes administration of the antibody construct (or pharmaceutical composition comprising such antibody construct) to the body of a patient in need thereof, or to excised tissues or cells from a patient or subject having a BCMA positive neoplasm as described herein, a symptom of such a neoplasm, or a predisposition to such a neoplasm, with the aim of eradicating, curing, ameliorating, alleviating, altering, repairing, ameliorating, improving, or affecting one or more symptoms of a BCMA positive neoplasm or a predisposition to a disease of the BCMA positive neoplasm.
[0026] The terms "subject in need," "patient," or "in need of treatment" include those already with a BCMA-positive neoplasm as well as those in a state of MRD and those in which a neoplasm is to be prevented. These terms include human and other mammalian subjects receiving either prophylactic or therapeutic treatment.
[0027] The term "amelioration," as used herein, refers to any improvement in a patient's disease state (disease being a BCMA positive neoplasm) by administration of an antibody construct according to the present invention to such a patient or subject in need thereof. Such improvement may be seen as a slowing or halting of progression of the patient's disease, and / or as a reduction in the severity of disease symptoms, an increase in the frequency or duration of disease symptom-free periods, or prevention of functional impairment or disability resulting from the disease.
[0028] The term "prevention", as used herein, means avoiding the occurrence or recurrence of a disease as specified herein by administration of an antibody construct according to the present invention to a subject in need thereof.
[0029] With multiple myeloma, symptoms and signs vary widely, as many organs may be affected by the disease. Common symptoms of multiple myeloma include high calcium levels, renal failure, anemia, and bone lesions (both of which are features of the "CRAB"). In advanced MM, bone pain, bleeding, and frequent infections may occur. Complications also include amyloidosis. The International Myeloma Working Group (IMWG) has established diagnostic criteria for MM that outline three "myeloma diagnostic events" (MDEs) in addition to the typical CRAB features. Bone marrow test shows 60% or more clonal plasma cells Serum engaged / unengaged free light chain ratio is 100 or greater with absolute levels of engaged light chains of at least 100 mg / L (the patient's "engaged" free light chains (either kappa or lambda) are above the normal reference range; "unengaged" free light chains are typically light chains that are within or below the normal range) Two or more focal lesions on MRI at least 5 mm in size The presence of at least one of these markers is considered sufficient for the diagnosis of multiple myeloma, regardless of the presence or absence of symptoms or CRAB features. See also Palumbo AJ Clin Oncol. 2014 Feb 20;32(6):587-600.
[0030] Bone pain affects nearly 70% of patients and is the most common symptom. It is usually associated with the spine and ribs. Vertebral involvement can lead to spinal cord compression or kyphosis. Myeloma bone disease is due to overexpression of receptor activator of nuclear factor kappa B ligand (RANKL) by bone marrow stroma. RANKL activates osteoclasts, which resorb bone. The resulting bone lesions are lytic in nature (i.e., they cause destruction) and are best seen on plain radiographs. Bone destruction also causes release of calcium into the blood, resulting in hypercalcemia and its associated symptoms.
[0031] The anemia seen in myeloma is usually normocytic and normochromic, resulting from replacement of normal bone marrow by infiltrating tumor cells and inhibition of normal red blood cell production (hematopoiesis) by cytokines.
[0032] A bone marrow biopsy can be performed to estimate the percentage of bone marrow occupied by plasma cells. This percentage is used in the diagnostic criteria for MM. Usually, MM patients have 10% or more clonal bone marrow plasma cells. Immunohistochemistry (using antibodies against surface proteins to stain specific cell types) can detect plasma cells that express immunoglobulins in the cytoplasm, and sometimes on the cell surface. For example, myeloma cells are typically positive for the markers CD56, CD38, CD138, CD319, but other markers may also be included to define or identify MM.
[0033] So-called "paraproteins" (also called myeloma proteins, monoclonal proteins or M proteins) are abnormal immunoglobulin fragments that are overproduced by the abnormal monoclonal proliferation of plasma cells, typically in MM. In theory, MM patients can produce all classes of immunoglobulins, but IgG paraproteins are the most common, followed by IgA and IgM, with IgD and IgE myelomas being very rare. In addition, antibody light and / or heavy chains can be secreted alone: kappa or lambda light chains or any of the five types of heavy chains (alpha, gamma, delta, epsilon or mu (μ)-heavy chains). This proliferation of paraproteins has several deleterious effects on the body, including impaired immune function, abnormally high blood viscosity and kidney damage. Patients without evidence of paraproteins may have "non-secretory" myelomas (which do not produce immunoglobulins). They account for approximately 3% of all MM patients. Except for patients with true non-secretory MM, the presence of paraproteins in serum and / or urine is indicative of MM. Quantitative measurement of the paraprotein in a patient's urine and / or serum can be used to establish a diagnosis and / or monitor the disease.
[0034] Renal failure can develop both acutely and chronically. The most common cause of renal failure in MM is due to proteins secreted by the malignant cells. Myeloma cells produce a variety of monoclonal proteins, most commonly immunoglobulins (antibodies) and free light chains, resulting in abnormally high levels of these proteins (paraproteins) in the blood. Depending on the size of these proteins, they can be excreted by the kidney, but the kidneys can also be damaged by their effects. Furthermore, increased bone resorption leads to hypercalcemia and causes nephrocalcinosis, thereby contributing to renal failure.
[0035] The most common infections occurring in MM are pneumonia and pyelonephritis. The increased risk of infection is due to immunodeficiency. Total immunoglobulin levels are typically elevated in MM, but the majority of antibodies are ineffective monoclonal antibodies from clonal plasma cells.
[0036] Administration of an antibody construct in the treatment or amelioration of a BCMA positive neoplasm according to the present invention comprises: reducing the levels of paraprotein or free light chain in urine and / or serum by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%, respectively, compared to the levels of paraprotein or free light chain in urine and / or serum before the start of treatment, i.e., before the first administration of the antibody construct (in this particular context, "before" means within 1, 2, 4, 6, 8, or 12 hours prior, within 1, 2, 3, 4, 5, or 6 days prior, within 1, 2, 3, or 4 weeks prior, or within 1, 2, 3, or 4 months prior); reduce the percentage of plasma cells in the bone marrow by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% compared to the percentage of plasma cells in the bone marrow before the start of treatment, i.e., before the first administration of the antibody construct (in this particular context, "before" means within 1, 2, 4, 6, 8, or 12 hours prior, within 1, 2, 3, 4, 5, or 6 days prior, within 1, 2, 3, or 4 weeks prior, or within 1, 2, 3, or 4 months prior); induce a reduction in any of the above symptoms by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% compared to the symptoms before the start of treatment, i.e., before the first administration of the antibody construct (in this particular context, "before" means within 1, 2, 4, 6, 8, or 12 hours, within 1, 2, 3, 4, 5, or 6 days, within 1, 2, 3, or 4 weeks, or within 1, 2, 3, or 4 months, depending on the symptom); inhibits tumor growth or tumor cell proliferation by at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% compared to an untreated patient or untreated cells; and / or It is envisaged that the therapy will induce lysis of at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80% or at least about 90% of cells of the BCMA positive neoplasm compared to untreated patients or untreated cells.
[0037] The ability of the antibody constructs of the present invention to inhibit tumor growth / tumor cell proliferation or induce cell lysis can be evaluated in animal models predictive of efficacy in human tumors or in vitro or ex vivo studies (such as antibody construct-induced depletion of BCMA-positive cells by autologous T cells from BM aspirates of multiple myeloma patients). Efficacy evaluation of the antibody constructs can be further performed as follows: Tumor evaluation can be performed by myeloma involvement rate analysis, FISH (fluorescence in situ hybridization) and bone marrow (BM) karyotyping. BM karyotyping and FISH data can be obtained from BM samples. Serum protein electrophoresis (SPEP) and urine protein electrophoresis (UPEP) allow for serum / urine M-protein measurement. Immunofixation is another means of detecting serum and / or urinary M-protein. It is also envisioned that serum free light chain assays and ratio analysis can be performed. In the case of free light chain (FLC) multiple myeloma, FLC can be analyzed in serum and urine (sFLC and uFLC). The levels of involved / uninvolved FLC, the ratio of monoclonal lambda-FLC / kappa-FLC and the ratio of monoclonal kappa-FLC / lambda-FLC can be determined. In addition, quantitative and qualitative immunoglobulins (Ig) can also be analyzed, and beta-2 microglobulin in serum can be evaluated. It is also envisioned that skeletal surveys and evaluation of plasmacytoma can be performed. Screening imaging to evaluate extramedullary recurrence using whole body MRI or PET / CT can be performed. Suitable imaging for evaluation of bone lesions includes, but is not limited to, CT scan, MRI, PET, PET-CT or other standard of care. It is also envisioned that minimal residual disease is measured by next generation sequencing (NGS) based assays. For this purpose, bone marrow aspirates can be collected from subjects believed to be complete responders. Plasma samples can additionally be collected from subjects at the same time that BM MRD samples are collected to assess the feasibility of detecting MRD in ctDNA (circulating tumor DNA). MRD response can be assessed by detecting <1 tumor cell / 10 in bone marrow per FACS using antibodies against cytIgλ, cytIgκ, CD19, CD56 or CD138, CD38 and CD45, as appropriate.4 In one embodiment of the present invention, these markers are sufficient to define a tumor cell in the context of the present invention.
[0038] It is envisaged that the response of a patient or subject to administration of an antibody construct according to the invention is measured in one of the following ways: Quantitative measurement of paraprotein (M protein) or free light chains in urine and / or crystals; Determination of the percentage of plasma cells in the bone marrow; and / or Imaging of extramedullary symptoms (CT, MRI).
[0039] The antibody constructs of the invention are administered for at least one cycle, although more administration cycles are envisaged, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 cycles, for example 1 to 5 administration cycles may be beneficial to a patient in need.
[0040] According to the present invention, a "cycle" includes an administration period of the antibody construct of at least 7 consecutive days (1 week). Furthermore, it is envisaged that a cycle includes an administration period of the antibody construct followed by a period without administration of the antibody construct (a "treatment holiday", "rest" or "interruption"). If a patient receives only one single cycle, this cycle ends on the last day of administration of the antibody construct. On the other hand, if a patient receives two or more cycles, each cycle includes an administration period followed by a period without administration. The period without administration of the antibody construct ("rest") is defined by its length, see below. If a patient receives two or more cycles (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10 cycles), it is envisaged that the last administration cycle does not include a period without administration of the antibody construct (i.e., the last cycle ends on the last day of administration).
[0041] The administration period of the antibody construct is at least 7 consecutive days (1 week). It is contemplated that the period can be up to 8 days. Any other period from 1 week to 8 weeks, such as 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, or 7 weeks, or any other period from 1 week to 8 weeks consisting of a specific number of weeks and a specific number of days (such as 1, 2, 3, 4, 5, or 6 days), is also contemplated. Thus, the administration period can be 7, 10, 14, 15, 20, 21, 25, 28, 30, 35, 40, 42, 45, 48, 50, 55, or 56 consecutive days. The administration period can be, for example, 1 to 8 weeks, 1 to 7 weeks, 2 to 6 weeks, 3 to 5 weeks, or 25 to 30 days. For example, it is contemplated that 4 weeks of administration (i.e., 28 consecutive days) within one cycle will be beneficial to a patient in need thereof. Regardless of its particular duration, it is envisioned that the administration period is characterized by daily administration of the antibody construct.
[0042] According to one embodiment of the present invention, the antibody construct-free period is at least 7 consecutive days (1 week) and may be up to 3 months. Periods of 1 week to 8 weeks, such as 2 weeks, 3 weeks, 4 weeks, 1 month, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 2 months, 9 weeks, 10 weeks, 11 weeks, 12 weeks or 13 weeks, or any other period of 1 week to 3 months consisting of a certain number of months and / or weeks and / or days (such as 1, 2, 3, 4, 5 or 6 days) are also envisaged. The antibody construct-free period may be, for example, 1 week to 3 months, 1 week to 2 months, 1 week to 1 month, 1 week to 4 weeks, 1 week to 3 weeks, 10 days to 20 days or 10 to 15 days. For example, 2 or 3 weeks without administration within one cycle may be particularly beneficial for patients in need. Beginning after the fourth cycle, longer periods without antibody construct administration may be performed, for example, 3-5 or 4 weeks.
[0043] According to one embodiment, the antibody construct is administered in 1 to 5 cycles, preferably 4 or 5 cycles, where a cycle comprises or consists of an administration period of 2 to 5 weeks (i.e., 14 to 35 consecutive days), preferably 4 weeks (i.e., 28 consecutive days), followed by a period of 1 to 4 weeks, preferably 2 or 3 weeks without administration.
[0044] The different dosing cycles that a patient may undergo need not be completely identical in terms of the length of the dosing period of the antibody construct and the length of the dosing-free period. As a result, the overall length of the different cycles is not necessarily the same. For example, the length of the dosing period may differ between different cycles; it may, for example, be longer or shorter from cycle to cycle or from one cycle to the next. Alternatively or in addition, the length of the dosing-free period may differ between different cycles; it may, for example, be longer or shorter from cycle to cycle or from one cycle to the next. The same is true for the dose of the antibody construct as described herein below.
[0045] According to the present invention, the antibody construct is administered at a dose of 6.5 μg / day to a maximum of 650 μg / day in at least one cycle, with one cycle comprising an administration period of the antibody construct of at least 7 consecutive days (1 week). This means that the antibody construct is administered at a dose of 6.5 μg / day to 650 μg / day and inclusive for at least 7 consecutive days. The dose of the antibody construct can be 6.5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 125, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600 or 650 μg / day. According to one embodiment, the dose is about 400 μg / day. Preferred doses or dose ranges of the antibody construct of the present invention are 6.5 to 650 μg / day, 10 to 600 μg / day, 20 to 600 μg / day, 30 to 600 μg / day, 40 to 600 μg / day, 50 to 600 μg / day, 60 to 600 μg / day, 70 to 600 μg / day, 80 to 600 μg / day, 90 to 60 The dose may be 0 μg / day, 100 to 600 μg / day, 150 to 650 μg / day, 200 to 600 μg / day, 300 to 600 μg / day, 250 to 550 μg / day, 300 to 550 μg / day, 300 to 500 μg / day, 350 to 450 μg / day, 350 to 650 μg / day, or 400 to 600 μg / day. It is envisioned that these doses can be applied to antibody constructs having molecular weights of about 20 to about 90 kDa, about 30 to about 80 kDa, about 40 to about 70 kDa, about 50 to about 60 kDa, about 52 to about 58 kDa, and preferably about 54 to about 56 kDa. When the antibody constructs have different (lower or higher) molecular weights, the respective equimolar doses can be easily determined. For example, assuming one preferred antibody construct according to the present invention has a molecular weight of 55 kDa, then 650 μg of this antibody construct would yield 1.18×10 -8 Similarly, 6.5 μg of this antibody construct corresponds to 1.18 × 10 mol. -10 corresponds to mol.
[0046] The antibody construct of the present invention is expected to have a molecular weight of about 20 to about 90 kDa, about 30 to about 80 kDa, about 40 to about 70 kDa, about 50 to about 60 kDa, about 52 to about 58 kDa, and preferably about 54 to about 56 kDa. The antibody construct of the present invention has a terminal elimination half-life or elimination half-life (T 1 / 2 ). "Half-life" is the time required for a quantity to decrease to half of its initial value. In medical science, it refers to the half-life of a substance or drug in the human body. In medical context, half-life may refer to such time until a substance / drug loses half of its activity, e.g., pharmacological, physiological or radiological activity. Half-life may also refer to such time until the plasma / serum concentration of a drug or substance reaches half of its steady-state value ("elimination half-life"). Typically, the elimination or removal of an administered substance / drug refers to the body's cleansing action through biological processes such as metabolism, excretion, and also involving the function of the kidney and liver. "First-pass metabolism" is a drug metabolism phenomenon in which the concentration of a drug decreases before it reaches the circulation. It is the proportion of the drug lost during the absorption process. Thus, "hepatic first-pass metabolism" refers to the tendency of a drug to be metabolized on its first contact with the liver, i.e., during its first pass through the liver.
[0047] It is envisioned that the antibody construct is administered at a dose of 6.5 μg / day to a maximum of 650 μg / day in at least one cycle, with a cycle including an administration period of at least 7 consecutive days (1 week), and the dose is constant during each cycle. A "constant" dose means that the same dose is administered to the patient every day during the administration period within a cycle. It is further envisioned that the antibody construct is administered at a dose of 6.5 μg / day to a maximum of 650 μg / day in two or more cycles (e.g., 1 to a maximum of 10 cycles), with a cycle including an administration period of at least 7 consecutive days (1 week), and the dose is constant during each cycle and from one cycle to the subsequent cycle. This can mean, for example, that the antibody construct is administered at the same dose in cycles 1 and 2, cycles 2 and 3, cycles 3 and 4, cycles 4 and 5, cycles 1-3, cycles 2-4, cycles 3-5, cycles 1-4, cycles 2-5, or cycles 1-5, etc. It is further envisioned that the antibody construct is administered at a dose of 6.5 μg / day up to 650 μg / day for two or more cycles (e.g., 1 to up to 10 cycles), with one cycle including an administration period of at least 7 consecutive days (1 week), and the dose is constant during each cycle, but varies between cycles. For example, the dose of the antibody construct may increase from one cycle to a subsequent cycle, or decrease from one cycle to a subsequent cycle. The antibody construct may be administered, for example, at a dose of 400 μg / day during one or more cycles (such as the first cycle or the first and second cycles), followed by a dose of 500 μg / day or 600 μg / day in one or more subsequent cycles (such as the second, third, fourth or fifth cycles). It is also envisioned that the antibody construct is administered at a dose of 6.5 μg / day up to 650 μg / day in at least one cycle, a cycle comprising an administration period of at least 7 consecutive days (1 week), and that the dose is escalated during at least one cycle. The dose escalation can be during the first cycle or during the first and second cycles, but also between more than the first two cycles.A low dose may be administered for 1-7 days, 1-5 days, 2-4 days or 3 days, followed by a high dose until the cycle is completed. For example, the low dose may be 100-300 μg / day or 200 μg / day, followed by a high dose of 350-450 μg / day or 400 μg / day; or the low dose may be, for example, 300-500 μg / day or 400 μg / day, followed by a high dose of 550-650 μg / day or 600 μg / day; or the low dose may be, for example, 200 μg / day for 3 days, for example during the first cycle, followed by a high dose of 400 or 600 or 650 μg / day until the first cycle is completed. In the latter case, it is envisaged that from the second cycle onwards, the respective higher doses are administered. It is envisaged that the higher doses do not exceed 650 μg / day.
[0048] The antibody constructs of the present invention are generally designed for a specific route and method of administration. A route of administration in pharmacology is the route by which a substance is taken into the body. Routes of administration are generally classified by where the substance is applied, which can be topical (localized), enteral (system-wide effect of the substance, but delivered via the gastrointestinal tract) or parenteral (systemic effect of the substance, but delivered by a route other than the gastrointestinal tract). In the context of the present invention, routes of administration include topical, enteral and parenteral routes. The reasons for choosing a drug administration route are influenced by various factors, such as: Physical and chemical properties of the drug. Physical properties are solid, liquid and gas. Chemical properties are solubility, stability, pH, irritancy etc. · Desired site of action: action may be local and accessible or systemic and inaccessible. The ratio of the extent of absorption of the drug from different routes. Patient condition.
[0049] The antibody constructs of the present invention (and pharmaceutical compositions comprising the antibody constructs) are particularly useful for parenteral administration. Parenteral administration is generally more rapid acting than topical or enteral administration and is often associated with very high bioavailability, up to 100%, especially in the case of IV administration. In general, parenteral administration includes, but is not limited to, intravenous, intracerebral, intraarterial, intraperitoneal, intraosseous, and intravesical delivery.
[0050] Administration according to the invention is preferably intravenous. Parenteral or intravenous administration can be performed by injection (e.g., using a needle and syringe) or infusion (e.g., via a catheter and pump system). It is therefore envisaged that administration according to the invention is by intravenous injection or infusion. Typically, IV infusion is administered through a line, port or central venous access or catheter (small, flexible tube) such as a central venous catheter (CVC), which is a catheter placed in a large vein, or a peripheral venous catheter (PVC), which is a catheter placed in a peripheral vein. Typically, the catheter or line can be placed in a vein in the neck (internal jugular vein), a vein in the chest (subclavian vein or axillary vein), a vein in the groin (femoral vein) or a vein in the arm (also called a PICC line or peripherally inserted central catheter). A central IV line has a catheter that is advanced through a vein and empties into a large central vein, usually the superior vena cava, the inferior vena cava or even the right atrium of the heart. A peripheral intravenous (PIV) line is used in peripheral veins (veins in the arms, hands, legs, and feet). A port is a central venous line that does not have an external connector; instead, it has a small reservoir covered in silicone rubber and implanted under the skin. Medication is administered intermittently by inserting a small needle into the skin, piercing the silicone and entering the reservoir. When the needle is withdrawn, the reservoir cover reseals itself. The cover can tolerate hundreds of needle sticks during its lifespan.
[0051] The present invention provides for bolus administration of the antibody construct of the present invention. A bolus is the administration of a discrete amount of a drug, agent or other compound within a specific negligible time, usually within 1-30 minutes. In most cases, the bolus administration is intravenous. A bolus is usually administered by injection (e.g., intravenous bolus injection), although bolus injection (e.g., intravenous bolus injection) is also possible. A short-term infusion is an injection (usually an IV infusion) of a small volume (such as 20 mL to 100 mL) that is administered over a period of up to 3 hours, usually 30-60 minutes.
[0052] Intravenous "intermittent infusion" is the infusion of a fixed amount of medication over a set period of time, such as 20-120 minutes or 30-60 minutes, at predetermined intervals, such as every 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 24 hours. The goal is to administer small amounts of medication on a regular basis. Intermittent medication, like any other form of infusion, can be administered by gravity or via an electronic infusion device (EID), also known as an infusion pump.
[0053] For infusion, an infusion pump can be used to infuse the agent (antibody construct) into the patient's circulatory system. Pumps are typically used intravenously, but arterial and epidural infusions by pumps are also possible. The solution for infusion can be prepared in a bag for IV infusion and delivered through an infusion line. Infusion pumps can administer liquids in an unreliable manner when performed manually. For example, liquids can be administered in injections of as little as 0.1 mL per hour, injections every minute, injections by repeated boluses up to a maximum number per hour, or amounts that vary depending on the time of day. It is also possible to perform the infusion using only gravity-supplied pressure. Different types of infusions according to the present invention include, but are not limited to, continuous infusion, bolus infusion, short-term infusion, and intermittent infusion. Continuous intravenous (cIV) administration or infusion is one preferred embodiment of administration of the antibody construct according to the present invention. For example, it is envisaged that the antibody construct is administered as a cIV infusion at a constant flow rate.
[0054] The present invention provides for continuous administration, i.e. uninterrupted or substantially uninterrupted administration of the antibody construct / composition comprising the antibody construct of the present invention. As a non-limiting example, this can be achieved by a small pump system worn by the patient to regulate the inflow of the therapeutic agent into the patient's body. The antibody construct of the present invention (or pharmaceutical composition comprising the antibody construct) can be administered using said pump system. Such pump systems are generally known in the art and typically rely on regular replacement of a cartridge containing the therapeutic agent to be infused. When replacing the cartridge in such a pump system, a momentary interruption in the otherwise uninterrupted inflow of the therapeutic agent into the patient's body may result. In such cases, the administration step before the cartridge replacement and the administration step after the cartridge replacement would still be considered within the meaning of the pharmaceutical means and methods of the present invention, both of which constitute the "uninterrupted administration" of such therapeutic agent. The same applies to the replacement of the bag, i.e. when the continuous administration is achieved by a bag (instead of a small cartridge) containing the antibody construct solution or other recipient or reservoir containing the antibody construct of the present invention for continuous administration. It is envisaged that the antibody construct of the present invention is provided in an infusion bag. These bags vary according to national regulations and local pharmacy standards for infusion of compounded sterile products, typically up to 48 hours in the United States and up to 96 hours in Australia and Europe.
[0055] Sustained or uninterrupted administration of the antibody construct of the present invention may be performed by a fluid delivery device or miniature pump system that includes a fluid pumping mechanism for pumping fluid from a reservoir and a drive mechanism for driving the pumping mechanism. The pump system for such administration may include a needle or cannula for penetrating the patient's skin and delivering the suitable composition into the patient's body. The pump system may be worn on the patient's skin for 24 hours up to several days. In some cases, the pump system may be a miniature pump system with a small reservoir volume. As a non-limiting example, the reservoir volume for the suitable pharmaceutical composition to be administered may be 0.1-50 ml.
[0056] The (daily) dose of the antibody construct may be administered, for example, as a bolus dose (bolus injection or bolus infusion), an injection, a continuous dose, a continuous infusion or a short-term infusion, with continuous administration being preferred and continuous IV (cIV) administration / continuous IV infusion being most preferred.
[0057] Pharmaceutical composition can be administered using medical device.Examples of medical device for administering pharmaceutical composition are described in U.S. Patent No. 4,475,196; U.S. Patent No. 4,439,196; U.S. Patent No. 4,447,224; U.S. Patent No. 4,447,233; U.S. Patent No. 4,486,194; U.S. Patent No. 4,487,603; U.S. Patent No. 4,596,556; U.S. Patent No. 4,790,824; U.S. Patent No. 4,941,880; U.S. Patent No. 5,064,413; U.S. Patent No. 5,312,335; U.S. Patent No. 5,312,335; U.S. Patent No. 5,383,851; and U.S. Patent No. 5,399,163.
[0058] In the context of the present invention, it is envisaged that the premedication is administered before the start of administration of the antibody construct in the first cycle and optionally also before the start of administration of the antibody construct in one or more of the subsequent cycles, such as the second, third, fourth and / or fifth. In this particular context, it is envisaged that "before" means within 24 hours, 18 hours, 12 hours, 6 hours, 5 hours, 4 hours or 3 hours and preferably within 120, 90, 60 or 30 minutes before the start of administration of the antibody construct. The premedication may be administered, for example, 30 to 120 minutes or 30 to 60 minutes before the start of administration of the antibody construct. It is also envisaged that the comedication is administered simultaneously or after the start of administration of the antibody construct in the first cycle and optionally also simultaneously or after the start of administration of the antibody construct in one or more of the subsequent cycles, such as the second, third, fourth and / or fifth. In this particular context, "after" is intended to mean within 24, 18, 12, 6, 5, 4 or 3 hours after the start of administration of the antibody construct, and preferably within 120, 90, 60, 30, 20, 15 or 10 minutes. Comedication may be administered, for example, 10-120 minutes, 10-60 minutes, 10-30 minutes or 15-20 minutes after the start of administration of the antibody construct. The purpose of premedication or comedication may be, for example, to prevent or reduce the severity of an infusion-related reaction. Premedication is preferred over comedication.
[0059] Pre-medication or comedication may include any one or a combination of the following: Paracetamol (acetaminophen, APAP) or equivalent; preferably administered orally (po) or intravenously; preferably in a dose of 100-4000mg, preferably 200-3000mg or 300-2500mg or 400-2000mg or 500-1500mg, preferably 600-1400mg, 700-1300mg, 800-1200mg, 900-1100mg or about 1000mg paracetamol (or equivalent dosages and / or equivalent doses for another route of administration) administered po. A person skilled in the art knows how to identify paracetamol equivalents. These include, but are not limited to, ibuprofen (e.g., administered at a dose of 100-3200 mg, preferably 200-3000 mg or 300-2500 mg or 400-2000 mg, preferably 500-1500 mg, 600-1200 mg, 700-1000 mg, 750-900 mg or about 800 mg) and metamizol (e.g., administered at a dose of 100-4000 mg, preferably 200-3000 mg or 300-2500 mg or 400-2000 mg or about 500-1000 mg). one or more painkillers selected from meperidine, dipyrone, hydromorphone, fentanyl, and tramadol -Antihistamines, preferably administered orally or intravenously, preferably at a dose equivalent to 50 mg of diphenhydramine iv. Those skilled in the art will know how to identify antihistamines. These include, but are not limited to, oral, parenteral or rectal antihistamines such as azatadine (maximum dose, e.g., 4 mg / day), bromphenylamine (maximum dose, e.g., 30 mg / day), cetirizine (maximum dose, e.g., 15 mg / day), chlorpheniramine (maximum dose, e.g., 30 mg / day), clemastine (maximum dose, e.g., 10 mg / day), cyproheptadine (maximum dose, e.g., 15 mg / day), desloratadine (maximum dose, e.g., 7 mg / day), dexchlorphenylamine (maximum dose, e.g., 15 mg / day), diphenhydramine (maximum dose, e.g., 350 / day), doxylamine (maximum dose, e.g., 180 mg / day), fexofenadine (maximum dose, e.g., 200 mg / day), loratadine (maximum dose, e.g., 15 mg / day), phenindamine (maximum dose, e.g., 180 mg / day). Glucocorticoids, preferably administered orally or intravenously, preferably in a dose equivalent to 4-20 mg, or 6-18 mg, or 8-16 mg, or 16 mg of dexamethasone given iv (equivalence referring to the potency of the glucocorticoid).
[0060] All of the above four substances or groups of substances may be administered as premedication or comedication or a combination of only two or three substances or only one of the four substances. It is envisaged that the dose of glucocorticoid (GC) administered before the start of the second cycle may be the same as the dose of GC administered before the start of the first cycle, or may be reduced to about 50% of the dose administered before the start of the first cycle, or may be omitted in the second (and possibly any subsequent) cycle. For example, if the antibody construct according to the invention is well tolerated during the first cycle without significant signs of infusion-related reactions, a reduction in the GC dose may be applied. It is further envisaged that the dose may be further reduced before the start of the third and any subsequent cycles. Alternatively, the GC is administered as a premedication (and potentially comedication) before the start of the first cycle, but no premedication or comedication of the GC is administered in the second, third, fourth and / or fifth cycles. In general, the dose of premedication or comedication used according to the embodiments of the invention will depend on the individual patient's circumstances.
[0061] Glucocorticoids are a class of corticosteroids, a class of steroid hormones. Glucocorticoids are corticosteroids that bind to the glucocorticoid receptor. A less common synonym is glucocorticosteroid. Cortisol (known as hydrocortisone when used as a drug) is the most important human glucocorticoid. Various synthetic glucocorticoids, much more potent than cortisol, have been made for therapeutic use. They differ in both pharmacokinetics (e.g., absorption coefficient, half-life, volume of distribution, clearance) and pharmacodynamics (e.g., glucocorticoid potency or mineralocorticoid potency). Cortisol is the standard of comparison for glucocorticoid potency. An example of a commonly prescribed alternative steroid equivalent may be prednisone (5 mg) = cortisone (25 mg) = dexamethasone (0.75 mg) = hydrocortisone (20 mg) = methylprednisolone (4 mg). These doses represent pharmacological dose equivalents to systemic administration of glucocorticoids. Another corticosteroid comparison chart showing the half-lives of various substances can be found, for example, at www.nadf.us / downloads / adrenalhormone.pdf.
[0062] Examples of GCs used in this embodiment as premedication or comedication include, but are not limited to, cortisone, hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, beclomethasone, budesonide, triamcinolone, cloprednol, deflazacort, fluocortolone, cortivazol, paramethasone, fluticasone, fluticasone propionate, triamcinolone acetonide, and combinations and / or pharmaceutically acceptable derivatives thereof. Different GCs may be used alone or in combination in the context of the present invention. Dexamethasone, prednisone and prednisolone are preferred embodiments of GCs.
[0063] It is envisioned that all substances already classified or to be classified as "glucocorticoids" may be used in the context of the present invention as well. Such future glucocorticoids include compounds that specifically bind to and activate the glucocorticoid receptor. The term "specifically binds to the GC receptor" means, according to the present invention, that the GC (or a compound assumed to act like a GC) associates (e.g., interacts) with the GC receptor (also known as NR3C1) to a statistically significant degree compared to association with proteins / receptors in general (i.e., non-specific binding). When the GC receptor binds to glucocorticoids, its primary mechanism of action is the regulation of gene transcription. In the absence of GC, the glucocorticoid receptor (GR) is present in the cellular matrix complexed with various proteins, including heat shock protein 90 (hsp90), heat shock protein 70 (hsp70), and the protein FKBP52 (FK506-binding protein 52). The binding of GC to glucocorticoid receptor leads to the release of heat shock protein.Therefore, it is expected that future GC or GC's pharma-ceutically acceptable derivative or salt can bind to GC receptor and release the above-mentioned heat shock protein.Then, the activated GR complex upregulates the expression of anti-inflammatory protein in nucleus, or suppresses the expression of pro-inflammatory protein in cytosol by preventing the translocation of other transcription factors from cytosol to nucleus.
[0064] The antibody construct of the invention comprises a first domain that binds to BCMA and a second domain that binds to CD3.
[0065] The term "antibody construct" refers to a molecule whose structure and / or function is based on that of an antibody, e.g., a full-length immunoglobulin molecule. Thus, an antibody construct comprises a domain that immunospecifically binds to its target or antigen and / or is derived from or is the heavy chain variable region (VH) and / or light chain variable region (VL) of an antibody. Furthermore, an antibody construct according to the invention comprises the minimum structural requirements of an antibody that allow immunospecific target binding. This minimum requirement may be defined, for example, by the presence of at least three light chain CDRs (i.e. CDR1, CDR2 and CDR3 of the VL region) and / or three heavy chain CDRs (i.e. CDR1, CDR2 and CDR3 of the VH region), preferably all six CDRs.
[0066] Within the definition of "antibody" according to the present invention are full-length antibodies, including camelid antibodies and other immunoglobulins produced by biotechnological or protein engineering methods or processes. Such full-length antibodies may be, for example, monoclonal, recombinant, chimeric, deimmunized, humanized and human antibodies as well as antibodies from other species such as mouse, hamster, rabbit, rat, goat or non-human primate.
[0067] An "antibody construct" of the invention may have the general structure of a full-length immunoglobulin as it occurs in nature. For example, an antibody construct may comprise (at least) two full-length antibody heavy chains and two full-length antibody light chains. However, given that the antibody construct according to the invention comprises one domain that binds to BCMA and another domain that binds to CD3, it does not occur in nature and its function is significantly different from the naturally occurring product. Thus, the antibody construct of the invention is an artificial "hybrid" molecule that comprises at least two distinct binding domains with different specificities.
[0068] "Antibody constructs" of the invention may also include fragments of full-length antibodies, such as VH, VHH, VL, (s)dAb, Fv, light chain (VL-CL), Fd (VH-CH1), heavy chain, Fab, Fab', F(ab')2 or "rIgG" (a "half antibody" consisting of a heavy and light chain). Antibody constructs according to the invention may also include modified fragments of antibodies, also referred to as antibody variants or antibody derivatives. Examples include, but are not limited to, scFv, di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabodies, single chain diabodies, tandem diabodies (Tandab's), tandem di-scFv, tandem tri-scFv, "minibodies" exemplified by structures as follows: (VH-VL-CH3)2, (scFv-CH3)2, ((scFv)2-CH3+CH3), ((scFv)2-CH3) or (scFv-CH3-scFv)2, multibodies such as triabodies or tetrabodies, and single domain antibodies such as nanobodies or single variable domain antibodies comprising only one variable region which may be VHH, VH or VL, which specifically bind to an antigen or target independent of other variable regions or domains. Further possible formats of antibody constructs according to the invention are crossbodies, maxibodies, hetero-Fc constructs, mono-Fc constructs and scFc constructs.
[0069] Furthermore, the definition of the term "antibody construct" includes bivalent and multivalent / multivalent constructs that specifically bind to two, three or more antigen structures via different binding domains. Thus, an antibody construct may have more valency than specificity, for example if it has two binding domains for a first target (BCMA) and one binding domain for a second target (CD3) or vice versa, in which case the construct is trivalent and bispecific. Furthermore, the definition of the term "antibody construct" includes molecules that consist of only one polypeptide chain, but also molecules that consist of two, three, four or more polypeptide chains, which chains may be the same (homodimers, homotrimers or homooligomers) or different (heterodimers, heterotrimers or heterooligomers). Examples of the above identified antibodies and their fragments, variants, derivatives and antibody constructs derived therefrom are described, inter alia, in Harlow and Lane, Antibodies: A laboratory manual, CSHL Press (1988); Kontermann and Duebel, Antibody Engineering, Springer, 2nd ed. 2010; and Little, Recombinant Antibodies for Immunotherapy, Cambridge University Press 2009. It is envisaged that the antibody construct is a single chain antibody construct / single chain polypeptide.
[0070] The term "binding domain" or "domain that binds to" in the context of the present invention characterizes a domain of an antibody construct that immunospecifically binds to / interacts with / recognizes a given epitope on a target or antigen (here, BCMA in the case of the first domain and CD3 in the case of the second domain). The structure and function of the first domain (binding to BCMA) and also preferably the structure and / or function of the second domain (binding to CD3) are based on the structure and / or function of an antibody, e.g. a full-length immunoglobulin molecule. Thus, a "binding domain" or "domain that binds to" may comprise the minimum structural requirement of an antibody that allows immunospecific target binding. This minimum structural requirement of the first domain may be defined, for example, by the presence of at least three light chain CDRs (i.e. CDR1, CDR2 and CDR3 of the VL region) and / or three heavy chain CDRs (i.e. CDR1, CDR2 and CDR3 of the VH region), preferably all six CDRs. It is envisaged that the second domain also comprises this minimum structural requirement of an antibody that allows immunospecific target binding. More preferably, the second domain also comprises at least three light chain CDRs (i.e. CDR1, CDR2 and CDR3 of the VL region) and / or three heavy chain CDRs (i.e. CDR1, CDR2 and CDR3 of the VH region), preferably all six CDRs. A "domain that binds to" (or "binding domain") may typically comprise an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH). However, it need not comprise both, and may comprise only VH or VL. Fd fragments, for example, often retain some antigen-binding function of an intact antigen-binding domain.
[0071] Examples of formats of a "domain that binds to" (or "binding domain") include, but are not limited to, a full length antibody, a fragment of a full length antibody (such as VH, VHH, VL), a (s)dAb, an Fv, a light chain (VL-CL), an Fd (VH-CH1), a heavy chain, a Fab, a Fab', an F(ab')2, or a "rAb" (or "rAb"). and single domain antibodies such as nanobodies or single variable domain antibodies comprising only one variable region which may be a VHH, VH or VL. Further examples of "domains that bind to" (or "binding domains") formats include: (1) an antibody fragment or variant comprising a VL, VH, CL, and CH1 (such as a Fab); (2) an antibody fragment or variant comprising two linked Fab fragments (such as an F(ab')2); (3) an antibody fragment or variant comprising a VH and CH1 (such as an Fd); (4) an antibody fragment or variant comprising a VL and a CL (such as a light chain); (5) an antibody fragment or variant comprising a VL and a VH (such as an Fv); (6) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which has a VH domain; (7) an antibody variant comprising at least three isolated CDRs of the heavy and / or light chain; and (8) a single chain Fv (scFv).Examples of embodiments of antibody constructs or binding domains according to the invention are described, for example, in WO 00 / 006605, WO 2005 / 040220, WO 2008 / 119567, WO 2010 / 037838, WO 2013 / 026837, WO 2013 / 026833, US Patent Application Publication Nos. 2014 / 0308285, 2014 / 0302037, WO 2014 / 144722, WO 2014 / 151910 and WO 2015 / 048272.
[0072] It is envisioned that the antibody construct according to the present invention may have a molecular weight of about 20 to about 90 kDa, about 30 to about 80 kDa, about 40 to about 70 kDa, about 50 to about 60 kDa, about 52 to about 58 kDa, preferably about 54 to about 56 kDa.
[0073] The terms "bind (specifically or immunospecifically) to", "recognize (specifically or immunospecifically) to" or "react (specifically or immunospecifically) with" mean, according to the present invention, that an antibody construct or binding domain interacts or (immuno)specifically interacts with a given epitope on a target molecule (antigen), here BCMA and CD3, respectively. This interaction or association occurs more frequently, more rapidly, of longer duration, with higher affinity, or any combination of the above, for an epitope on a particular target compared to alternative substances (non-target molecules). However, due to sequence similarity between homologous proteins in different species, an antibody construct or binding domain that immunospecifically binds to its target (such as a human target) may cross-react with a homologous target molecule from a different species (such as a non-human primate, e.g. macaque). Thus, the term "specific / immunospecific binding" may include binding by an antibody construct or binding domain to an epitope in more than one species, or to structurally related epitopes.
[0074] In the context of the present invention, the term "epitope" refers to the part or region of an antigen that is recognized / immunospecifically recognized by a binding domain. An "epitope" is antigenic, and therefore the term epitope is also sometimes referred to as an "antigenic structure" or "antigenic determinant". The part of the binding domain that binds to the epitope is called the paratope. Specific binding is believed to be achieved by specific motifs in the amino acid sequence of the binding domain and the antigen. Thus, binding is realized as a result of its primary, secondary and / or tertiary structure and as a result of potential secondary modifications of said structure. The site may simply bind to the antigen if the paratope specifically interacts with its antigenic determinant. In some cases, the specific interaction may instead or additionally trigger a signal, for example due to induction of a conformational change in the antigen, oligomerization of the antigen, etc.
[0075] Epitopes of protein antigens are classified into two categories, conformational epitopes and linear epitopes, based on their structure and interaction with the paratope. Conformational epitopes are composed of discontinuous sections of the antigen's amino acid sequence. Such epitopes interact with the paratope based on the three-dimensional surface features and shape or tertiary structure (folding) of the antigen. Methods for determining the conformation of an epitope include, but are not limited to, X-ray crystallography, two-dimensional nuclear magnetic resonance (2D-NMR) spectroscopy, and site-directed spin labeling and electron paramagnetic resonance (EPR) spectroscopy. In contrast, linear epitopes interact with the paratope based on their primary structure. Linear epitopes are formed by a contiguous amino acid sequence from the antigen, typically comprising at least 3 or at least 4 and more usually at least 5, or at least 6, or at least 7, e.g., about 8 to about 10 amino acids in a unique sequence.
[0076] The interaction between the binding domain and the epitope of the target antigen indicates that the binding domain exhibits a recognizable or significant affinity for the epitope / target antigen (here, BCMA and CD3, respectively). Generally, it does not further exhibit significant affinity for proteins or antigens other than the target antigen (here, BCMA / CD3) - even if there is cross-reactivity with, for example, homologous targets from other species, as discussed above. "Significant affinity" refers to an affinity of ≦10 -6 The binding may be with an affinity (dissociation constant, KD) of M. Preferably, the binding affinity is ≦10 -7 M, ≦10 -8 M, ≦10 -9 M, ≦10 -10 M or further ≦10 -11 M or ≦10 -12 M is considered specific. Whether a binding domain (immune) specifically reacts or binds to a target can be easily tested, for example, by comparing the affinity of said binding domain for its desired target protein or antigen with the affinity of said binding domain for a non-target protein or antigen (here, a protein other than BCMA or CD3, respectively). Preferably, the antibody construct of the invention does not significantly bind to a protein or antigen other than BCMA or CD3, respectively (i.e., the first domain does not bind to a protein other than BCMA and the second domain does not bind to a protein other than CD3). For example, it is envisaged that the antibody construct of the invention (more specifically, its first domain) does not significantly bind, interact, recognise or cross-react with human BAFF-R and / or human TACI.
[0077] The equilibrium dissociation constant (KD) of the antibody constructs of the invention for BCMA can be determined by Scatchard or Biacore analysis, for example, as described in WO 2013 / 072406. KD values for CD3 can be determined, for example, by surface plasmon resonance analysis, for example, as described in WO 2013 / 072406. It is envisaged that the antibody constructs of the invention have KD values for BCMA and / or CD3 in the double or single digit nanomolar range or the triple or even double digit picomolar range.
[0078] The term "does not bind significantly" means that the antibody construct or binding domain of the invention does not bind to proteins or antigens other than BCMA or CD3, i.e. exhibits no more than 30%, preferably no more than 20%, more preferably no more than 10%, and particularly preferably no more than 9%, 8%, 7%, 6% or 5% reactivity to proteins or antigens other than BCMA or CD3, when binding to BCMA or CD3, respectively, is taken as 100%.
[0079] According to one embodiment of the antibody construct of the present invention, the first and / or second domain is in scFv format. In scFv, the VH and VL regions are arranged in the order VH-VL or VL-VH (from N-terminus to C-terminus). It is envisaged that the VH and VL regions of the first and / or second binding domain are connected via a linker, preferably a peptide linker. According to one embodiment of the first and / or second domain, the VH region is located at the N-terminus side of the linker and the VL region is located at the C-terminus side of the linker. It is further envisaged that the first and second domains of the antibody construct are connected via a linker, preferably a peptide linker. The linker is preferably a peptide linker, more preferably a short-chain peptide linker. Examples are shown in SEQ ID NOs: 686-699. In this context, a "short-chain" linker has 2-50 amino acids, preferably 3-35, 4-30, 5-25, 6-20 or 6-17 amino acids. The linker between the two variable regions of one binding domain may have a different length (e.g., may be longer) than the linker between the two binding domains. For example, the linker between the two variable regions of one binding domain may have a length of 7-15 amino acids, preferably 9-13, and the linker between the two binding domains may have a length of 3-10 amino acids, preferably 4-8. It is further envisaged that the peptide linker is a glycine / serine linker, such as those shown in SEQ ID NOs: 687, 689-699.
[0080] Regarding the antibody construct of the present invention, a) the antibody construct is a single chain polypeptide; b) the first domain is in scFv format; c) the second domain is in scFv format, and / or d) It is envisaged that the first domain and the second domain are connected via a linker, preferably a peptide linker, more preferably a glycine / serine linker.
[0081] The first domain of the antibody construct of the present invention binds to BCMA (B cell maturation antigen, TNFRSF17, CD269). More preferably, it binds to BCMA on the surface of a target cell. A "target cell" can be any prokaryotic or eukaryotic cell expressing BCMA on its surface. Preferably, the target cell is a cell of a part of the human or animal body, such as a specific BCMA-expressing cancer or tumor cell or a cell of a BCMA-positive neoplasm. It is further envisaged that the first domain binds to human BCMA, preferably human BCMA on the surface of the target cell. It is also envisaged that the first domain binds to macaque BCMA, preferably macaque BCMA on the surface of the target cell. Preferred amino acid sequences are shown in SEQ ID NO: 647 for human BCMA, SEQ ID NO: 648 for macaque BCMA, SEQ ID NO: 649 for the extracellular domain of human BCMA and SEQ ID NO: 650 for the extracellular domain of macaque BCMA.
[0082] In one embodiment of the invention, the first domain of the antibody construct binds to epitope cluster 3 of BCMA. More preferably, the first domain of the antibody construct binds to epitope cluster 3 of human BCMA. A preferred amino acid sequence for epitope cluster 3 of human BCMA is shown in SEQ ID NO: 651. Antibody constructs having a domain that binds to said epitope cluster 3 of BCMA are described in detail in WO 2013 / 072406, the contents of which are incorporated herein by reference. These antibody constructs are shown in WO 2013 / 072406 to have very beneficial epitope / activity relationships.
[0083] The method of BCMA epitope mapping is used in WO 2013 / 072406 and is described as follows: one or more predefined regions (each in the form of a contiguous amino acid stretch) within the extracellular domain of human BCMA are exchanged / substituted with the corresponding region of a rodent BCMA molecule (such as murine BCMA, but other rodent species are also contemplated as long as the binding domain is not cross-reactive with the rodent species used). These human BCMA / rodent (murine) BCMA chimeras are expressed on the surface of host cells (such as CHO cells). Binding of antibodies or antibody constructs can be tested by FACS analysis. When complete or significantly reduced binding by the antibody or antibody construct to the chimeric molecule is observed, it can be concluded that the region of human BCMA removed from this chimeric molecule is relevant for immune specific epitope-paratope recognition. The reduction in binding is preferably at least 10%, 20%, 30%, 40% or 50% compared to binding to human (wild type) BCMA; more preferably at least 60%, 70% or 80% and most preferably 90%, 95% or even 100% (wherein binding to human BCMA is taken as 100%). Alternatively or additionally, the epitope mapping analysis described above may be modified by introducing one or more point mutations into the sequence of the extracellular domain of BCMA.
[0084] Further, for the antibody construct of the invention, the first domain that binds to BCMA comprises: (1) CDR-H1 as set forth in SEQ ID NO:1, CDR-H2 as set forth in SEQ ID NO:2, CDR-H3 as set forth in SEQ ID NO:3, CDR-L1 as set forth in SEQ ID NO:4, CDR-L2 as set forth in SEQ ID NO:5, and CDR-L3 as set forth in SEQ ID NO:6; (2) CDR-H1 as set forth in SEQ ID NO:11, CDR-H2 as set forth in SEQ ID NO:12, CDR-H3 as set forth in SEQ ID NO:13, CDR-L1 as set forth in SEQ ID NO:14, CDR-L2 as set forth in SEQ ID NO:15, and CDR-L3 as set forth in SEQ ID NO:16; (3) CDR-H1 as set forth in SEQ ID NO:21, CDR-H2 as set forth in SEQ ID NO:22, CDR-H3 as set forth in SEQ ID NO:23, CDR-L1 as set forth in SEQ ID NO:24, CDR-L2 as set forth in SEQ ID NO:25, and CDR-L3 as set forth in SEQ ID NO:26; (4) CDR-H1 as set forth in SEQ ID NO: 31, CDR-H2 as set forth in SEQ ID NO: 32, CDR-H3 as set forth in SEQ ID NO: 33, CDR-L1 as set forth in SEQ ID NO: 34, CDR-L2 as set forth in SEQ ID NO: 35, and CDR-L3 as set forth in SEQ ID NO: 36; (5) CDR-H1 as set forth in SEQ ID NO: 41, CDR-H2 as set forth in SEQ ID NO: 42, CDR-H3 as set forth in SEQ ID NO: 43, CDR-L1 as set forth in SEQ ID NO: 44, CDR-L2 as set forth in SEQ ID NO: 45, and CDR-L3 as set forth in SEQ ID NO: 46; (6) CDR-H1 as set forth in SEQ ID NO: 51, CDR-H2 as set forth in SEQ ID NO: 52, CDR-H3 as set forth in SEQ ID NO: 53, CDR-L1 as set forth in SEQ ID NO: 54, CDR-L2 as set forth in SEQ ID NO: 55, and CDR-L3 as set forth in SEQ ID NO: 56; (7) CDR-H1 as set forth in SEQ ID NO: 61, CDR-H2 as set forth in SEQ ID NO: 62, CDR-H3 as set forth in SEQ ID NO: 63, CDR-L1 as set forth in SEQ ID NO: 64, CDR-L2 as set forth in SEQ ID NO: 65, and CDR-L3 as set forth in SEQ ID NO: 66; (8) CDR-H1 as set forth in SEQ ID NO: 71, CDR-H2 as set forth in SEQ ID NO: 72, CDR-H3 as set forth in SEQ ID NO: 73, CDR-L1 as set forth in SEQ ID NO: 74, CDR-L2 as set forth in SEQ ID NO: 75, and CDR-L3 as set forth in SEQ ID NO: 76; (9) CDR-H1 as set forth in SEQ ID NO: 81, CDR-H2 as set forth in SEQ ID NO: 82, CDR-H3 as set forth in SEQ ID NO: 83, CDR-L1 as set forth in SEQ ID NO: 84, CDR-L2 as set forth in SEQ ID NO: 85, and CDR-L3 as set forth in SEQ ID NO: 86; (10) CDR-H1 as set forth in SEQ ID NO: 91, CDR-H2 as set forth in SEQ ID NO: 92, CDR-H3 as set forth in SEQ ID NO: 93, CDR-L1 as set forth in SEQ ID NO: 94, CDR-L2 as set forth in SEQ ID NO: 95, and CDR-L3 as set forth in SEQ ID NO: 96; (11) CDR-H1 as set forth in SEQ ID NO: 101, CDR-H2 as set forth in SEQ ID NO: 102, CDR-H3 as set forth in SEQ ID NO: 103, CDR-L1 as set forth in SEQ ID NO: 104, CDR-L2 as set forth in SEQ ID NO: 105, and CDR-L3 as set forth in SEQ ID NO: 106; (12) CDR-H1 as set forth in SEQ ID NO: 111, CDR-H2 as set forth in SEQ ID NO: 112, CDR-H3 as set forth in SEQ ID NO: 113, CDR-L1 as set forth in SEQ ID NO: 114, CDR-L2 as set forth in SEQ ID NO: 115, and CDR-L3 as set forth in SEQ ID NO: 116; (13) CDR-H1 as set forth in SEQ ID NO: 121, CDR-H2 as set forth in SEQ ID NO: 122, CDR-H3 as set forth in SEQ ID NO: 123, CDR-L1 as set forth in SEQ ID NO: 124, CDR-L2 as set forth in SEQ ID NO: 125, and CDR-L3 as set forth in SEQ ID NO: 126; (14) CDR-H1 as set forth in SEQ ID NO: 131, CDR-H2 as set forth in SEQ ID NO: 132, CDR-H3 as set forth in SEQ ID NO: 133, CDR-L1 as set forth in SEQ ID NO: 134, CDR-L2 as set forth in SEQ ID NO: 135, and CDR-L3 as set forth in SEQ ID NO: 136; (15) CDR-H1 as set forth in SEQ ID NO: 141, CDR-H2 as set forth in SEQ ID NO: 142, CDR-H3 as set forth in SEQ ID NO: 143, CDR-L1 as set forth in SEQ ID NO: 144, CDR-L2 as set forth in SEQ ID NO: 145, and CDR-L3 as set forth in SEQ ID NO: 146; (16) CDR-H1 as set forth in SEQ ID NO: 151, CDR-H2 as set forth in SEQ ID NO: 152, CDR-H3 as set forth in SEQ ID NO: 153, CDR-L1 as set forth in SEQ ID NO: 154, CDR-L2 as set forth in SEQ ID NO: 155, and CDR-L3 as set forth in SEQ ID NO: 156; (17) CDR-H1 as set forth in SEQ ID NO: 161, CDR-H2 as set forth in SEQ ID NO: 162, CDR-H3 as set forth in SEQ ID NO: 163, CDR-L1 as set forth in SEQ ID NO: 164, CDR-L2 as set forth in SEQ ID NO: 165, and CDR-L3 as set forth in SEQ ID NO: 166; (18) CDR-H1 as set forth in SEQ ID NO: 171, CDR-H2 as set forth in SEQ ID NO: 172, CDR-H3 as set forth in SEQ ID NO: 173, CDR-L1 as set forth in SEQ ID NO: 174, CDR-L2 as set forth in SEQ ID NO: 175, and CDR-L3 as set forth in SEQ ID NO: 176; (19) CDR-H1 as set forth in SEQ ID NO: 181, CDR-H2 as set forth in SEQ ID NO: 182, CDR-H3 as set forth in SEQ ID NO: 183, CDR-L1 as set forth in SEQ ID NO: 184, CDR-L2 as set forth in SEQ ID NO: 185, and CDR-L3 as set forth in SEQ ID NO: 186; (20) CDR-H1 as set forth in SEQ ID NO: 191, CDR-H2 as set forth in SEQ ID NO: 192, CDR-H3 as set forth in SEQ ID NO: 193, CDR-L1 as set forth in SEQ ID NO: 194, CDR-L2 as set forth in SEQ ID NO: 195, and CDR-L3 as set forth in SEQ ID NO: 196; (21) CDR-H1 as set forth in SEQ ID NO: 201, CDR-H2 as set forth in SEQ ID NO: 202, CDR-H3 as set forth in SEQ ID NO: 203, CDR-L1 as set forth in SEQ ID NO: 204, CDR-L2 as set forth in SEQ ID NO: 205, and CDR-L3 as set forth in SEQ ID NO: 206; (22) CDR-H1 as set forth in SEQ ID NO: 211, CDR-H2 as set forth in SEQ ID NO: 212, CDR-H3 as set forth in SEQ ID NO: 213, CDR-L1 as set forth in SEQ ID NO: 214, CDR-L2 as set forth in SEQ ID NO: 215, and CDR-L3 as set forth in SEQ ID NO: 216; (23) CDR-H1 as set forth in SEQ ID NO: 221, CDR-H2 as set forth in SEQ ID NO: 222, CDR-H3 as set forth in SEQ ID NO: 223, CDR-L1 as set forth in SEQ ID NO: 224, CDR-L2 as set forth in SEQ ID NO: 225, and CDR-L3 as set forth in SEQ ID NO: 226; (24) CDR-H1 as set forth in SEQ ID NO: 231, CDR-H2 as set forth in SEQ ID NO: 232, CDR-H3 as set forth in SEQ ID NO: 233, CDR-L1 as set forth in SEQ ID NO: 234, CDR-L2 as set forth in SEQ ID NO: 235, and CDR-L3 as set forth in SEQ ID NO: 236; (25) CDR-H1 as set forth in SEQ ID NO: 241, CDR-H2 as set forth in SEQ ID NO: 242, CDR-H3 as set forth in SEQ ID NO: 243, CDR-L1 as set forth in SEQ ID NO: 244, CDR-L2 as set forth in SEQ ID NO: 245, and CDR-L3 as set forth in SEQ ID NO: 246; (26) CDR-H1 as set forth in SEQ ID NO: 251, CDR-H2 as set forth in SEQ ID NO: 252, CDR-H3 as set forth in SEQ ID NO: 253, CDR-L1 as set forth in SEQ ID NO: 254, CDR-L2 as set forth in SEQ ID NO: 255, and CDR-L3 as set forth in SEQ ID NO: 256; (27) CDR-H1 as set forth in SEQ ID NO: 261, CDR-H2 as set forth in SEQ ID NO: 262, CDR-H3 as set forth in SEQ ID NO: 263, CDR-L1 as set forth in SEQ ID NO: 264, CDR-L2 as set forth in SEQ ID NO: 265, and CDR-L3 as set forth in SEQ ID NO: 266; (28) CDR-H1 as set forth in SEQ ID NO: 271, CDR-H2 as set forth in SEQ ID NO: 272, CDR-H3 as set forth in SEQ ID NO: 273, CDR-L1 as set forth in SEQ ID NO: 274, CDR-L2 as set forth in SEQ ID NO: 275, and CDR-L3 as set forth in SEQ ID NO: 276; (29) CDR-H1 as set forth in SEQ ID NO: 281, CDR-H2 as set forth in SEQ ID NO: 282, CDR-H3 as set forth in SEQ ID NO: 283, CDR-L1 as set forth in SEQ ID NO: 284, CDR-L2 as set forth in SEQ ID NO: 285, and CDR-L3 as set forth in SEQ ID NO: 286; (30) CDR-H1 as set forth in SEQ ID NO: 291, CDR-H2 as set forth in SEQ ID NO: 292, CDR-H3 as set forth in SEQ ID NO: 293, CDR-L1 as set forth in SEQ ID NO: 294, CDR-L2 as set forth in SEQ ID NO: 295, and CDR-L3 as set forth in SEQ ID NO: 296; (31) CDR-H1 as set forth in SEQ ID NO: 301, CDR-H2 as set forth in SEQ ID NO: 302, CDR-H3 as set forth in SEQ ID NO: 303, CDR-L1 as set forth in SEQ ID NO: 304, CDR-L2 as set forth in SEQ ID NO: 305, and CDR-L3 as set forth in SEQ ID NO: 306; (32) CDR-H1 as set forth in SEQ ID NO: 311, CDR-H2 as set forth in SEQ ID NO: 312, CDR-H3 as set forth in SEQ ID NO: 313, CDR-L1 as set forth in SEQ ID NO: 314, CDR-L2 as set forth in SEQ ID NO: 315, and CDR-L3 as set forth in SEQ ID NO: 316; (33) CDR-H1 as set forth in SEQ ID NO: 321, CDR-H2 as set forth in SEQ ID NO: 322, CDR-H3 as set forth in SEQ ID NO: 323, CDR-L1 as set forth in SEQ ID NO: 324, CDR-L2 as set forth in SEQ ID NO: 325, and CDR-L3 as set forth in SEQ ID NO: 326; (34) CDR-H1 as set forth in SEQ ID NO: 331, CDR-H2 as set forth in SEQ ID NO: 332, CDR-H3 as set forth in SEQ ID NO: 333, CDR-L1 as set forth in SEQ ID NO: 334, CDR-L2 as set forth in SEQ ID NO: 335, and CDR-L3 as set forth in SEQ ID NO: 336; (35) CDR-H1 as set forth in SEQ ID NO: 341, CDR-H2 as set forth in SEQ ID NO: 342, CDR-H3 as set forth in SEQ ID NO: 343, CDR-L1 as set forth in SEQ ID NO: 344, CDR-L2 as set forth in SEQ ID NO: 345, and CDR-L3 as set forth in SEQ ID NO: 346; (36) CDR-H1 as set forth in SEQ ID NO: 351, CDR-H2 as set forth in SEQ ID NO: 352, CDR-H3 as set forth in SEQ ID NO: 353, CDR-L1 as set forth in SEQ ID NO: 354, CDR-L2 as set forth in SEQ ID NO: 355, and CDR-L3 as set forth in SEQ ID NO: 356; (37) CDR-H1 as set forth in SEQ ID NO: 361, CDR-H2 as set forth in SEQ ID NO: 362, CDR-H3 as set forth in SEQ ID NO: 363, CDR-L1 as set forth in SEQ ID NO: 364, CDR-L2 as set forth in SEQ ID NO: 365, and CDR-L3 as set forth in SEQ ID NO: 366; (38) CDR-H1 as set forth in SEQ ID NO: 371, CDR-H2 as set forth in SEQ ID NO: 372, CDR-H3 as set forth in SEQ ID NO: 373, CDR-L1 as set forth in SEQ ID NO: 374, CDR-L2 as set forth in SEQ ID NO: 375, and CDR-L3 as set forth in SEQ ID NO: 376; (39) CDR-H1 as set forth in SEQ ID NO: 381, CDR-H2 as set forth in SEQ ID NO: 382, CDR-H3 as set forth in SEQ ID NO: 383, CDR-L1 as set forth in SEQ ID NO: 384, CDR-L2 as set forth in SEQ ID NO: 385, and CDR-L3 as set forth in SEQ ID NO: 386; (40) CDR-H1 as set forth in SEQ ID NO: 391, CDR-H2 as set forth in SEQ ID NO: 392, CDR-H3 as set forth in SEQ ID NO: 393, CDR-L1 as set forth in SEQ ID NO: 394, CDR-L2 as set forth in SEQ ID NO: 395, and CDR-L3 as set forth in SEQ ID NO: 396; (41) CDR-H1 as set forth in SEQ ID NO: 401, CDR-H2 as set forth in SEQ ID NO: 402, CDR-H3 as set forth in SEQ ID NO: 403, CDR-L1 as set forth in SEQ ID NO: 404, CDR-L2 as set forth in SEQ ID NO: 405, and CDR-L3 as set forth in SEQ ID NO: 406; (42) CDR-H1 as set forth in SEQ ID NO: 411, CDR-H2 as set forth in SEQ ID NO: 412, CDR-H3 as set forth in SEQ ID NO: 413, CDR-L1 as set forth in SEQ ID NO: 414, CDR-L2 as set forth in SEQ ID NO: 415, and CDR-L3 as set forth in SEQ ID NO: 416; (43) CDR-H1 as set forth in SEQ ID NO: 421, CDR-H2 as set forth in SEQ ID NO: 422, CDR-H3 as set forth in SEQ ID NO: 423, CDR-L1 as set forth in SEQ ID NO: 424, CDR-L2 as set forth in SEQ ID NO: 425, and CDR-L3 as set forth in SEQ ID NO: 426; (44) CDR-H1 as set forth in SEQ ID NO: 431, CDR-H2 as set forth in SEQ ID NO: 432, CDR-H3 as set forth in SEQ ID NO: 433, CDR-L1 as set forth in SEQ ID NO: 434, CDR-L2 as set forth in SEQ ID NO: 435, and CDR-L3 as set forth in SEQ ID NO: 436; (45) CDR-H1 as set forth in SEQ ID NO: 441, CDR-H2 as set forth in SEQ ID NO: 442, CDR-H3 as set forth in SEQ ID NO: 443, CDR-L1 as set forth in SEQ ID NO: 444, CDR-L2 as set forth in SEQ ID NO: 445, and CDR-L3 as set forth in SEQ ID NO: 446; (46) CDR-H1 as set forth in SEQ ID NO: 451, CDR-H2 as set forth in SEQ ID NO: 452, CDR-H3 as set forth in SEQ ID NO: 453, CDR-L1 as set forth in SEQ ID NO: 454, CDR-L2 as set forth in SEQ ID NO: 455, and CDR-L3 as set forth in SEQ ID NO: 456; (47) CDR-H1 as set forth in SEQ ID NO: 461, CDR-H2 as set forth in SEQ ID NO: 462, CDR-H3 as set forth in SEQ ID NO: 463, CDR-L1 as set forth in SEQ ID NO: 464, CDR-L2 as set forth in SEQ ID NO: 465, and CDR-L3 as set forth in SEQ ID NO: 466; (48) CDR-H1 as set forth in SEQ ID NO: 471, CDR-H2 as set forth in SEQ ID NO: 472, CDR-H3 as set forth in SEQ ID NO: 473, CDR-L1 as set forth in SEQ ID NO: 474, CDR-L2 as set forth in SEQ ID NO: 475, and CDR-L3 as set forth in SEQ ID NO: 476; (49) CDR-H1 as set forth in SEQ ID NO: 481, CDR-H2 as set forth in SEQ ID NO: 482, CDR-H3 as set forth in SEQ ID NO: 483, CDR-L1 as set forth in SEQ ID NO: 484, CDR-L2 as set forth in SEQ ID NO: 485, and CDR-L3 as set forth in SEQ ID NO: 486; (50) CDR-H1 as set forth in SEQ ID NO: 491, CDR-H2 as set forth in SEQ ID NO: 492, CDR-H3 as set forth in SEQ ID NO: 493, CDR-L1 as set forth in SEQ ID NO: 494, CDR-L2 as set forth in SEQ ID NO: 495, and CDR-L3 as set forth in SEQ ID NO: 496; (51) CDR-H1 as set forth in SEQ ID NO: 501, CDR-H2 as set forth in SEQ ID NO: 502, CDR-H3 as set forth in SEQ ID NO: 503, CDR-L1 as set forth in SEQ ID NO: 504, CDR-L2 as set forth in SEQ ID NO: 505, and CDR-L3 as set forth in SEQ ID NO: 506; (52) CDR-H1 as set forth in SEQ ID NO: 511, CDR-H2 as set forth in SEQ ID NO: 512, CDR-H3 as set forth in SEQ ID NO: 513, CDR-L1 as set forth in SEQ ID NO: 514, CDR-L2 as set forth in SEQ ID NO: 515, and CDR-L3 as set forth in SEQ ID NO: 516; and (53) CDR-H1 as set forth in SEQ ID NO: 521, CDR-H2 as set forth in SEQ ID NO: 522, CDR-H3 as set forth in SEQ ID NO: 523, CDR-L1 as set forth in SEQ ID NO: 524, CDR-L2 as set forth in SEQ ID NO: 525, and CDR-L3 as set forth in SEQ ID NO: 526. It is envisaged that the VH region comprises CDR-H1, CDR-H2 and CDR-H3, and a VL region comprises CDR-L1, CDR-L2 and CDR-L3 selected from:
[0085] It is also envisaged that for the antibody constructs of the invention, the first domain that binds BCMA comprises a VL region having an amino acid sequence selected from the group consisting of those set out in SEQ ID NOs: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98, 108, 118, 128, 138, 148, 158, 168, 178, 188, 198, 208, 218, 228, 238, 248, 258, 268, 278, 288, 298, 308, 318, 328, 338, 348, 358, 368, 378, 388, 398, 408, 418, 428, 438, 448, 458, 468, 478, 488, 498, 508, 518 and 528. The first domain is envisaged to comprise a VL region having an amino acid sequence as set forth in SEQ ID NO:178.
[0086] It is further envisaged that the first domain which binds BCMA comprises a VH region having an amino acid sequence selected from the group consisting of those set out in SEQ ID NOs: 7, 17, 27, 37, 47, 57, 67, 77, 87, 97, 107, 117, 127, 137, 147, 157, 167, 177, 187, 197, 207, 217, 227, 237, 247, 257, 267, 277, 287, 307, 317, 327, 337, 347, 357, 367, 377, 387, 397, 407, 417, 427, 437, 447, 457, 467, 477, 487, 497, 507, 517 and 527. The first domain is envisaged to comprise a VL region having an amino acid sequence as set forth in SEQ ID NO:177.
[0087] Furthermore, for the antibody construct of the present invention, the first domain that binds to BCMA comprises: (1) a VH region as set forth in SEQ ID NO:7 and a VL region as set forth in SEQ ID NO:8; (2) a VH region as set forth in SEQ ID NO:17 and a VL region as set forth in SEQ ID NO:18; (3) a VH region as set forth in SEQ ID NO:27 and a VL region as set forth in SEQ ID NO:28; (4) a VH region as set forth in SEQ ID NO:37 and a VL region as set forth in SEQ ID NO:38; (5) a VH region as set forth in SEQ ID NO:47 and a VL region as set forth in SEQ ID NO:48; (6) a VH region as set forth in SEQ ID NO:57 and a VL region as set forth in SEQ ID NO:58; (7) a VH region as set forth in SEQ ID NO:67 and a VL region as set forth in SEQ ID NO:68; (8) a VH region as set forth in SEQ ID NO: 77 and a VL region as set forth in SEQ ID NO: 78; (9) a VH region as set forth in SEQ ID NO: 87 and a VL region as set forth in SEQ ID NO: 88; (10) a VH region as set forth in SEQ ID NO: 97 and a VL region as set forth in SEQ ID NO: 98; (11) a VH region as set forth in SEQ ID NO: 107 and a VL region as set forth in SEQ ID NO: 108; (12) a VH region as set forth in SEQ ID NO: 117 and a VL region as set forth in SEQ ID NO: 118; (13) a VH region as set forth in SEQ ID NO: 127 and a VL region as set forth in SEQ ID NO: 128; (14) a VH region as set forth in SEQ ID NO: 137 and a VL region as set forth in SEQ ID NO: 138; (15) a VH region as set forth in SEQ ID NO: 147 and a VL region as set forth in SEQ ID NO: 148; (16) a VH region as set forth in SEQ ID NO: 157 and a VL region as set forth in SEQ ID NO: 158; (17) a VH region as set forth in SEQ ID NO: 167 and a VL region as set forth in SEQ ID NO: 168; (18) a VH region as set forth in SEQ ID NO: 177 and a VL region as set forth in SEQ ID NO: 178; (19) a VH region as set forth in SEQ ID NO: 187 and a VL region as set forth in SEQ ID NO: 188; (20) a VH region as set forth in SEQ ID NO: 197 and a VL region as set forth in SEQ ID NO: 198; (21) a VH region as set forth in SEQ ID NO: 207 and a VL region as set forth in SEQ ID NO: 208; (22) a VH region as set forth in SEQ ID NO: 217 and a VL region as set forth in SEQ ID NO: 218; (23) a VH region as set forth in SEQ ID NO: 227 and a VL region as set forth in SEQ ID NO: 228; (24) a VH region as set forth in SEQ ID NO: 237 and a VL region as set forth in SEQ ID NO: 238; (25) a VH region as set forth in SEQ ID NO: 247 and a VL region as set forth in SEQ ID NO: 248; (26) a VH region as set forth in SEQ ID NO: 257 and a VL region as set forth in SEQ ID NO: 258; (27) a VH region as set forth in SEQ ID NO: 267 and a VL region as set forth in SEQ ID NO: 268; (28) a VH region as set forth in SEQ ID NO: 277 and a VL region as set forth in SEQ ID NO: 278; (29) a VH region as set forth in SEQ ID NO: 287 and a VL region as set forth in SEQ ID NO: 288; (30) a VH region as set forth in SEQ ID NO: 297 and a VL region as set forth in SEQ ID NO: 298; (31) a VH region as set forth in SEQ ID NO: 307 and a VL region as set forth in SEQ ID NO: 308; (32) the VH region as set forth in SEQ ID NO: 317 and the VL region as set forth in SEQ ID NO: 318; (33) a VH region as set forth in SEQ ID NO: 327 and a VL region as set forth in SEQ ID NO: 328; (34) a VH region as set forth in SEQ ID NO: 337 and a VL region as set forth in SEQ ID NO: 338; (35) a VH region as set forth in SEQ ID NO: 347 and a VL region as set forth in SEQ ID NO: 348; (36) the VH region as set forth in SEQ ID NO: 357 and the VL region as set forth in SEQ ID NO: 358; (37) a VH region as set forth in SEQ ID NO: 367 and a VL region as set forth in SEQ ID NO: 368; (38) a VH region as set forth in SEQ ID NO: 377 and a VL region as set forth in SEQ ID NO: 378; (39) the VH region as set forth in SEQ ID NO: 387 and the VL region as set forth in SEQ ID NO: 388; (40) the VH region as set forth in SEQ ID NO: 397 and the VL region as set forth in SEQ ID NO: 398; (41) The VH region as set forth in SEQ ID NO: 407 and the VL region as set forth in SEQ ID NO: 408; (42) the VH region as set forth in SEQ ID NO: 417 and the VL region as set forth in SEQ ID NO: 418; (43) the VH region as set forth in SEQ ID NO: 427 and the VL region as set forth in SEQ ID NO: 428; (44) the VH region as set forth in SEQ ID NO: 437 and the VL region as set forth in SEQ ID NO: 438; (45) the VH region as set forth in SEQ ID NO: 447 and the VL region as set forth in SEQ ID NO: 448; (46) the VH region as set forth in SEQ ID NO: 457 and the VL region as set forth in SEQ ID NO: 458; (47) The VH region as set forth in SEQ ID NO: 467 and the VL region as set forth in SEQ ID NO: 468; (48) the VH region as set forth in SEQ ID NO: 477 and the VL region as set forth in SEQ ID NO: 478; (49) the VH region as set forth in SEQ ID NO: 487 and the VL region as set forth in SEQ ID NO: 488; (50) the VH region as set forth in SEQ ID NO: 497 and the VL region as set forth in SEQ ID NO: 498; (51) The VH region as set forth in SEQ ID NO: 507 and the VL region as set forth in SEQ ID NO: 508; (52) the VH region as set forth in SEQ ID NO: 517 and the VL region as set forth in SEQ ID NO: 518; and (53) The VH region as set forth in SEQ ID NO: 527 and the VL region as set forth in SEQ ID NO: 528. It is envisaged that the antibody comprises a VH region and a VL region selected from the group consisting of:
[0088] The first domain is envisaged to comprise a VH region having the amino acid sequence as set forth in SEQ ID NO:177 and a VL region having the amino acid sequence as set forth in SEQ ID NO:178.
[0089] It is also envisaged that for the antibody constructs of the invention the first domain that binds BCMA comprises or consists of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 9, 19, 29, 39, 49, 59, 69, 79, 89, 109, 129, 139, 149, 159, 169, 179, 189, 199, 209, 219, 229, 239, 249, 259, 269, 279, 289, 299, 309, 319, 329, 339, 349, 359, 369, 379, 389, 399, 409, 419, 429, 439, 449, 459, 469, 479, 489, 499, 519 and 529. It is envisaged that the first domain comprises or consists of a polypeptide having an amino acid sequence as set forth in SEQ ID NO:179.
[0090] "T cells" or T lymphocytes are a type of lymphocyte (itself a type of white blood cell) that plays a central role in cell-mediated immunity. There are several subsets of T cells, each with different functions. T cells can be distinguished from other lymphocytes, such as B cells and NK cells, by the presence of a T cell receptor (TCR) on the cell surface. The TCR is responsible for the recognition of antigens bound to major histocompatibility complex (MHC) molecules and is composed of two different protein chains. In 95% of T cells, the TCR consists of an alpha (α) chain and a beta (β) chain. Engagement of the TCR with an antigen peptide and MHC (peptide / MHC complex) activates the T lymphocyte through a series of biochemical events mediated by associated enzymes, co-receptors, specialized adaptor molecules, and activated or released transcription factors.
[0091] "CD3" (cluster of differentiation 3) is a T cell coreceptor composed of four chains. In mammals, the CD3 protein complex contains the CD3γ (gamma) chain, the CD3δ (delta) chain, and two CD3ε (epsilon) chains. These four chains associate with the T cell receptor (TCR) and the so-called ζ (zeta) chain to form the "T cell receptor complex" and generate activation signals in T lymphocytes. The CD3γ (gamma), CD3δ (delta) and CD3ε (epsilon) chains are highly related cell surface proteins of the immunoglobulin superfamily, each containing a single extracellular immunoglobulin domain. The intracellular tail of the CD3 molecule contains a single conserved motif, known as the immunoreceptor tyrosine-based activation motif (ITAM), which is essential for the signaling capacity of the TCR. The CD3 epsilon molecule is a polypeptide encoded by the CD3E gene, which is present on chromosome 11 in humans.
[0092] Lysis of target cells redirected via recruitment of T cells by antibody constructs that bind to CD3 on T cells and target proteins on target cells generally involves cytolytic synapse formation and delivery of perforin and granzymes. Engaged T cells are capable of continuous target cell lysis and are not subject to immune evasion mechanisms that prevent peptide antigen processing and presentation or clonal T cell differentiation (see, e.g., WO 2007 / 042261).
[0093] Cytotoxicity mediated by BCMAxCD3 antibody constructs can be measured in a variety of ways. 50 ) is commonly used as a measure of potency of biologically active molecules, such as the antibody constructs of the present invention. It is expressed in molar units. In this case, the EC 50Values refer to the concentration of antibody constructs that produce a cytotoxic response (lysis of target cells) halfway between baseline and maximum. Effector cells in cytotoxicity assays can be, for example, stimulated enriched (human) CD8 positive T cells or unstimulated (human) peripheral blood mononuclear cells (PBMCs). Target cells must express BCMA on the surface of the cell. Preferably, target cells express (at least) the extracellular domain of BCMA on the surface of the cell. Target cells can be cell lines (such as CHO) that are stably or transiently transfected with BCMA, e.g., human BCMA. Alternatively, target cells can be cell lines that are natural expressers of BCMA positivity, such as the human multiple myeloma cell lines L363 or NCI-H929.
[0094] The effector to target cell (E:T) ratio in the cytotoxicity assay is usually about 10:1, but this can also vary. The cytotoxic activity of the BCMAxCD3 antibody construct can be measured in a 51-chromium release assay (e.g., with an incubation time of about 18 hours) or a FACS-based cytotoxicity assay (e.g., with an incubation time of about 48 hours). Modification of the incubation time (cytotoxic response) is also envisaged. Other methods of measuring cytotoxicity are well known and include MTT or MTS assays, ATP-based assays including bioluminescence assays, sulforhodamine B (SRB) assays, WST assays, clonogenic assays and ECIS techniques.
[0095] According to one embodiment, the cytotoxic activity mediated by the BCMAxCD3 antibody construct of the invention is measured in a FACS-based cytotoxicity assay. 50It is envisaged that the values are ≦5000pM or ≦4000pM, more preferably ≦3000pM or ≦2000pM, even more preferably ≦1000pM or ≦500pM, even more preferably ≦400pM or ≦300pM, even more preferably ≦200pM, even more preferably ≦100pM, even more preferably ≦50pM, even more preferably ≦20pM or ≦10pM, most preferably ≦5pM. It is also envisaged that the antibody constructs of the invention have EC50 values in the triple, double or single digit pg / ml range as measured in a FACS based cytotoxicity assay. The assay may be performed using L363 or NCI-H929 cell lines or BCMA transfected CHO cells as target cells and stimulated enriched (human) CD8 positive T cells or unstimulated (human) (PBMC) as effector cells. See also WO 2013 / 072406.
[0096] The second domain of the antibody construct of the present invention binds to CD3. More preferably, it binds to CD3 on the surface of a T cell. It is further envisaged that the second domain binds to human CD3, preferably human CD3 on the surface of a T cell. It is also envisaged that the second domain binds to CD3ε. More preferably, it binds to human CD3ε, e.g. human CD3ε on the surface of a T cell. A preferred amino acid sequence for the extracellular domain of human CD3ε is shown in SEQ ID NO: 653.
[0097] In one embodiment of the invention, the second domain of the antibody construct binds to human CD3ε (or human CD3ε on the surface of T cells) and Callithrix jacchus or Saimiri sciureus CD3ε. It is also envisaged that the second domain binds to an extracellular epitope of CD3ε, preferably an extracellular epitope of human CD3ε. It is also envisaged that the second domain binds to an extracellular epitope of the human and Macaca CD3ε chains. One preferred epitope of CD3ε is included within amino acid residues 1-27 of the human CD3ε extracellular domain (see SEQ ID NO: 654). Even more specifically, the epitope comprises at least the amino acid sequence Gln-Asp-Gly-Asn-Glu. The common marmoset (Callithrix jacchus) is a New World primate belonging to the marmoset family (Callitrichidae), while the squirrel monkey (Saimiri sciureus) is a New World primate belonging to the capuchin family (Cebidae). A conjugate with these characteristics is described in detail in WO 2008 / 119567.
[0098] Antibodies or bispecific antibody constructs against (human) CD3 or specifically against CD3ε are known in the art, whose CDR, VH and VL sequences can serve as the basis for the second binding domain of the antibody construct of the present invention. For example, Kung et al. reported in 1979 the development of OKT3 (Ortho Kung T3), the first mAb that recognizes CD3 (specifically the ε chain of CD3) on human T cells. OKT3 (muromonab) was the first mouse-derived monoclonal antibody available for therapy in humans. Recent anti-CD3 monoclonal antibodies include otelixizumab (TRX4), teplizumab (MGA031), foralumab and visilizumab, all of which target the ε chain of CD3. Bispecific antibody constructs against (cancer) targets and CD3 are also being developed and (pre)clinical tested, whose CD3 binding domains (CDR, VH, VL) may serve as the basis for the second binding domain of the antibody construct of the invention. Examples include, but are not limited to, blinatumomab, solitomab (MT110, AMG110), catumaxomab, duvortuxizumab, ertumaxomab, mosunetuzumab, FBTA05 (Bi20, TPBs05), CEA-TCB (RG7802, RO6958688), AFM11 and MGD006 (S80880). Other examples of CD3 binding domains are disclosed, for example, in U.S. Pat. Nos. 7,994,289 B2, 7,728,114 B2, 7,381,803 B1, and 6,706,265 B1.
[0099] For the antibody construct of the present invention, the second domain that binds to CD3 comprises: (a) CDR-L1 as set forth in SEQ ID NO:542, CDR-L2 as set forth in SEQ ID NO:543, and CDR-L3 as set forth in SEQ ID NO:544; (b) CDR-L1 as set forth in SEQ ID NO: 599, CDR-L2 as set forth in SEQ ID NO: 600, and CDR-L3 as set forth in SEQ ID NO: 601; and (c) CDR-L1, CDR-L2 and CDR-L3 selected from CDR-L1 as set forth in SEQ ID NO: 621, CDR-L2 as set forth in SEQ ID NO: 622 and CDR-L3 as set forth in SEQ ID NO: 623. It is envisaged that the VL region comprises
[0100] Furthermore, for the antibody construct of the present invention, the second domain that binds to CD3 is (a) CDR-H1 as set forth in SEQ ID NO:534, CDR-H2 as set forth in SEQ ID NO:535, and CDR-H3 as set forth in SEQ ID NO:536; (b) CDR-H1 as set forth in SEQ ID NO:545, CDR-H2 as set forth in SEQ ID NO:546, and CDR-H3 as set forth in SEQ ID NO:547; (c) CDR-H1 as set forth in SEQ ID NO: 557, CDR-H2 as set forth in SEQ ID NO: 558, and CDR-H3 as set forth in SEQ ID NO: 559; (d) CDR-H1 as set forth in SEQ ID NO: 568, CDR-H2 as set forth in SEQ ID NO: 569, and CDR-H3 as set forth in SEQ ID NO: 570; (e) CDR-H1 as set forth in SEQ ID NO: 579, CDR-H2 as set forth in SEQ ID NO: 580, and CDR-H3 as set forth in SEQ ID NO: 581; (f) CDR-H1 as set forth in SEQ ID NO:591, CDR-H2 as set forth in SEQ ID NO:592, and CDR-H3 as set forth in SEQ ID NO:593; (g) CDR-H1 as set forth in SEQ ID NO:602, CDR-H2 as set forth in SEQ ID NO:603, and CDR-H3 as set forth in SEQ ID NO:604; (h) CDR-H1 as set forth in SEQ ID NO:613, CDR-H2 as set forth in SEQ ID NO:614, and CDR-H3 as set forth in SEQ ID NO:615; (i) CDR-H1 as set forth in SEQ ID NO: 624, CDR-H2 as set forth in SEQ ID NO: 625, and CDR-H3 as set forth in SEQ ID NO: 626; and (j) CDR-H1 as set forth in SEQ ID NO: 636, CDR-H2 as set forth in SEQ ID NO: 637, and CDR-H3 as set forth in SEQ ID NO: 638. It is also contemplated that the VH region comprises a CDR-H1, CDR-H2 and CDR-H3 selected from:
[0101] Further, for the antibody construct of the present invention, the second domain that binds to CD3 comprises: (a) CDR-L1 as set forth in SEQ ID NO: 531, CDR-L2 as set forth in SEQ ID NO: 532, CDR-L3 as set forth in SEQ ID NO: 533, CDR-H1 as set forth in SEQ ID NO: 534, CDR-H2 as set forth in SEQ ID NO: 535, and CDR-H3 as set forth in SEQ ID NO: 536; (b) CDR-L1 as set forth in SEQ ID NO: 542, CDR-L2 as set forth in SEQ ID NO: 543, CDR-L3 as set forth in SEQ ID NO: 544, CDR-H1 as set forth in SEQ ID NO: 545, CDR-H2 as set forth in SEQ ID NO: 546, and CDR-H3 as set forth in SEQ ID NO: 547; (c) CDR-L1 as set forth in SEQ ID NO: 554, CDR-L2 as set forth in SEQ ID NO: 555, CDR-L3 as set forth in SEQ ID NO: 556, CDR-H1 as set forth in SEQ ID NO: 557, CDR-H2 as set forth in SEQ ID NO: 558, and CDR-H3 as set forth in SEQ ID NO: 559; (d) CDR-L1 as set forth in SEQ ID NO:565, CDR-L2 as set forth in SEQ ID NO:566, CDR-L3 as set forth in SEQ ID NO:567, CDR-H1 as set forth in SEQ ID NO:568, CDR-H2 as set forth in SEQ ID NO:569, and CDR-H3 as set forth in SEQ ID NO:570; (e) CDR-L1 as set forth in SEQ ID NO: 576, CDR-L2 as set forth in SEQ ID NO: 577, CDR-L3 as set forth in SEQ ID NO: 578, CDR-H1 as set forth in SEQ ID NO: 579, CDR-H2 as set forth in SEQ ID NO: 580, and CDR-H3 as set forth in SEQ ID NO: 581; (f) CDR-L1 as set forth in SEQ ID NO:588, CDR-L2 as set forth in SEQ ID NO:589, CDR-L3 as set forth in SEQ ID NO:590, CDR-H1 as set forth in SEQ ID NO:591, CDR-H2 as set forth in SEQ ID NO:592, and CDR-H3 as set forth in SEQ ID NO:593; (g) CDR-L1 as set forth in SEQ ID NO:599, CDR-L2 as set forth in SEQ ID NO:600, CDR-L3 as set forth in SEQ ID NO:601, CDR-H1 as set forth in SEQ ID NO:602, CDR-H2 as set forth in SEQ ID NO:603, and CDR-H3 as set forth in SEQ ID NO:604; (h) CDR-L1 as set forth in SEQ ID NO:610, CDR-L2 as set forth in SEQ ID NO:611, CDR-L3 as set forth in SEQ ID NO:612, CDR-H1 as set forth in SEQ ID NO:613, CDR-H2 as set forth in SEQ ID NO:614, and CDR-H3 as set forth in SEQ ID NO:615; (i) CDR-L1 as set forth in SEQ ID NO: 621, CDR-L2 as set forth in SEQ ID NO: 622, CDR-L3 as set forth in SEQ ID NO: 623, CDR-H1 as set forth in SEQ ID NO: 624, CDR-H2 as set forth in SEQ ID NO: 625, and CDR-H3 as set forth in SEQ ID NO: 626; and (j) CDR-L1 as set forth in SEQ ID NO: 633, CDR-L2 as set forth in SEQ ID NO: 634, CDR-L3 as set forth in SEQ ID NO: 635, CDR-H1 as set forth in SEQ ID NO: 636, CDR-H2 as set forth in SEQ ID NO: 637, and CDR-H3 as set forth in SEQ ID NO: 638. It is envisaged that the VL region comprises CDR-L1, CDR-L2 and CDR-L3 selected from the group consisting of:
[0102] For the antibody construct of the present invention, it is also envisaged that the second domain that binds to CD3 comprises a VL region having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO:550, SEQ ID NO:551, SEQ ID NO:584, SEQ ID NO:585, SEQ ID NO:629 and SEQ ID NO:630.
[0103] It is further envisaged that the second domain that binds to CD3 comprises a VH region having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO:537, SEQ ID NO:538, SEQ ID NO:548, SEQ ID NO:549, SEQ ID NO:560, SEQ ID NO:561, SEQ ID NO:571, SEQ ID NO:572, SEQ ID NO:582, SEQ ID NO:583, SEQ ID NO:594, SEQ ID NO:595, SEQ ID NO:605, SEQ ID NO:606, SEQ ID NO:616, SEQ ID NO:617, SEQ ID NO:627, SEQ ID NO:628, SEQ ID NO:639, SEQ ID NO:640 and SEQ ID NO:644.
[0104] For the antibody construct of the present invention, the second domain that binds to CD3 comprises: (a) a VL region as set forth in SEQ ID NO: 539 or 521 and a VH region as set forth in SEQ ID NO: 537 or 538; (b) a VL region as set forth in SEQ ID NO: 550 or 521 and a VH region as set forth in SEQ ID NO: 548 or 549; (c) a VL region as set forth in SEQ ID NO: 562 or 521 and a VH region as set forth in SEQ ID NO: 560 or 561; (d) a VL region as set forth in SEQ ID NO: 573 or 521 and a VH region as set forth in SEQ ID NO: 571 or 572; (e) a VL region as set forth in SEQ ID NO: 584 or 585 and a VH region as set forth in SEQ ID NO: 582 or 583; (f) a VL region as set forth in SEQ ID NO: 596 or 521 and a VH region as set forth in SEQ ID NO: 594 or 595; (g) a VL region as set forth in SEQ ID NO: 607 or 585 and a VH region as set forth in SEQ ID NO: 605 or 606; (h) a VL region as set forth in SEQ ID NO: 618 or 521 and a VH region as set forth in SEQ ID NO: 616 or 617; (i) a VL region as set forth in SEQ ID NO: 629 or 630 and a VH region as set forth in SEQ ID NO: 627 or 628; (j) a VL region as set forth in SEQ ID NO: 641 or 630 and a VH region as set forth in SEQ ID NO: 639 or 640; and (k) a VL region as set forth in SEQ ID NO: 645 and a VH region as set forth in SEQ ID NO: 644 It is also envisaged that the VL and VH regions comprise a VL region and a VH region selected from the group consisting of:
[0105] For the antibody constructs of the present invention, it is also envisaged that the second domain that binds to CD3 comprises or consists of a polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NOs: 540, 541, 552, 553, 563, 564, 574, 575, 586, 587, 597, 598, 608, 609, 619, 620, 631, 632, 642, 643 and 646.
[0106] The antibody construct of the present invention comprises: a) an antibody or antibody construct comprising a domain that binds to CD3 on the surface of a T cell, said domain comprising a VH region comprising CDR-H1 as set forth in SEQ ID NO: 636, CDR-H2 as set forth in SEQ ID NO: 637 and CDR-H3 as set forth in SEQ ID NO: 638, and a VL region comprising CDR-L1 as set forth in SEQ ID NO: 633, CDR-L2 as set forth in SEQ ID NO: 634, CDR-L3 as set forth in SEQ ID NO: 635; b) an antibody or antibody construct comprising a domain that binds to CD3 on the surface of a T cell, said domain comprising a VH region as set forth in SEQ ID NO: 639 and a VL region as set forth in SEQ ID NO: 641; c) an antibody construct comprising a domain that binds to CD3 on the surface of a T cell, said domain comprising an amino acid sequence as set forth in SEQ ID NO: 642; or d) an antibody construct having an amino acid sequence as set forth in SEQ ID NO: 661; It is also anticipated that it will compete with CD3 for binding to CD3.
[0107] The antibody construct of the present invention comprises: a) an antibody or antibody construct comprising a domain that binds to CD3 on the surface of a T cell, said domain comprising a VH region comprising CDR-H1 as set forth in SEQ ID NO: 636, CDR-H2 as set forth in SEQ ID NO: 637 and CDR-H3 as set forth in SEQ ID NO: 638, and a VL region comprising CDR-L1 as set forth in SEQ ID NO: 633, CDR-L2 as set forth in SEQ ID NO: 634, CDR-L3 as set forth in SEQ ID NO: 635; b) an antibody or antibody construct comprising a domain that binds to CD3 on the surface of a T cell, said domain comprising a VH region as set forth in SEQ ID NO: 639 and a VL region as set forth in SEQ ID NO: 641; c) an antibody construct comprising a domain that binds to CD3 on the surface of a T cell, said domain comprising an amino acid sequence as set forth in SEQ ID NO: 642; or d) an antibody construct having an amino acid sequence as set forth in SEQ ID NO: 661; It is also predicted that it binds to the same epitope on CD3 as
[0108] It is further contemplated that the antibody construct of the present invention comprises a polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NOs: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520 and 530. An antibody construct of the present invention is envisaged comprising a polypeptide having an amino acid sequence as set forth in SEQ ID NO:180.
[0109] The antibody constructs of the present invention are selected from the group consisting of SEQ ID NOs: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390 It is also envisaged that the polypeptide comprises or consists of a polypeptide having an amino acid sequence selected from the group consisting of those shown in Tables 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520 and 530, linked at its N-terminus or its C-terminus with a protein purification tag, preferably via a peptide bond (amide bond). Linkage of the protein purification tag at the C-terminus of the polypeptide is preferred. It is envisaged that the protein purification tag is a short peptide. For example, the length of the short peptide can be 2-30 amino acids, 4-25 amino acids, 5-20 amino acids or 6-19 amino acids.Examples of protein purification tags include, but are not limited to, an AU1 epitope (e.g., as set forth in SEQ ID NO: 666), an AU5 epitope (e.g., as set forth in SEQ ID NO: 667), a T7 tag (e.g., as set forth in SEQ ID NO: 668), a V5 tag (e.g., as set forth in SEQ ID NO: 669), a B tag (e.g., as set forth in SEQ ID NO: 670), an E2 epitope (e.g., as set forth in SEQ ID NO: 671), a FLAG epitope / FLAG tag (e.g., as set forth in SEQ ID NO: 672), a Glu-Glu tag (e.g., as set forth in SEQ ID NO: 673 or 674), an HA tag, a histidine affinity tag (e.g., as set forth in SEQ ID NO: 675), an HSV epitope (e.g., as set forth in SEQ ID NO: 676), a KT3 epitope (e.g., as set forth in SEQ ID NO: 677), a FLAG epitope / FLAG tag (e.g., as set forth in SEQ ID NO: 678), a Glu-Glu tag (e.g., as set forth in SEQ ID NO: 679), a Glu-Glu tag (e.g., as set forth in SEQ ID NO: 680), a Glu-Glu tag (e.g., as set forth in SEQ ID NO: 681), a Glu-Glu tag (e.g., as set forth in SEQ ID NO: 682), a Glu-Glu tag (e.g., as set forth in SEQ ID NO: 683), a Glu-Glu tag (e.g., as set forth in SEQ ID NO: 684), a Glu-Glu tag (e.g., as set 7), Myc epitope (e.g., as shown in SEQ ID NO: 678), polyarginine tag (5-6 Arg residues), polyaspartate tag (5-16 Asp residues), polyhistidine tag (2-10 His residues, usually 6 His residues, see e.g. SEQ ID NOs: 662-665), polyphenylalanine tag (usually 11 Phe residues), S1 tag (e.g., as shown in SEQ ID NO: 679), S tag (e.g., as shown in SEQ ID NO: 680), Strep tag (e.g., as shown in SEQ ID NO: 681 or 682), universal tag (e.g., as shown in SEQ ID NO: 683), VSV-G (e.g., as shown in SEQ ID NO: 684), protein C (e.g., as shown in SEQ ID NO: 685), and protein A. Histidine tags, particularly the 6xHis tag (SEQ ID NO: 663), are preferred.Accordingly, it is further envisaged that the antibody construct of the present invention comprises a polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NOs: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520 and 530, linked at its C-terminus via a peptide bond to a 6xHis tag. One embodiment of the antibody construct of the invention has the amino acid sequence as shown in SEQ ID NO:661.
[0110] The antibody construct of the present invention comprises: a) an antibody or antibody construct comprising a domain that binds to BCMA on the surface of a target cell, said domain comprising a VH region comprising CDR-H1 as set forth in SEQ ID NO: 171, CDR-H2 as set forth in SEQ ID NO: 172 and CDR-H3 as set forth in SEQ ID NO: 173, and a VL region comprising CDR-L1 as set forth in SEQ ID NO: 174, CDR-L2 as set forth in SEQ ID NO: 175 and CDR-L3 as set forth in SEQ ID NO: 176; b) an antibody or antibody construct comprising a domain that binds to BCMA on the surface of a target cell, said domain comprising a VH region as set forth in SEQ ID NO: 177 and a VL region as set forth in SEQ ID NO: 178; c) an antibody construct comprising a domain that binds to BCMA on the surface of a target cell, said domain comprising an amino acid sequence as set forth in SEQ ID NO: 179; or d) an antibody construct having an amino acid sequence as set forth in SEQ ID NO: 661; It is also anticipated that it will bind to the same epitope on BCMA as
[0111] Whether an antibody, antibody construct or binding domain binds to the same epitope of BCMA / BCMA on the surface of a target cell as another given antibody, antibody construct or binding domain can be determined by various analyses, for example epitope mapping on chimeric or mutated BCMA molecules, as described in WO 2013 / 072406. Another possibility to identify epitopes in a target is the alanine scanning assay (see, for example, Morrison KL&Weiss GA.Curr Opin Chem Biol.2001 Jun;5(3):302-7), in which each residue in the target to be analyzed (herein, BCMA) is replaced with alanine, for example by site-directed mutagenesis. Alanine is used because it is not bulky, is chemically inert, and yet has a methyl functionality that mimics the secondary structure criteria that many other amino acids have. If it is desirable to preserve the size of the residue to be mutated, sometimes bulky amino acids such as valine or leucine can be used. Alanine scanning is usually achieved by site-directed mutagenesis or random PCR library creation. In addition, computational methods have been developed to estimate thermodynamic parameters based on theoretical alanine substitutions. The data can be examined by IR, NMR spectroscopy, mathematical methods, bioassays, etc. Of course, the same analysis can be applied to other targets such as CD3.
[0112] The antibody construct of the present invention comprises: a) an antibody or antibody construct comprising a domain that binds to BCMA on the surface of a target cell, said domain comprising a VH region comprising CDR-H1 as set forth in SEQ ID NO: 171, CDR-H2 as set forth in SEQ ID NO: 172 and CDR-H3 as set forth in SEQ ID NO: 173, and a VL region comprising CDR-L1 as set forth in SEQ ID NO: 174, CDR-L2 as set forth in SEQ ID NO: 175 and CDR-L3 as set forth in SEQ ID NO: 176; b) an antibody or antibody construct comprising a domain that binds to BCMA on the surface of a target cell, said domain comprising a VH region as set forth in SEQ ID NO: 177 and a VL region as set forth in SEQ ID NO: 178; c) an antibody construct comprising a domain that binds to BCMA on the surface of a target cell, said domain comprising an amino acid sequence as set forth in SEQ ID NO: 179; or d) an antibody construct having an amino acid sequence as set forth in SEQ ID NO: 661; It is also envisaged that it competes with for binding to BCMA.
[0113] Whether an antibody or antibody construct competes with another given antibody or antibody construct for binding to BCMA / BCMA on the surface of target cells can be measured in a competition assay such as a competitive ELISA or a cell-based competition assay (using either cells naturally expressing BCMA or cells stably or transiently transformed with BCMA). Avidin-conjugated microparticles (beads) can also be used. Similar to an avidin-coated ELISA plate, each of these beads, when reacted with a biotinylated protein, can be used as a substrate on which an assay can be performed. The antigen is coated onto the beads, which are then pre-coated with the first antibody. A secondary antibody is added and any further binding is determined. A flow cytometric read is taken. The term "competes for binding" in this context means that there is at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% competition between the two test antibodies as determined by any one of the assays disclosed above. Of course, the same analysis can be applied for other targets, such as CD3.
[0114] One or both of the antibody constructs or binding domains thereof of the present invention may be "humanized" or "human". "Humanized" antibodies, variants or fragments thereof, antibody constructs and binding domains are based primarily on human sequence immunoglobulins, which contain minimal sequence derived from non-human immunoglobulin. In most cases, humanized antibodies, variants or fragments thereof, antibody constructs and binding domains are based on a human immunoglobulin (recipient antibody) in which residues from the hypervariable region or CDR are replaced by hypervariable region or CDR residues of a non-human species (donor antibody) such as a rodent (e.g., mouse, hamster, rat or rabbit) having the desired specificity, affinity, capacity and / or biological activity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, "humanized" antibodies, variants or fragments thereof, antibody constructs and binding domains as used herein may also include residues that are not found in either the recipient antibody or the donor antibody. These modifications are made to further refine and optimize antibody performance. Humanized antibodies, variants or fragments thereof, antibody constructs and binding domains can also comprise at least a portion of an immunoglobulin constant region (such as Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature, 321:522-525 (1986); Reichmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992).
[0115] The human anti-mouse antibody (HAMA) response has led the industry to prepare chimeric or other humanized antibodies / antibody constructs. However, it is expected that some human anti-chimeric antibody (HACA) response will be observed, especially with chronic or high dose use of antibodies or antibody constructs. It would therefore be desirable to provide an antibody construct that includes a human binding domain against BCMA and / or a human binding domain against CD3 to address concerns and / or effects of HAMA or HACA responses.
[0116] Thus, according to one embodiment, the antibody construct, the first binding domain and / or the second binding domain are "human". The terms "human antibody", "human antibody construct" and "human binding domain" include antibodies, antibody constructs and binding domains, respectively, having antibody-derived regions, such as variable and constant regions or domains, that substantially correspond to human germline immunoglobulin sequences known in the art, including, for example, those described by Kabat et al. (1991) supra. The human antibody constructs or binding domains of the invention may comprise amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs, particularly CDR3. The human antibody constructs or binding domains may have at least one, two, three, four, five or more positions replaced with amino acid residues not encoded by human germline immunoglobulin sequences. The definition of human antibodies, antibody constructs and binding domains as used herein also contemplates fully human antibodies, antibody constructs and binding domains that contain only non-artificially and / or genetically modified human sequences of antibodies, such as those that may be derived using technologies or systems such as Xenomouse.
[0117] Antibody constructs comprising at least one human binding domain avoid some of the problems associated with antibodies or antibody constructs having non-human, e.g. rodent (e.g. mouse, rat, hamster or rabbit) variable and / or constant regions. The presence of such rodent-derived proteins may lead to rapid clearance of the antibody or antibody construct or to the development of an immune response against the antibody or antibody construct by the patient. To avoid the use of rodent-derived antibody constructs, human antibody functions can be introduced into rodents to generate humanized or fully human antibody constructs, such that the rodents produce fully human antibodies.
[0118] In some embodiments, the antibody construct of the present invention is an "isolated" or "substantially pure" antibody construct. "Isolated" or "substantially pure" as used to describe the antibody construct disclosed herein means an antibody construct that has been identified, separated and / or recovered from components of its production environment. Preferably, the antibody construct is free or substantially free of association with all other components from its production environment. Contaminant components of its production environment, such as those resulting from recombinant transfected cells, are materials that may interfere with diagnostic or therapeutic uses of the antibody construct and may include enzymes, hormones and other proteinaceous or non-proteinaceous compounds. It is understood that an isolated or substantially pure antibody construct may represent 5% to 99.9% by weight of the total protein / polypeptide content in a given sample, depending on the circumstances. The desired antibody construct may be produced at significantly higher concentrations by using inducible or high expression promoters. This definition includes production of the antibody construct in a variety of organisms and / or host cells known in the art. In certain embodiments, the antibody construct will be purified (1) sufficiently to obtain at least 15 residues of N-terminal or internal amino acid sequence by using a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver staining. Ordinarily, however, an isolated antibody construct will be prepared by at least one purification step.
[0119] According to one embodiment, the entire antibody construct and / or binding domain is in the form of one or more polypeptides or in the form of a protein. In addition to the proteinaceous moieties, such polypeptides or proteins may contain non-proteinaceous moieties (e.g., chemical linkers or chemical cross-linking agents, such as glutaraldehyde).
[0120] Peptides are short chains of amino acid monomers linked by covalent peptide (amide) bonds. Thus, peptides are classified in the broad chemical class of biological oligomers and polymers. The amino acids that are part of a peptide or polypeptide chain may be referred to as "residues" and numbered consecutively. All peptides, except cyclic peptides, have an N-terminal residue at one end of the peptide and a C-terminal residue at the other end. Oligopeptides consist of very few amino acids (usually 2-20). Polypeptides are longer continuous unbranched peptide chains. Peptides are distinguished from proteins on the basis of size, and may be understood to include up to about 50 amino acids as an arbitrary criterion. Proteins usually consist of one or more polypeptides arranged in a biologically functional manner. Although aspects of the experimental techniques applied to peptides and polypeptides and proteins (e.g., details of electrophoresis, chromatography, etc.) differ, the size boundaries that distinguish peptides from polypeptides and proteins are not absolute. Thus, in the context of the present invention, the terms "peptide", "polypeptide" and "protein" may be used interchangeably, with the term "polypeptide" often being preferred.
[0121] Polypeptides may further form multimers consisting of two or more polypeptide molecules, such as dimers, trimers and higher oligomers. The polypeptide molecules forming such dimers, trimers, etc. may be identical or non-identical. The corresponding structures of such higher multimers are therefore referred to as homodimers or heterodimers, homotrimers or heterotrimers, etc. An example of a heteromultimer is an antibody or immunoglobulin molecule, which in its naturally occurring form consists of two identical light polypeptide chains and two identical heavy polypeptide chains. The terms "peptide", "polypeptide" and "protein" also refer to naturally occurring modified peptides / polypeptides / proteins, where the modification is achieved, for example, by post-translational modifications such as glycosylation, acetylation, phosphorylation, etc. A "peptide", "polypeptide" or "protein" as referred to herein may also be chemically modified, such as pegylation. Such modifications are well known in the art.
[0122] The antibody constructs of the present invention are typically formulated in pharmaceutical compositions or formulations. The materials of the pharmaceutical compositions are usually formulated in concentrations that are acceptable to the site of administration. Thus, the formulations and compositions according to the present invention can be designed for delivery by any suitable route of administration.
[0123] As used herein, the term "pharmaceutical composition" relates to a composition suitable for administration to a patient, preferably a human patient. Particularly preferred pharmaceutical compositions of the present invention comprise one or more antibody constructs of the present invention, usually in a therapeutically effective amount. The pharmaceutical composition may further comprise a suitable formulation of one or more (pharmaceutical effective) carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers, preservatives and / or adjuvants. Acceptable components of the composition are typically non-toxic to recipients at the dosages and concentrations used. Pharmaceutical compositions of the present invention include, but are not limited to, liquid, frozen and lyophilized compositions. If the pharmaceutical composition is lyophilized, the lyophilized material is reconstituted with a suitable liquid prior to administration. The lyophilized material may be reconstituted, for example, with bacteriostatic water for injection (BWFI), saline, phosphate buffered saline (PBS) or the same formulation in which the protein was before lyophilization.
[0124] The composition may include a pharmaceutically acceptable carrier. In general, as used herein, "pharmaceutically acceptable carrier" refers to any aqueous and non-aqueous solution, sterile solution, solvent, buffer solution, such as phosphate buffered saline (PBS) solution, water, suspension, emulsion such as oil / water emulsion, various wetting agents, liposome, dispersion medium and coating that are compatible with pharmaceutical administration, particularly parenteral administration. The use of such media and agents in pharmaceutical compositions is well known in the art, and compositions containing such carriers can be formulated by well-known conventional methods.
[0125] Certain embodiments provide pharmaceutical compositions comprising an antibody construct of the invention and one or more additional excipients. Excipients can be used for a variety of purposes, such as adjusting the physical, chemical or biological properties of the formulations of the methods of the invention, such as adjusting the viscosity, to improve efficacy and / or stabilize such formulations and processes against degradation and deterioration due to stresses encountered during and after, for example, manufacture, shipping, storage, preparation for use, administration. Excipients should generally be used at their lowest effective concentration.
[0126] In certain embodiments, pharmaceutical compositions may also contain formulatory materials / substances for the purpose of modifying, maintaining or preserving certain characteristics of the composition, such as pH, osmolality, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissolution or release rate, adsorption or permeability, etc. (see Remington's Pharmaceutical Sciences, 18" Edition, 1990, Mack Publishing Company).
[0127] The present invention relates to the following items.
[0128] Item 1. An antibody construct comprising a first domain that binds BCMA and a second domain that binds CD3, for use in treating or ameliorating a BCMA positive neoplasm, wherein the antibody construct is administered at a dose of 6.5 μg / day to a maximum of 650 μg / day in at least one cycle, wherein one cycle comprises a period of administration of the antibody construct of at least 7 consecutive days.
[0129] Item 2. The antibody construct of item 1, administered for 2, 3, 4, 5, 6, 7, 8, 9 or 10 cycles.
[0130] Item 3. The antibody construct of any one of items 1 or 2, wherein one cycle comprises a period of administration of the antibody construct followed by a period without administration of the antibody construct.
[0131] Item 4. The antibody construct according to any one of Items 1 to 3, wherein the administration period of the antibody construct is 1 to 8 weeks, preferably 2 to 6 weeks, and more preferably 25 to 30 days.
[0132] Item 5. The antibody construct according to item 3 or 4, wherein the period without administration of the antibody construct is at least 7 consecutive days.
[0133] Item 6. The antibody construct according to any one of Items 3 to 6, wherein the period without administration of the antibody construct is 1 week to 3 months, preferably 1 week to 2 months, and more preferably 1 week to 1 month.
[0134] Item 7. The antibody construct of any one of items 1 to 6, wherein the dose of the antibody construct is constant during each cycle.
[0135] Item 8. The antibody construct according to any one of items 1 to 7, wherein the dose of the antibody construct is constant during each cycle and from one cycle to the subsequent cycle.
[0136] Item 9. The antibody construct according to any one of items 1 to 8, which is administered parenterally, preferably intravenously, more preferably via continuous intravenous administration.
[0137] Item 10. The antibody construct according to any one of items 1 to 9, wherein the BCMA-positive neoplasm is selected from the group consisting of multiple myeloma, relapsed and / or refractory multiple myeloma, heavy chain multiple myeloma, light chain multiple myeloma, extramedullary myeloma, plasmacytoma, plasma cell leukemia, Waldenstrom's macroglobulinemia and smoldering myeloma.
[0138] Item 11. a) a single chain polypeptide, b) the first domain is in scFv format; c) the second domain is in scFv format, and / or d) The antibody construct according to any one of items 1 to 10, wherein the first domain and the second domain are connected via a linker, preferably a peptide linker, more preferably a glycine / serine linker.
[0139] Item 12.a) An antibody or antibody construct comprising a domain that binds to BCMA on the surface of a target cell, said domain comprising a VH region comprising CDR-H1 as set forth in SEQ ID NO: 171, CDR-H2 as set forth in SEQ ID NO: 172 and CDR-H3 as set forth in SEQ ID NO: 173, and a VL region comprising CDR-L1 as set forth in SEQ ID NO: 174, CDR-L2 as set forth in SEQ ID NO: 175 and CDR-L3 as set forth in SEQ ID NO: 176; b) an antibody or antibody construct comprising a domain that binds to BCMA on the surface of a target cell, said domain comprising a VH region as set forth in SEQ ID NO: 177 and a VL region as set forth in SEQ ID NO: 178; c) an antibody construct comprising a domain that binds to BCMA on the surface of a target cell, said domain comprising an amino acid sequence as set forth in SEQ ID NO: 179; or d) an antibody construct having an amino acid sequence as set forth in SEQ ID NO: 661; 12. The antibody construct according to any one of items 1 to 11, which competes for binding to BCMA with or binds to the same epitope on BCMA as
[0140] Item 13.a) An antibody or antibody construct comprising a domain that binds to CD3 on the surface of a T cell, said domain comprising a VH region comprising CDR-H1 as set forth in SEQ ID NO: 636, CDR-H2 as set forth in SEQ ID NO: 637 and CDR-H3 as set forth in SEQ ID NO: 638, and a VL region comprising CDR-L1 as set forth in SEQ ID NO: 633, CDR-L2 as set forth in SEQ ID NO: 634 and CDR-L3 as set forth in SEQ ID NO: 635; b) an antibody or antibody construct comprising a domain that binds to CD3 on the surface of a T cell, said domain comprising a VH region as set forth in SEQ ID NO: 639 and a VL region as set forth in SEQ ID NO: 641; c) an antibody construct comprising a domain that binds to CD3 on the surface of a T cell, said domain comprising an amino acid sequence as set forth in SEQ ID NO: 642; or d) an antibody construct having an amino acid sequence as set forth in SEQ ID NO: 661; 13. The antibody construct according to any one of items 1 to 12, which competes for binding to CD3 with or binds to the same epitope on CD3 as
[0141] Item 14. The first domain that binds to BCMA is (1) CDR-H1 as set forth in SEQ ID NO:1, CDR-H2 as set forth in SEQ ID NO:2, CDR-H3 as set forth in SEQ ID NO:3, CDR-L1 as set forth in SEQ ID NO:4, CDR-L2 as set forth in SEQ ID NO:5, and CDR-L3 as set forth in SEQ ID NO:6; (2) CDR-H1 as set forth in SEQ ID NO:11, CDR-H2 as set forth in SEQ ID NO:12, CDR-H3 as set forth in SEQ ID NO:13, CDR-L1 as set forth in SEQ ID NO:14, CDR-L2 as set forth in SEQ ID NO:15, and CDR-L3 as set forth in SEQ ID NO:16; (3) CDR-H1 as set forth in SEQ ID NO:21, CDR-H2 as set forth in SEQ ID NO:22, CDR-H3 as set forth in SEQ ID NO:23, CDR-L1 as set forth in SEQ ID NO:24, CDR-L2 as set forth in SEQ ID NO:25, and CDR-L3 as set forth in SEQ ID NO:26; (4) CDR-H1 as set forth in SEQ ID NO: 31, CDR-H2 as set forth in SEQ ID NO: 32, CDR-H3 as set forth in SEQ ID NO: 33, CDR-L1 as set forth in SEQ ID NO: 34, CDR-L2 as set forth in SEQ ID NO: 35, and CDR-L3 as set forth in SEQ ID NO: 36; (5) CDR-H1 as set forth in SEQ ID NO: 41, CDR-H2 as set forth in SEQ ID NO: 42, CDR-H3 as set forth in SEQ ID NO: 43, CDR-L1 as set forth in SEQ ID NO: 44, CDR-L2 as set forth in SEQ ID NO: 45, and CDR-L3 as set forth in SEQ ID NO: 46; (6) CDR-H1 as set forth in SEQ ID NO: 51, CDR-H2 as set forth in SEQ ID NO: 52, CDR-H3 as set forth in SEQ ID NO: 53, CDR-L1 as set forth in SEQ ID NO: 54, CDR-L2 as set forth in SEQ ID NO: 55, and CDR-L3 as set forth in SEQ ID NO: 56; (7) CDR-H1 as set forth in SEQ ID NO: 61, CDR-H2 as set forth in SEQ ID NO: 62, CDR-H3 as set forth in SEQ ID NO: 63, CDR-L1 as set forth in SEQ ID NO: 64, CDR-L2 as set forth in SEQ ID NO: 65, and CDR-L3 as set forth in SEQ ID NO: 66; (8) CDR-H1 as set forth in SEQ ID NO: 71, CDR-H2 as set forth in SEQ ID NO: 72, CDR-H3 as set forth in SEQ ID NO: 73, CDR-L1 as set forth in SEQ ID NO: 74, CDR-L2 as set forth in SEQ ID NO: 75, and CDR-L3 as set forth in SEQ ID NO: 76; (9) CDR-H1 as set forth in SEQ ID NO: 81, CDR-H2 as set forth in SEQ ID NO: 82, CDR-H3 as set forth in SEQ ID NO: 83, CDR-L1 as set forth in SEQ ID NO: 84, CDR-L2 as set forth in SEQ ID NO: 85, and CDR-L3 as set forth in SEQ ID NO: 86; (10) CDR-H1 as set forth in SEQ ID NO: 91, CDR-H2 as set forth in SEQ ID NO: 92, CDR-H3 as set forth in SEQ ID NO: 93, CDR-L1 as set forth in SEQ ID NO: 94, CDR-L2 as set forth in SEQ ID NO: 95, and CDR-L3 as set forth in SEQ ID NO: 96; (11) CDR-H1 as set forth in SEQ ID NO: 101, CDR-H2 as set forth in SEQ ID NO: 102, CDR-H3 as set forth in SEQ ID NO: 103, CDR-L1 as set forth in SEQ ID NO: 104, CDR-L2 as set forth in SEQ ID NO: 105, and CDR-L3 as set forth in SEQ ID NO: 106; (12) CDR-H1 as set forth in SEQ ID NO: 111, CDR-H2 as set forth in SEQ ID NO: 112, CDR-H3 as set forth in SEQ ID NO: 113, CDR-L1 as set forth in SEQ ID NO: 114, CDR-L2 as set forth in SEQ ID NO: 115, and CDR-L3 as set forth in SEQ ID NO: 116; (13) CDR-H1 as set forth in SEQ ID NO: 121, CDR-H2 as set forth in SEQ ID NO: 122, CDR-H3 as set forth in SEQ ID NO: 123, CDR-L1 as set forth in SEQ ID NO: 124, CDR-L2 as set forth in SEQ ID NO: 125, and CDR-L3 as set forth in SEQ ID NO: 126; (14) CDR-H1 as set forth in SEQ ID NO: 131, CDR-H2 as set forth in SEQ ID NO: 132, CDR-H3 as set forth in SEQ ID NO: 133, CDR-L1 as set forth in SEQ ID NO: 134, CDR-L2 as set forth in SEQ ID NO: 135, and CDR-L3 as set forth in SEQ ID NO: 136; (15) CDR-H1 as set forth in SEQ ID NO: 141, CDR-H2 as set forth in SEQ ID NO: 142, CDR-H3 as set forth in SEQ ID NO: 143, CDR-L1 as set forth in SEQ ID NO: 144, CDR-L2 as set forth in SEQ ID NO: 145, and CDR-L3 as set forth in SEQ ID NO: 146; (16) CDR-H1 as set forth in SEQ ID NO: 151, CDR-H2 as set forth in SEQ ID NO: 152, CDR-H3 as set forth in SEQ ID NO: 153, CDR-L1 as set forth in SEQ ID NO: 154, CDR-L2 as set forth in SEQ ID NO: 155, and CDR-L3 as set forth in SEQ ID NO: 156; (17) CDR-H1 as set forth in SEQ ID NO: 161, CDR-H2 as set forth in SEQ ID NO: 162, CDR-H3 as set forth in SEQ ID NO: 163, CDR-L1 as set forth in SEQ ID NO: 164, CDR-L2 as set forth in SEQ ID NO: 165, and CDR-L3 as set forth in SEQ ID NO: 166; (18) CDR-H1 as set forth in SEQ ID NO: 171, CDR-H2 as set forth in SEQ ID NO: 172, CDR-H3 as set forth in SEQ ID NO: 173, CDR-L1 as set forth in SEQ ID NO: 174, CDR-L2 as set forth in SEQ ID NO: 175, and CDR-L3 as set forth in SEQ ID NO: 176; (19) CDR-H1 as set forth in SEQ ID NO: 181, CDR-H2 as set forth in SEQ ID NO: 182, CDR-H3 as set forth in SEQ ID NO: 183, CDR-L1 as set forth in SEQ ID NO: 184, CDR-L2 as set forth in SEQ ID NO: 185, and CDR-L3 as set forth in SEQ ID NO: 186; (20) CDR-H1 as set forth in SEQ ID NO: 191, CDR-H2 as set forth in SEQ ID NO: 192, CDR-H3 as set forth in SEQ ID NO: 193, CDR-L1 as set forth in SEQ ID NO: 194, CDR-L2 as set forth in SEQ ID NO: 195, and CDR-L3 as set forth in SEQ ID NO: 196; (21) CDR-H1 as set forth in SEQ ID NO: 201, CDR-H2 as set forth in SEQ ID NO: 202, CDR-H3 as set forth in SEQ ID NO: 203, CDR-L1 as set forth in SEQ ID NO: 204, CDR-L2 as set forth in SEQ ID NO: 205, and CDR-L3 as set forth in SEQ ID NO: 206; (22) CDR-H1 as set forth in SEQ ID NO: 211, CDR-H2 as set forth in SEQ ID NO: 212, CDR-H3 as set forth in SEQ ID NO: 213, CDR-L1 as set forth in SEQ ID NO: 214, CDR-L2 as set forth in SEQ ID NO: 215, and CDR-L3 as set forth in SEQ ID NO: 216; (23) CDR-H1 as set forth in SEQ ID NO: 221, CDR-H2 as set forth in SEQ ID NO: 222, CDR-H3 as set forth in SEQ ID NO: 223, CDR-L1 as set forth in SEQ ID NO: 224, CDR-L2 as set forth in SEQ ID NO: 225, and CDR-L3 as set forth in SEQ ID NO: 226; (24) CDR-H1 as set forth in SEQ ID NO: 231, CDR-H2 as set forth in SEQ ID NO: 232, CDR-H3 as set forth in SEQ ID NO: 233, CDR-L1 as set forth in SEQ ID NO: 234, CDR-L2 as set forth in SEQ ID NO: 235, and CDR-L3 as set forth in SEQ ID NO: 236; (25) CDR-H1 as set forth in SEQ ID NO: 241, CDR-H2 as set forth in SEQ ID NO: 242, CDR-H3 as set forth in SEQ ID NO: 243, CDR-L1 as set forth in SEQ ID NO: 244, CDR-L2 as set forth in SEQ ID NO: 245, and CDR-L3 as set forth in SEQ ID NO: 246; (26) CDR-H1 as set forth in SEQ ID NO: 251, CDR-H2 as set forth in SEQ ID NO: 252, CDR-H3 as set forth in SEQ ID NO: 253, CDR-L1 as set forth in SEQ ID NO: 254, CDR-L2 as set forth in SEQ ID NO: 255, and CDR-L3 as set forth in SEQ ID NO: 256; (27) CDR-H1 as set forth in SEQ ID NO: 261, CDR-H2 as set forth in SEQ ID NO: 262, CDR-H3 as set forth in SEQ ID NO: 263, CDR-L1 as set forth in SEQ ID NO: 264, CDR-L2 as set forth in SEQ ID NO: 265, and CDR-L3 as set forth in SEQ ID NO: 266; (28) CDR-H1 as set forth in SEQ ID NO: 271, CDR-H2 as set forth in SEQ ID NO: 272, CDR-H3 as set forth in SEQ ID NO: 273, CDR-L1 as set forth in SEQ ID NO: 274, CDR-L2 as set forth in SEQ ID NO: 275, and CDR-L3 as set forth in SEQ ID NO: 276; (29) CDR-H1 as set forth in SEQ ID NO: 281, CDR-H2 as set forth in SEQ ID NO: 282, CDR-H3 as set forth in SEQ ID NO: 283, CDR-L1 as set forth in SEQ ID NO: 284, CDR-L2 as set forth in SEQ ID NO: 285, and CDR-L3 as set forth in SEQ ID NO: 286; (30) CDR-H1 as set forth in SEQ ID NO: 291, CDR-H2 as set forth in SEQ ID NO: 292, CDR-H3 as set forth in SEQ ID NO: 293, CDR-L1 as set forth in SEQ ID NO: 294, CDR-L2 as set forth in SEQ ID NO: 295, and CDR-L3 as set forth in SEQ ID NO: 296; (31) CDR-H1 as set forth in SEQ ID NO: 301, CDR-H2 as set forth in SEQ ID NO: 302, CDR-H3 as set forth in SEQ ID NO: 303, CDR-L1 as set forth in SEQ ID NO: 304, CDR-L2 as set forth in SEQ ID NO: 305, and CDR-L3 as set forth in SEQ ID NO: 306; (32) CDR-H1 as set forth in SEQ ID NO: 311, CDR-H2 as set forth in SEQ ID NO: 312, CDR-H3 as set forth in SEQ ID NO: 313, CDR-L1 as set forth in SEQ ID NO: 314, CDR-L2 as set forth in SEQ ID NO: 315, and CDR-L3 as set forth in SEQ ID NO: 316; (33) CDR-H1 as set forth in SEQ ID NO: 321, CDR-H2 as set forth in SEQ ID NO: 322, CDR-H3 as set forth in SEQ ID NO: 323, CDR-L1 as set forth in SEQ ID NO: 324, CDR-L2 as set forth in SEQ ID NO: 325, and CDR-L3 as set forth in SEQ ID NO: 326; (34) CDR-H1 as set forth in SEQ ID NO: 331, CDR-H2 as set forth in SEQ ID NO: 332, CDR-H3 as set forth in SEQ ID NO: 333, CDR-L1 as set forth in SEQ ID NO: 334, CDR-L2 as set forth in SEQ ID NO: 335, and CDR-L3 as set forth in SEQ ID NO: 336; (35) CDR-H1 as set forth in SEQ ID NO: 341, CDR-H2 as set forth in SEQ ID NO: 342, CDR-H3 as set forth in SEQ ID NO: 343, CDR-L1 as set forth in SEQ ID NO: 344, CDR-L2 as set forth in SEQ ID NO: 345, and CDR-L3 as set forth in SEQ ID NO: 346; (36) CDR-H1 as set forth in SEQ ID NO: 351, CDR-H2 as set forth in SEQ ID NO: 352, CDR-H3 as set forth in SEQ ID NO: 353, CDR-L1 as set forth in SEQ ID NO: 354, CDR-L2 as set forth in SEQ ID NO: 355, and CDR-L3 as set forth in SEQ ID NO: 356; (37) CDR-H1 as set forth in SEQ ID NO: 361, CDR-H2 as set forth in SEQ ID NO: 362, CDR-H3 as set forth in SEQ ID NO: 363, CDR-L1 as set forth in SEQ ID NO: 364, CDR-L2 as set forth in SEQ ID NO: 365, and CDR-L3 as set forth in SEQ ID NO: 366; (38) CDR-H1 as set forth in SEQ ID NO: 371, CDR-H2 as set forth in SEQ ID NO: 372, CDR-H3 as set forth in SEQ ID NO: 373, CDR-L1 as set forth in SEQ ID NO: 374, CDR-L2 as set forth in SEQ ID NO: 375, and CDR-L3 as set forth in SEQ ID NO: 376; (39) CDR-H1 as set forth in SEQ ID NO: 381, CDR-H2 as set forth in SEQ ID NO: 382, CDR-H3 as set forth in SEQ ID NO: 383, CDR-L1 as set forth in SEQ ID NO: 384, CDR-L2 as set forth in SEQ ID NO: 385, and CDR-L3 as set forth in SEQ ID NO: 386; (40) CDR-H1 as set forth in SEQ ID NO: 391, CDR-H2 as set forth in SEQ ID NO: 392, CDR-H3 as set forth in SEQ ID NO: 393, CDR-L1 as set forth in SEQ ID NO: 394, CDR-L2 as set forth in SEQ ID NO: 395, and CDR-L3 as set forth in SEQ ID NO: 396; (41) CDR-H1 as set forth in SEQ ID NO: 401, CDR-H2 as set forth in SEQ ID NO: 402, CDR-H3 as set forth in SEQ ID NO: 403, CDR-L1 as set forth in SEQ ID NO: 404, CDR-L2 as set forth in SEQ ID NO: 405, and CDR-L3 as set forth in SEQ ID NO: 406; (42) CDR-H1 as set forth in SEQ ID NO: 411, CDR-H2 as set forth in SEQ ID NO: 412, CDR-H3 as set forth in SEQ ID NO: 413, CDR-L1 as set forth in SEQ ID NO: 414, CDR-L2 as set forth in SEQ ID NO: 415, and CDR-L3 as set forth in SEQ ID NO: 416; (43) CDR-H1 as set forth in SEQ ID NO: 421, CDR-H2 as set forth in SEQ ID NO: 422, CDR-H3 as set forth in SEQ ID NO: 423, CDR-L1 as set forth in SEQ ID NO: 424, CDR-L2 as set forth in SEQ ID NO: 425, and CDR-L3 as set forth in SEQ ID NO: 426; (44) CDR-H1 as set forth in SEQ ID NO: 431, CDR-H2 as set forth in SEQ ID NO: 432, CDR-H3 as set forth in SEQ ID NO: 433, CDR-L1 as set forth in SEQ ID NO: 434, CDR-L2 as set forth in SEQ ID NO: 435, and CDR-L3 as set forth in SEQ ID NO: 436; (45) CDR-H1 as set forth in SEQ ID NO: 441, CDR-H2 as set forth in SEQ ID NO: 442, CDR-H3 as set forth in SEQ ID NO: 443, CDR-L1 as set forth in SEQ ID NO: 444, CDR-L2 as set forth in SEQ ID NO: 445, and CDR-L3 as set forth in SEQ ID NO: 446; (46) CDR-H1 as set forth in SEQ ID NO: 451, CDR-H2 as set forth in SEQ ID NO: 452, CDR-H3 as set forth in SEQ ID NO: 453, CDR-L1 as set forth in SEQ ID NO: 454, CDR-L2 as set forth in SEQ ID NO: 455, and CDR-L3 as set forth in SEQ ID NO: 456; (47) CDR-H1 as set forth in SEQ ID NO: 461, CDR-H2 as set forth in SEQ ID NO: 462, CDR-H3 as set forth in SEQ ID NO: 463, CDR-L1 as set forth in SEQ ID NO: 464, CDR-L2 as set forth in SEQ ID NO: 465, and CDR-L3 as set forth in SEQ ID NO: 466; (48) CDR-H1 as set forth in SEQ ID NO: 471, CDR-H2 as set forth in SEQ ID NO: 472, CDR-H3 as set forth in SEQ ID NO: 473, CDR-L1 as set forth in SEQ ID NO: 474, CDR-L2 as set forth in SEQ ID NO: 475, and CDR-L3 as set forth in SEQ ID NO: 476; (49) CDR-H1 as set forth in SEQ ID NO: 481, CDR-H2 as set forth in SEQ ID NO: 482, CDR-H3 as set forth in SEQ ID NO: 483, CDR-L1 as set forth in SEQ ID NO: 484, CDR-L2 as set forth in SEQ ID NO: 485, and CDR-L3 as set forth in SEQ ID NO: 486; (50) CDR-H1 as set forth in SEQ ID NO: 491, CDR-H2 as set forth in SEQ ID NO: 492, CDR-H3 as set forth in SEQ ID NO: 493, CDR-L1 as set forth in SEQ ID NO: 494, CDR-L2 as set forth in SEQ ID NO: 495, and CDR-L3 as set forth in SEQ ID NO: 496; (51) CDR-H1 as set forth in SEQ ID NO: 501, CDR-H2 as set forth in SEQ ID NO: 502, CDR-H3 as set forth in SEQ ID NO: 503, CDR-L1 as set forth in SEQ ID NO: 504, CDR-L2 as set forth in SEQ ID NO: 505, and CDR-L3 as set forth in SEQ ID NO: 506; (52) CDR-H1 as set forth in SEQ ID NO: 511, CDR-H2 as set forth in SEQ ID NO: 512, CDR-H3 as set forth in SEQ ID NO: 513, CDR-L1 as set forth in SEQ ID NO: 514, CDR-L2 as set forth in SEQ ID NO: 515, and CDR-L3 as set forth in SEQ ID NO: 516; and (53) CDR-H1 as set forth in SEQ ID NO: 521, CDR-H2 as set forth in SEQ ID NO: 522, CDR-H3 as set forth in SEQ ID NO: 523, CDR-L1 as set forth in SEQ ID NO: 524, CDR-L2 as set forth in SEQ ID NO: 525, and CDR-L3 as set forth in SEQ ID NO: 526. 14. The antibody construct according to any one of items 1 to 13, comprising a VH region comprising CDR-H1, CDR-H2 and CDR-H3, and a VL region comprising CDR-L1, CDR-L2 and CDR-L3, selected from:
[0142] Item 15. The antibody construct according to any one of items 1 to 14, wherein the first domain that binds to BCMA comprises a VH region having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NOs: 7, 17, 27, 37, 47, 57, 67, 77, 87, 97, 107, 117, 127, 137, 147, 157, 167, 177, 187, 197, 207, 217, 227, 237, 247, 257, 267, 277, 287, 307, 317, 327, 337, 347, 357, 367, 377, 387, 397, 407, 417, 427, 437, 447, 457, 467, 477, 487, 497, 507, 517 and 527.
[0143] Item 16. The antibody construct according to any one of items 1 to 15, wherein the first domain that binds to BCMA comprises a VL region having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NOs: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98, 108, 118, 128, 138, 148, 158, 168, 178, 188, 198, 208, 218, 228, 238, 248, 258, 268, 278, 288, 298, 308, 318, 328, 338, 348, 358, 368, 378, 388, 398, 408, 418, 428, 438, 448, 458, 468, 478, 488, 498, 508, 518 and 528.
[0144] Item 17. The first domain that binds to BCMA is (1) a VH region as set forth in SEQ ID NO:7 and a VL region as set forth in SEQ ID NO:8; (2) a VH region as set forth in SEQ ID NO:17 and a VL region as set forth in SEQ ID NO:18; (3) a VH region as set forth in SEQ ID NO:27 and a VL region as set forth in SEQ ID NO:28; (4) a VH region as set forth in SEQ ID NO:37 and a VL region as set forth in SEQ ID NO:38; (5) a VH region as set forth in SEQ ID NO:47 and a VL region as set forth in SEQ ID NO:48; (6) a VH region as set forth in SEQ ID NO:57 and a VL region as set forth in SEQ ID NO:58; (7) a VH region as set forth in SEQ ID NO:67 and a VL region as set forth in SEQ ID NO:68; (8) a VH region as set forth in SEQ ID NO: 77 and a VL region as set forth in SEQ ID NO: 78; (9) a VH region as set forth in SEQ ID NO: 87 and a VL region as set forth in SEQ ID NO: 88; (10) a VH region as set forth in SEQ ID NO: 97 and a VL region as set forth in SEQ ID NO: 98; (11) a VH region as set forth in SEQ ID NO: 107 and a VL region as set forth in SEQ ID NO: 108; (12) a VH region as set forth in SEQ ID NO: 117 and a VL region as set forth in SEQ ID NO: 118; (13) a VH region as set forth in SEQ ID NO: 127 and a VL region as set forth in SEQ ID NO: 128; (14) a VH region as set forth in SEQ ID NO: 137 and a VL region as set forth in SEQ ID NO: 138; (15) a VH region as set forth in SEQ ID NO: 147 and a VL region as set forth in SEQ ID NO: 148; (16) a VH region as set forth in SEQ ID NO: 157 and a VL region as set forth in SEQ ID NO: 158; (17) a VH region as set forth in SEQ ID NO: 167 and a VL region as set forth in SEQ ID NO: 168; (18) a VH region as set forth in SEQ ID NO: 177 and a VL region as set forth in SEQ ID NO: 178; (19) a VH region as set forth in SEQ ID NO: 187 and a VL region as set forth in SEQ ID NO: 188; (20) a VH region as set forth in SEQ ID NO: 197 and a VL region as set forth in SEQ ID NO: 198; (21) a VH region as set forth in SEQ ID NO: 207 and a VL region as set forth in SEQ ID NO: 208; (22) a VH region as set forth in SEQ ID NO: 217 and a VL region as set forth in SEQ ID NO: 218; (23) a VH region as set forth in SEQ ID NO: 227 and a VL region as set forth in SEQ ID NO: 228; (24) a VH region as set forth in SEQ ID NO: 237 and a VL region as set forth in SEQ ID NO: 238; (25) a VH region as set forth in SEQ ID NO: 247 and a VL region as set forth in SEQ ID NO: 248; (26) a VH region as set forth in SEQ ID NO: 257 and a VL region as set forth in SEQ ID NO: 258; (27) a VH region as set forth in SEQ ID NO: 267 and a VL region as set forth in SEQ ID NO: 268; (28) a VH region as set forth in SEQ ID NO: 277 and a VL region as set forth in SEQ ID NO: 278; (29) a VH region as set forth in SEQ ID NO: 287 and a VL region as set forth in SEQ ID NO: 288; (30) a VH region as set forth in SEQ ID NO: 297 and a VL region as set forth in SEQ ID NO: 298; (31) a VH region as set forth in SEQ ID NO: 307 and a VL region as set forth in SEQ ID NO: 308; (32) the VH region as set forth in SEQ ID NO: 317 and the VL region as set forth in SEQ ID NO: 318; (33) a VH region as set forth in SEQ ID NO: 327 and a VL region as set forth in SEQ ID NO: 328; (34) a VH region as set forth in SEQ ID NO: 337 and a VL region as set forth in SEQ ID NO: 338; (35) a VH region as set forth in SEQ ID NO: 347 and a VL region as set forth in SEQ ID NO: 348; (36) the VH region as set forth in SEQ ID NO: 357 and the VL region as set forth in SEQ ID NO: 358; (37) a VH region as set forth in SEQ ID NO: 367 and a VL region as set forth in SEQ ID NO: 368; (38) the VH region as set forth in SEQ ID NO: 377 and the VL region as set forth in SEQ ID NO: 378; (39) the VH region as set forth in SEQ ID NO: 387 and the VL region as set forth in SEQ ID NO: 388; (40) the VH region as set forth in SEQ ID NO: 397 and the VL region as set forth in SEQ ID NO: 398; (41) The VH region as set forth in SEQ ID NO: 407 and the VL region as set forth in SEQ ID NO: 408; (42) the VH region as set forth in SEQ ID NO: 417 and the VL region as set forth in SEQ ID NO: 418; (43) the VH region as set forth in SEQ ID NO: 427 and the VL region as set forth in SEQ ID NO: 428; (44) the VH region as set forth in SEQ ID NO: 437 and the VL region as set forth in SEQ ID NO: 438; (45) the VH region as set forth in SEQ ID NO: 447 and the VL region as set forth in SEQ ID NO: 448; (46) the VH region as set forth in SEQ ID NO: 457 and the VL region as set forth in SEQ ID NO: 458; (47) The VH region as set forth in SEQ ID NO: 467 and the VL region as set forth in SEQ ID NO: 468; (48) the VH region as set forth in SEQ ID NO: 477 and the VL region as set forth in SEQ ID NO: 478; (49) The VH region as set forth in SEQ ID NO: 487 and the VL region as set forth in SEQ ID NO: 488; (50) the VH region as set forth in SEQ ID NO: 497 and the VL region as set forth in SEQ ID NO: 498; (51) The VH region as set forth in SEQ ID NO: 507 and the VL region as set forth in SEQ ID NO: 508; (52) the VH region as set forth in SEQ ID NO: 517 and the VL region as set forth in SEQ ID NO: 518; and (53) The VH region as set forth in SEQ ID NO: 527 and the VL region as set forth in SEQ ID NO: 528. 17. The antibody construct according to any one of items 1 to 16, comprising a VH domain and a VL domain selected from the group consisting of:
[0145] Item 18. The antibody construct according to any one of items 1 to 17, wherein the first domain that binds to BCMA comprises or consists of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 9, 19, 29, 39, 49, 59, 69, 79, 89, 109, 129, 139, 149, 159, 169, 179, 189, 199, 209, 219, 229, 239, 249, 259, 269, 279, 289, 299, 309, 319, 329, 339, 349, 359, 369, 379, 389, 399, 409, 419, 429, 439, 449, 459, 469, 479, 489, 499, 519 and 529.
[0146] Item 19. The second domain that binds to CD3 is (a) CDR-L1 as set forth in SEQ ID NO:542, CDR-L2 as set forth in SEQ ID NO:543, and CDR-L3 as set forth in SEQ ID NO:544; (b) CDR-L1 as set forth in SEQ ID NO: 599, CDR-L2 as set forth in SEQ ID NO: 600, and CDR-L3 as set forth in SEQ ID NO: 601; and (c) CDR-L1 as set forth in SEQ ID NO: 621, CDR-L2 as set forth in SEQ ID NO: 622, and CDR-L3 as set forth in SEQ ID NO: 623. 19. The antibody construct according to any one of items 1 to 18, comprising a VL region comprising CDR-L1, CDR-L2 and CDR-L3 selected from the group consisting of:
[0147] Item 20. The second domain that binds to CD3 is (a) CDR-H1 as set forth in SEQ ID NO:534, CDR-H2 as set forth in SEQ ID NO:535, and CDR-H3 as set forth in SEQ ID NO:536; (b) CDR-H1 as set forth in SEQ ID NO:545, CDR-H2 as set forth in SEQ ID NO:546, and CDR-H3 as set forth in SEQ ID NO:547; (c) CDR-H1 as set forth in SEQ ID NO: 557, CDR-H2 as set forth in SEQ ID NO: 558, and CDR-H3 as set forth in SEQ ID NO: 559; (d) CDR-H1 as set forth in SEQ ID NO: 568, CDR-H2 as set forth in SEQ ID NO: 569, and CDR-H3 as set forth in SEQ ID NO: 570; (e) CDR-H1 as set forth in SEQ ID NO: 579, CDR-H2 as set forth in SEQ ID NO: 580, and CDR-H3 as set forth in SEQ ID NO: 581; (f) CDR-H1 as set forth in SEQ ID NO:591, CDR-H2 as set forth in SEQ ID NO:592, and CDR-H3 as set forth in SEQ ID NO:593; (g) CDR-H1 as set forth in SEQ ID NO:602, CDR-H2 as set forth in SEQ ID NO:603, and CDR-H3 as set forth in SEQ ID NO:604; (h) CDR-H1 as set forth in SEQ ID NO:613, CDR-H2 as set forth in SEQ ID NO:614, and CDR-H3 as set forth in SEQ ID NO:615; (i) CDR-H1 as set forth in SEQ ID NO: 624, CDR-H2 as set forth in SEQ ID NO: 625, and CDR-H3 as set forth in SEQ ID NO: 626; and (j) CDR-H1 as set forth in SEQ ID NO: 636, CDR-H2 as set forth in SEQ ID NO: 637, and CDR-H3 as set forth in SEQ ID NO: 638. 20. The antibody construct according to any one of items 1 to 19, comprising a VH region comprising CDR-H1, CDR-H2 and CDR-H3 selected from the group consisting of:
[0148] Item 21. The second domain that binds to CD3 is (a) CDR-L1 as set forth in SEQ ID NO: 531, CDR-L2 as set forth in SEQ ID NO: 532, CDR-L3 as set forth in SEQ ID NO: 533, CDR-H1 as set forth in SEQ ID NO: 534, CDR-H2 as set forth in SEQ ID NO: 535, and CDR-H3 as set forth in SEQ ID NO: 536; (b) CDR-L1 as set forth in SEQ ID NO: 542, CDR-L2 as set forth in SEQ ID NO: 543, CDR-L3 as set forth in SEQ ID NO: 544, CDR-H1 as set forth in SEQ ID NO: 545, CDR-H2 as set forth in SEQ ID NO: 546, and CDR-H3 as set forth in SEQ ID NO: 547; (c) CDR-L1 as set forth in SEQ ID NO: 554, CDR-L2 as set forth in SEQ ID NO: 555, CDR-L3 as set forth in SEQ ID NO: 556, CDR-H1 as set forth in SEQ ID NO: 557, CDR-H2 as set forth in SEQ ID NO: 558, and CDR-H3 as set forth in SEQ ID NO: 559; (d) CDR-L1 as set forth in SEQ ID NO:565, CDR-L2 as set forth in SEQ ID NO:566, CDR-L3 as set forth in SEQ ID NO:567, CDR-H1 as set forth in SEQ ID NO:568, CDR-H2 as set forth in SEQ ID NO:569, and CDR-H3 as set forth in SEQ ID NO:570; (e) CDR-L1 as set forth in SEQ ID NO: 576, CDR-L2 as set forth in SEQ ID NO: 577, CDR-L3 as set forth in SEQ ID NO: 578, CDR-H1 as set forth in SEQ ID NO: 579, CDR-H2 as set forth in SEQ ID NO: 580, and CDR-H3 as set forth in SEQ ID NO: 581; (f) CDR-L1 as set forth in SEQ ID NO:588, CDR-L2 as set forth in SEQ ID NO:589, CDR-L3 as set forth in SEQ ID NO:590, CDR-H1 as set forth in SEQ ID NO:591, CDR-H2 as set forth in SEQ ID NO:592, and CDR-H3 as set forth in SEQ ID NO:593; (g) CDR-L1 as set forth in SEQ ID NO:599, CDR-L2 as set forth in SEQ ID NO:600, CDR-L3 as set forth in SEQ ID NO:601, CDR-H1 as set forth in SEQ ID NO:602, CDR-H2 as set forth in SEQ ID NO:603, and CDR-H3 as set forth in SEQ ID NO:604; (h) CDR-L1 as set forth in SEQ ID NO:610, CDR-L2 as set forth in SEQ ID NO:611, CDR-L3 as set forth in SEQ ID NO:612, CDR-H1 as set forth in SEQ ID NO:613, CDR-H2 as set forth in SEQ ID NO:614, and CDR-H3 as set forth in SEQ ID NO:615; (i) CDR-L1 as set forth in SEQ ID NO: 621, CDR-L2 as set forth in SEQ ID NO: 622, CDR-L3 as set forth in SEQ ID NO: 623, CDR-H1 as set forth in SEQ ID NO: 624, CDR-H2 as set forth in SEQ ID NO: 625, and CDR-H3 as set forth in SEQ ID NO: 626; and (j) CDR-L1 as set forth in SEQ ID NO: 633, CDR-L2 as set forth in SEQ ID NO: 634, CDR-L3 as set forth in SEQ ID NO: 635, CDR-H1 as set forth in SEQ ID NO: 636, CDR-H2 as set forth in SEQ ID NO: 637, and CDR-H3 as set forth in SEQ ID NO: 638. 21. The antibody construct according to any one of items 1 to 20, comprising a VL region comprising CDR-L1, CDR-L2 and CDR-L3, and a VH region comprising CDR-H1, CDR-H2 and CDR-H3, selected from the group consisting of:
[0149] Item 22. The antibody construct according to any one of Items 1 to 21, wherein the second domain that binds to CD3 comprises a VL region having an amino acid sequence selected from the group consisting of those shown in SEQ ID NO: 550, SEQ ID NO: 551, SEQ ID NO: 584, SEQ ID NO: 585, SEQ ID NO: 629 and SEQ ID NO: 630.
[0150] Item 23. The antibody construct according to any one of Items 1 to 22, wherein the second domain binding to CD3 comprises a VH region having an amino acid sequence selected from the group consisting of those shown in SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 548, SEQ ID NO: 549, SEQ ID NO: 560, SEQ ID NO: 561, SEQ ID NO: 571, SEQ ID NO: 572, SEQ ID NO: 582, SEQ ID NO: 583, SEQ ID NO: 594, SEQ ID NO: 595, SEQ ID NO: 605, SEQ ID NO: 606, SEQ ID NO: 616, SEQ ID NO: 617, SEQ ID NO: 627, SEQ ID NO: 628, SEQ ID NO: 639, SEQ ID NO: 640 and SEQ ID NO: 644.
[0151] Item 24. The second domain that binds to CD3 is (a) a VL region as set forth in SEQ ID NO: 539 or 521 and a VH region as set forth in SEQ ID NO: 537 or 538; (b) a VL region as set forth in SEQ ID NO: 550 or 521 and a VH region as set forth in SEQ ID NO: 548 or 549; (c) a VL region as set forth in SEQ ID NO: 562 or 521 and a VH region as set forth in SEQ ID NO: 560 or 561; (d) a VL region as set forth in SEQ ID NO: 573 or 521 and a VH region as set forth in SEQ ID NO: 571 or 572; (e) a VL region as set forth in SEQ ID NO: 584 or 585 and a VH region as set forth in SEQ ID NO: 582 or 583; (f) a VL region as set forth in SEQ ID NO: 596 or 521 and a VH region as set forth in SEQ ID NO: 594 or 595; (g) a VL region as set forth in SEQ ID NO: 607 or 585 and a VH region as set forth in SEQ ID NO: 605 or 606; (h) a VL region as set forth in SEQ ID NO: 618 or 521 and a VH region as set forth in SEQ ID NO: 616 or 617; (i) a VL region as set forth in SEQ ID NO: 629 or 630 and a VH region as set forth in SEQ ID NO: 627 or 628; (j) a VL region as set forth in SEQ ID NO: 641 or 630 and a VH region as set forth in SEQ ID NO: 639 or 640; and (k) a VL region as set forth in SEQ ID NO: 645 and a VH region as set forth in SEQ ID NO: 644 24. The antibody construct according to any one of items 1 to 23, comprising a VL region and a VH region selected from the group consisting of:
[0152] Item 25. The antibody construct according to any one of items 1 to 24, wherein the second domain that binds to CD3 comprises or consists of a polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NOs: 540, 541, 552, 553, 563, 564, 574, 575, 586, 587, 597, 598, 608, 609, 619, 620, 631, 632, 642, 643 and 646.
[0153] Item 26. The antibody construct according to any one of items 1 to 25, comprising a polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NOs: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530 and 661.
[0154] Item 27. The antibody construct according to any one of Items 1 to 26, having a molecular weight of about 20 to about 90 kDa, about 30 to about 80 kDa, about 40 to about 70 kDa, about 50 to about 60 kDa, about 52 to about 58 kDa, preferably about 54 to about 56 kDa.
[0155] Item 28. Elimination half-life (T 1 / 2 28. The antibody construct according to any one of items 1 to 27,
[0156] As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a reagent" includes one or more of such various reagents, and reference to "a method" includes reference to equivalent steps and methods known to those of skill in the art that may be modified or substituted for the methods described herein.
[0157] Unless otherwise indicated, the term "at least" preceding a series of elements should be understood to refer to every element in the series. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by this invention.
[0158] The term "and / or", wherever used in this specification, includes the meanings "and", "or" and "any other combination of the elements connected by said term".
[0159] The terms "about" or "approximately" as used herein mean within ±20%, preferably within ±15%, more preferably within ±10%, and most preferably within ±5% of a given value or range, including specific values, for example, "about 50" includes the value "50."
[0160] Throughout this specification and claims, unless the context otherwise requires, the words "comprise" and variations such as "comprises" and "comprising" will be understood to imply the inclusion of a stated whole or step or whole or steps, but not the exclusion of any other whole or step or whole or steps. As used herein, the term "comprising" can be substituted with the terms "containing" or "including" or, as sometimes used herein, the term "having."
[0161] As used herein, "consisting of" excludes any element, step, or ingredient not specified in the claim component. As used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim.
[0162] In each instance herein, any of the terms "comprising," "consisting essentially of," and "consisting of" may be replaced with one of the other two terms.
[0163] The above description and the following examples provide exemplary configurations, however, it should be understood that the invention is not limited to the particular methodology, techniques, protocols, materials, reagents, substances, etc. described herein, as such may vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention, which is defined solely by the claims. Aspects of the invention are provided in the independent claims. Some optional features of the invention are provided in the dependent claims.
[0164] All publications and patents cited throughout the text of this specification, whether supra or infra, including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc., are hereby incorporated by reference in their entirety. Nothing herein should be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention. To the extent that material incorporated by reference is inconsistent or inconsistent with the present specification, the present specification will take precedence over any such material.
[0165] A better understanding of the present invention and its advantages will be had from the following examples, which are provided for illustrative purposes only and are not intended, and should not be construed, as limiting the scope of the invention in any way. EXAMPLES
[0166] 1. Clinical Trial Research Protocol AMG420 was administered as a continuous IV (cIV) infusion for 4 weeks, followed by a 2-week treatment holiday with dose escalation ranging from 0.2 μg / day to 800 μg / day. A single patient cohort (0.2 μg / day-0.4 μg / day-0.8 μg / day-1.6 μg / day) was followed by cohorts of 3 to 6 patients (3.2 μg / day-6.5 μg / day-13 μg / day-25 μg / day-50 μg / day-100 μg / day-200 μg / day-400 μg / day-800 μg / day). Overall, 13 dose cohorts were completed. Treatment was continued for up to five 4-weeks-on / 2-weeks-off cycles. Five additional cycles were given if clinical benefit was observed. Eligible patients were aged 18 years or older and had relapsed / refractory MM and progression after ≥3 prior lines of therapy (including both ≥1 proteasome inhibitor and ≥1 immunomodulatory agent = IMiD). For this study, MRD response was defined as <1 tumor cell / 10 in bone marrow per FACS using antibodies against cytIgλ, cytIgκ, CD19, CD56 or CD138, CD38 and CD45. 4 were defined as normal cells.
[0167] 2.Results Thirty-five patients received AMG 420 (0.2-800 μg / day). The mean (SD) age was 63.8 (8.7) years, the median age was 65 years, and the minimum-maximum age was 39-79 years. Twenty-two (63%) of the patients were male. Two patients completed 10 cycles. The 35 patients were treated with a mean (SD) of 2.3 (2.3) cycles and a median (min-max) of 1 (1-10) cycles. Responders (n=8) were treated with a mean (SD) of 6.8 (4.5) cycles and a median (min-max) of 3.5 (2-10) cycles.
[0168] Anti-AMG420 antibodies were not detected up to and including 800 μg / day, and no dose-limiting toxicities (DLTs) were observed up to 400 μg / day. Two of three patients receiving 800 μg / day AMG420 experienced DLTs: one patient with grade 3 cytokine release syndrome (CRS) within 1 day of starting treatment with fever, hypertension, tachycardia, and retrograde amnesia (symptoms resolved after stopping the drug); and one patient with grade 3 polyneuropathy (PPN) requiring hospitalization and subsequent full recovery. In the latter case, M-protein was reduced by 60% after 15 days of treatment.
[0169] Six patients had a complete response (CR) as assessed using IMWG response criteria: one patient each at 6.5 μg / day, 100 μg / day, and 200 μg / day and three patients at 400 μg / day; the responses in these last three patients were ongoing (>4.6 months). There were also two partial responses: one partial response (PR) at 50 μg / day and one very good partial response (VGPR) at 800 μg / day. Response duration was up to 8 cycles: one patient had a partial response at cycles 3-10. Four of the six subjects in CR were MRD negative: one patient at 200 μg / day and three patients, all at 400 μg / day. In an additional dose confirmation cohort (400 μg / day), two of three patients had a PR at cycle 1. Thus, at a dose of 400 μg / day, the objective response rate (ORR) was 5 / 6; and all five patients responded with at least 2 months (ongoing treatment) and up to 7 months or more (ongoing treatment).
[0170] After cIV infusion of AMG420, free steady-state concentrations (Css) were reached in approximately 2 days and remained stable for the duration of the infusion. Mean free AMG420 Css values generally increased with increasing doses of AMG420.
[0171] 3. Updated Results The next results update will include the results above (item 2) and add information on additional patients treated with AMG420 as described in the clinical trial study protocol (item 1). 42 patients received AMG420 at 0.2-800 μg / day. Median age was 65 years and median disease duration was 5.2 years. 64% of patients were male. Patients were treated for a median (range) 1 (1-10) cycles. Responders were treated for a median (range) 7 (1-10) cycles. Eight patients completed 5 cycles and have since either completed 10 cycles (n=3), discontinued (n=3), or are still on treatment (n=2). No anti-AMG420 antibodies were detected in any patient.
[0172] CR, PR, and VGPR were evaluated using IMWG response criteria. During dose escalation, responses were evident beginning at 6.5 μg / day (one CR at this dose level). There was one PR at 50 μg / day, a CR at 100 μg / day, and an MRD-negative CR at 200 μg / day. At 400 μg / day, the response rate was 70% (7 / 10), including five MRD-negative CRs (50%), one VGPR, and one PR. Thus, at the 400 μg / day dose, the objective response rate (ORR) was 7 / 10 (70%). All seven patients responded in the first cycle, and some responses lasted for more than a year. Responses at this dose lasted for at least a median of 9.0 months (range, 5.8-13.6+ months), with two patients continuing treatment. Overall, at data cutoff, six patients had an MRD-negative CR (one at 200 μg / day and five at 400 μg / day), three more CRs (6.5, 100, and 800 μg / day), two VGPRs (400 and 800 μg / day), and two PRs (50 and 400 μg / day). The median time to any response was one month, with 11 of the 13 responding patients (i.e., all responders receiving ≥100 μg / day) responding in the first cycle. Best responses occurred during cycle 1 (n=4), cycle 2 (n=2), cycle 3 (n=5), or follow-up (n=2). Responses lasted at least a median of 8.4 months (range, 2.5-15.5 months) and lasted for more than a year in three patients: responses were ongoing at last observation in 7 / 13 patients. For the three patients with posttreatment data, the responses continued for up to 11 months after treatment at last observation. In one case, a patient who discontinued treatment 2 weeks after polyneuropathy developed a CR almost 9 months later. MRD-negative responses lasted a median of 9.6 months (range, 2.8-12.8 months). Responses were seen in patients in all cytogenetic risk categories, including 5 / 13 responders with high-risk cytogenetics.
[0173] In this study, 800 μg / day was deemed intolerable due to grade 3 cytokine release syndrome and grade 3 polyneuropathy, both of which resolved. These DLTs were seen in 2 of 3 patients at 800 μg / day.
[0174] Examination of baseline cell surface BCMA expression revealed that BCMA was expressed on myeloma cells in all patients, with no differences in expression levels by response status, and there were no differences between responders and non-responders in the percentage of bone marrow plasma cells or bone marrow myeloma cells that were BCMA positive at baseline.
[0175] The IMWG response criteria for complete response (see also http: / / imwg.myeloma.org / international-myeloma-working-group-imwg-uniform-response-criteria-for-multiple-myeloma / ) are: Negative M protein immunofixation in serum and urine; Disappearance of soft tissue plasmacytomas, and Fewer than 5% plasma cells in bone marrow It is.
[0176] The IMWG response criteria for partial response are: M-protein electrophoresis: Serum M-protein is reduced by 50% or more, and urinary M-protein is reduced by 90% or more within 24 hours or to less than 200 mg / 24 hours Free light chains (FLC): If serum and urine M-protein are not measurable, a 50% or greater reduction in the difference between involved and uninvolved FLC levels is required in lieu of the M-protein criterion. If serum and urine M protein cannot be measured and serum-free photoassay cannot be measured: If baseline bone marrow plasma cell percentage was 30% or higher, plasma cell reduction of 50% or higher is required to replace M protein. In addition to the above criteria, a 50% or greater reduction in size of soft tissue plasmacytoma, if present at baseline, is also required.
[0177] The IMWG response criteria for very good partial response were: Serum and urinary M-protein detectable by immunofixation but not by electrophoresis, or ≥90% reduction in serum M-protein + urinary M-protein levels <100mg / 24 hours It is.
Claims
1. 1. An antibody construct comprising a first domain that binds to BCMA and a second domain that binds to CD3 for use in treating or ameliorating a BCMA positive neoplasm, the antibody construct being administered at a dose of 6.5 μg / day to a maximum of 650 μg / day in at least one cycle, wherein one cycle comprises a period of administration of the antibody construct of at least 7 consecutive days.
2. The antibody construct of claim 1 , administered for 2, 3, 4, 5, 6, 7, 8, 9 or 10 cycles.
3. The antibody construct of claim 1 or 2, wherein one cycle comprises a period of administration of the antibody construct followed by a period of no administration of the antibody construct.
4. The antibody construct according to any one of claims 1 to 3, wherein the administration period of the antibody construct is from 1 to 8 weeks, preferably from 2 to 6 weeks, more preferably from 25 to 30 days.
5. The antibody construct of claim 3 or 4, wherein the period without administration of the antibody construct is at least 7 consecutive days.
6. The antibody construct according to any one of claims 3 to 6, wherein the administration-free period of the antibody construct is from 1 week to 3 months, preferably from 1 week to 2 months, more preferably from 1 week to 1 month.
7. The antibody construct of any one of claims 1 to 6, wherein the dose of the antibody construct is constant during each cycle.
8. The antibody construct of any one of claims 1 to 7, wherein the dose of the antibody construct is constant during each cycle and from one cycle to a subsequent cycle.
9. The antibody construct according to any one of claims 1 to 8, which is administered parenterally, preferably intravenously, more preferably via continuous intravenous administration.
10. The antibody construct of any one of claims 1 to 9, wherein the BCMA positive neoplasm is selected from the group consisting of multiple myeloma, relapsed and / or refractory multiple myeloma, heavy chain multiple myeloma, light chain multiple myeloma, extramedullary myeloma, plasmacytoma, plasma cell leukemia, Waldenstrom's macroglobulinemia and smoldering myeloma.
11. a) is a single chain polypeptide, b) said first domain is in scFv format; c) said second domain is in scFv format; and / or d) The antibody construct according to any one of claims 1 to 10, wherein the first domain and the second domain are connected via a linker, preferably a peptide linker, more preferably a glycine / serine linker.
12. a) an antibody or antibody construct comprising a domain that binds to BCMA on the surface of a target cell, said domain comprising a VH region comprising CDR-H1 as set forth in SEQ ID NO: 171, CDR-H2 as set forth in SEQ ID NO: 172 and CDR-H3 as set forth in SEQ ID NO: 173, and a VL region comprising CDR-L1 as set forth in SEQ ID NO: 174, CDR-L2 as set forth in SEQ ID NO: 175 and CDR-L3 as set forth in SEQ ID NO: 176; b) an antibody or antibody construct comprising a domain that binds to BCMA on the surface of a target cell, said domain comprising a VH region as set forth in SEQ ID NO: 177 and a VL region as set forth in SEQ ID NO: 178; c) an antibody construct comprising a domain that binds to BCMA on the surface of a target cell, said domain comprising an amino acid sequence as set forth in SEQ ID NO: 179; or d) An antibody construct having an amino acid sequence as set forth in SEQ ID NO:
661.
12. The antibody construct of claim 1, which competes for binding to BCMA with or binds to the same epitope on BCMA as said antibody construct.
13. a) an antibody or antibody construct comprising a domain that binds to CD3 on the surface of a T cell, said domain comprising a VH region comprising CDR-H1 as set forth in SEQ ID NO: 636, CDR-H2 as set forth in SEQ ID NO: 637 and CDR-H3 as set forth in SEQ ID NO: 638, and a VL region comprising CDR-L1 as set forth in SEQ ID NO: 633, CDR-L2 as set forth in SEQ ID NO: 634, CDR-L3 as set forth in SEQ ID NO: 635; b) an antibody or antibody construct comprising a domain that binds to CD3 on the surface of a T cell, said domain comprising a VH region as set forth in SEQ ID NO: 639 and a VL region as set forth in SEQ ID NO: 641; c) an antibody construct comprising a domain that binds to CD3 on the surface of a T cell, said domain comprising an amino acid sequence as set forth in SEQ ID NO: 642; or d) An antibody construct having an amino acid sequence as set forth in SEQ ID NO:
661.
13. The antibody construct of claim 1, which competes for binding to CD3 with or binds to the same epitope on CD3 as said antibody construct.
14. The first domain that binds to BCMA is (1) CDR-H1 as set forth in SEQ ID NO:1, CDR-H2 as set forth in SEQ ID NO:2, CDR-H3 as set forth in SEQ ID NO:3, CDR-L1 as set forth in SEQ ID NO:4, CDR-L2 as set forth in SEQ ID NO:5, and CDR-L3 as set forth in SEQ ID NO:6; (2) CDR-H1 as set forth in SEQ ID NO:11, CDR-H2 as set forth in SEQ ID NO:12, CDR-H3 as set forth in SEQ ID NO:13, CDR-L1 as set forth in SEQ ID NO:14, CDR-L2 as set forth in SEQ ID NO:15, and CDR-L3 as set forth in SEQ ID NO:16; (3) CDR-H1 as set forth in SEQ ID NO:21, CDR-H2 as set forth in SEQ ID NO:22, CDR-H3 as set forth in SEQ ID NO:23, CDR-L1 as set forth in SEQ ID NO:24, CDR-L2 as set forth in SEQ ID NO:25, and CDR-L3 as set forth in SEQ ID NO:26; (4) CDR-H1 as set forth in SEQ ID NO:31, CDR-H2 as set forth in SEQ ID NO:32, CDR-H3 as set forth in SEQ ID NO:33, CDR-L1 as set forth in SEQ ID NO:34, CDR-L2 as set forth in SEQ ID NO:35, and CDR-L3 as set forth in SEQ ID NO:36; (5) CDR-H1 as set forth in SEQ ID NO: 41, CDR-H2 as set forth in SEQ ID NO: 42, CDR-H3 as set forth in SEQ ID NO: 43, CDR-L1 as set forth in SEQ ID NO: 44, CDR-L2 as set forth in SEQ ID NO: 45, and CDR-L3 as set forth in SEQ ID NO: 46; (6) CDR-H1 as set forth in SEQ ID NO:51, CDR-H2 as set forth in SEQ ID NO:52, CDR-H3 as set forth in SEQ ID NO:53, CDR-L1 as set forth in SEQ ID NO:54, CDR-L2 as set forth in SEQ ID NO:55, and CDR-L3 as set forth in SEQ ID NO:56; (7) CDR-H1 as set forth in SEQ ID NO:61, CDR-H2 as set forth in SEQ ID NO:62, CDR-H3 as set forth in SEQ ID NO:63, CDR-L1 as set forth in SEQ ID NO:64, CDR-L2 as set forth in SEQ ID NO:65, and CDR-L3 as set forth in SEQ ID NO:66; (8) CDR-H1 as set forth in SEQ ID NO: 71, CDR-H2 as set forth in SEQ ID NO: 72, CDR-H3 as set forth in SEQ ID NO: 73, CDR-L1 as set forth in SEQ ID NO: 74, CDR-L2 as set forth in SEQ ID NO: 75, and CDR-L3 as set forth in SEQ ID NO: 76; (9) CDR-H1 as set forth in SEQ ID NO: 81, CDR-H2 as set forth in SEQ ID NO: 82, CDR-H3 as set forth in SEQ ID NO: 83, CDR-L1 as set forth in SEQ ID NO: 84, CDR-L2 as set forth in SEQ ID NO: 85, and CDR-L3 as set forth in SEQ ID NO: 86; (10) CDR-H1 as set forth in SEQ ID NO: 91, CDR-H2 as set forth in SEQ ID NO: 92, CDR-H3 as set forth in SEQ ID NO: 93, CDR-L1 as set forth in SEQ ID NO: 94, CDR-L2 as set forth in SEQ ID NO: 95, and CDR-L3 as set forth in SEQ ID NO: 96; (11) CDR-H1 as set forth in SEQ ID NO: 101, CDR-H2 as set forth in SEQ ID NO: 102, CDR-H3 as set forth in SEQ ID NO: 103, CDR-L1 as set forth in SEQ ID NO: 104, CDR-L2 as set forth in SEQ ID NO: 105, and CDR-L3 as set forth in SEQ ID NO: 106; (12) CDR-H1 as set forth in SEQ ID NO:111, CDR-H2 as set forth in SEQ ID NO:112, CDR-H3 as set forth in SEQ ID NO:113, CDR-L1 as set forth in SEQ ID NO:114, CDR-L2 as set forth in SEQ ID NO:115, and CDR-L3 as set forth in SEQ ID NO:116; (13) CDR-H1 as set forth in SEQ ID NO: 121, CDR-H2 as set forth in SEQ ID NO: 122, CDR-H3 as set forth in SEQ ID NO: 123, CDR-L1 as set forth in SEQ ID NO: 124, CDR-L2 as set forth in SEQ ID NO: 125, and CDR-L3 as set forth in SEQ ID NO: 126; (14) CDR-H1 as set forth in SEQ ID NO: 131, CDR-H2 as set forth in SEQ ID NO: 132, CDR-H3 as set forth in SEQ ID NO: 133, CDR-L1 as set forth in SEQ ID NO: 134, CDR-L2 as set forth in SEQ ID NO: 135, and CDR-L3 as set forth in SEQ ID NO: 136; (15) CDR-H1 as set forth in SEQ ID NO: 141, CDR-H2 as set forth in SEQ ID NO: 142, CDR-H3 as set forth in SEQ ID NO: 143, CDR-L1 as set forth in SEQ ID NO: 144, CDR-L2 as set forth in SEQ ID NO: 145, and CDR-L3 as set forth in SEQ ID NO: 146; (16) CDR-H1 as set forth in SEQ ID NO: 151, CDR-H2 as set forth in SEQ ID NO: 152, CDR-H3 as set forth in SEQ ID NO: 153, CDR-L1 as set forth in SEQ ID NO: 154, CDR-L2 as set forth in SEQ ID NO: 155, and CDR-L3 as set forth in SEQ ID NO: 156; (17) CDR-H1 as set forth in SEQ ID NO: 161, CDR-H2 as set forth in SEQ ID NO: 162, CDR-H3 as set forth in SEQ ID NO: 163, CDR-L1 as set forth in SEQ ID NO: 164, CDR-L2 as set forth in SEQ ID NO: 165, and CDR-L3 as set forth in SEQ ID NO: 166; (18) CDR-H1 as set forth in SEQ ID NO: 171, CDR-H2 as set forth in SEQ ID NO: 172, CDR-H3 as set forth in SEQ ID NO: 173, CDR-L1 as set forth in SEQ ID NO: 174, CDR-L2 as set forth in SEQ ID NO: 175, and CDR-L3 as set forth in SEQ ID NO: 176; (19) CDR-H1 as set forth in SEQ ID NO: 181, CDR-H2 as set forth in SEQ ID NO: 182, CDR-H3 as set forth in SEQ ID NO: 183, CDR-L1 as set forth in SEQ ID NO: 184, CDR-L2 as set forth in SEQ ID NO: 185, and CDR-L3 as set forth in SEQ ID NO: 186; (20) CDR-H1 as set forth in SEQ ID NO: 191, CDR-H2 as set forth in SEQ ID NO: 192, CDR-H3 as set forth in SEQ ID NO: 193, CDR-L1 as set forth in SEQ ID NO: 194, CDR-L2 as set forth in SEQ ID NO: 195, and CDR-L3 as set forth in SEQ ID NO: 196; (21) CDR-H1 as set forth in SEQ ID NO:201, CDR-H2 as set forth in SEQ ID NO:202, CDR-H3 as set forth in SEQ ID NO:203, CDR-L1 as set forth in SEQ ID NO:204, CDR-L2 as set forth in SEQ ID NO:205, and CDR-L3 as set forth in SEQ ID NO:206; (22) CDR-H1 as set forth in SEQ ID NO:211, CDR-H2 as set forth in SEQ ID NO:212, CDR-H3 as set forth in SEQ ID NO:213, CDR-L1 as set forth in SEQ ID NO:214, CDR-L2 as set forth in SEQ ID NO:215, and CDR-L3 as set forth in SEQ ID NO:216; (23) CDR-H1 as set forth in SEQ ID NO:221, CDR-H2 as set forth in SEQ ID NO:222, CDR-H3 as set forth in SEQ ID NO:223, CDR-L1 as set forth in SEQ ID NO:224, CDR-L2 as set forth in SEQ ID NO:225, and CDR-L3 as set forth in SEQ ID NO:226; (24) CDR-H1 as set forth in SEQ ID NO:231, CDR-H2 as set forth in SEQ ID NO:232, CDR-H3 as set forth in SEQ ID NO:233, CDR-L1 as set forth in SEQ ID NO:234, CDR-L2 as set forth in SEQ ID NO:235, and CDR-L3 as set forth in SEQ ID NO:236; (25) CDR-H1 as set forth in SEQ ID NO:241, CDR-H2 as set forth in SEQ ID NO:242, CDR-H3 as set forth in SEQ ID NO:243, CDR-L1 as set forth in SEQ ID NO:244, CDR-L2 as set forth in SEQ ID NO:245, and CDR-L3 as set forth in SEQ ID NO:246; (26) CDR-H1 as set forth in SEQ ID NO:251, CDR-H2 as set forth in SEQ ID NO:252, CDR-H3 as set forth in SEQ ID NO:253, CDR-L1 as set forth in SEQ ID NO:254, CDR-L2 as set forth in SEQ ID NO:255, and CDR-L3 as set forth in SEQ ID NO:256; (27) CDR-H1 as set forth in SEQ ID NO:261, CDR-H2 as set forth in SEQ ID NO:262, CDR-H3 as set forth in SEQ ID NO:263, CDR-L1 as set forth in SEQ ID NO:264, CDR-L2 as set forth in SEQ ID NO:265, and CDR-L3 as set forth in SEQ ID NO:266; (28) CDR-H1 as set forth in SEQ ID NO:271, CDR-H2 as set forth in SEQ ID NO:272, CDR-H3 as set forth in SEQ ID NO:273, CDR-L1 as set forth in SEQ ID NO:274, CDR-L2 as set forth in SEQ ID NO:275, and CDR-L3 as set forth in SEQ ID NO:276; (29) CDR-H1 as set forth in SEQ ID NO:281, CDR-H2 as set forth in SEQ ID NO:282, CDR-H3 as set forth in SEQ ID NO:283, CDR-L1 as set forth in SEQ ID NO:284, CDR-L2 as set forth in SEQ ID NO:285, and CDR-L3 as set forth in SEQ ID NO:286; (30) CDR-H1 as set forth in SEQ ID NO:291, CDR-H2 as set forth in SEQ ID NO:292, CDR-H3 as set forth in SEQ ID NO:293, CDR-L1 as set forth in SEQ ID NO:294, CDR-L2 as set forth in SEQ ID NO:295, and CDR-L3 as set forth in SEQ ID NO:296; (31) CDR-H1 as set forth in SEQ ID NO: 301, CDR-H2 as set forth in SEQ ID NO: 302, CDR-H3 as set forth in SEQ ID NO: 303, CDR-L1 as set forth in SEQ ID NO: 304, CDR-L2 as set forth in SEQ ID NO: 305, and CDR-L3 as set forth in SEQ ID NO: 306; (32) CDR-H1 as set forth in SEQ ID NO: 311, CDR-H2 as set forth in SEQ ID NO: 312, CDR-H3 as set forth in SEQ ID NO: 313, CDR-L1 as set forth in SEQ ID NO: 314, CDR-L2 as set forth in SEQ ID NO: 315, and CDR-L3 as set forth in SEQ ID NO: 316; (33) CDR-H1 as set forth in SEQ ID NO: 321, CDR-H2 as set forth in SEQ ID NO: 322, CDR-H3 as set forth in SEQ ID NO: 323, CDR-L1 as set forth in SEQ ID NO: 324, CDR-L2 as set forth in SEQ ID NO: 325, and CDR-L3 as set forth in SEQ ID NO: 326; (34) CDR-H1 as set forth in SEQ ID NO: 331, CDR-H2 as set forth in SEQ ID NO: 332, CDR-H3 as set forth in SEQ ID NO: 333, CDR-L1 as set forth in SEQ ID NO: 334, CDR-L2 as set forth in SEQ ID NO: 335, and CDR-L3 as set forth in SEQ ID NO: 336; (35) CDR-H1 as set forth in SEQ ID NO: 341, CDR-H2 as set forth in SEQ ID NO: 342, CDR-H3 as set forth in SEQ ID NO: 343, CDR-L1 as set forth in SEQ ID NO: 344, CDR-L2 as set forth in SEQ ID NO: 345, and CDR-L3 as set forth in SEQ ID NO: 346; (36) CDR-H1 as set forth in SEQ ID NO: 351, CDR-H2 as set forth in SEQ ID NO: 352, CDR-H3 as set forth in SEQ ID NO: 353, CDR-L1 as set forth in SEQ ID NO: 354, CDR-L2 as set forth in SEQ ID NO: 355, and CDR-L3 as set forth in SEQ ID NO: 356; (37) CDR-H1 as set forth in SEQ ID NO: 361, CDR-H2 as set forth in SEQ ID NO: 362, CDR-H3 as set forth in SEQ ID NO: 363, CDR-L1 as set forth in SEQ ID NO: 364, CDR-L2 as set forth in SEQ ID NO: 365, and CDR-L3 as set forth in SEQ ID NO: 366; (38) CDR-H1 as set forth in SEQ ID NO: 371, CDR-H2 as set forth in SEQ ID NO: 372, CDR-H3 as set forth in SEQ ID NO: 373, CDR-L1 as set forth in SEQ ID NO: 374, CDR-L2 as set forth in SEQ ID NO: 375, and CDR-L3 as set forth in SEQ ID NO: 376; (39) CDR-H1 as set forth in SEQ ID NO: 381, CDR-H2 as set forth in SEQ ID NO: 382, CDR-H3 as set forth in SEQ ID NO: 383, CDR-L1 as set forth in SEQ ID NO: 384, CDR-L2 as set forth in SEQ ID NO: 385, and CDR-L3 as set forth in SEQ ID NO: 386; (40) CDR-H1 as set forth in SEQ ID NO:391, CDR-H2 as set forth in SEQ ID NO:392, CDR-H3 as set forth in SEQ ID NO:393, CDR-L1 as set forth in SEQ ID NO:394, CDR-L2 as set forth in SEQ ID NO:395, and CDR-L3 as set forth in SEQ ID NO:396; (41) CDR-H1 as set forth in SEQ ID NO: 401, CDR-H2 as set forth in SEQ ID NO: 402, CDR-H3 as set forth in SEQ ID NO: 403, CDR-L1 as set forth in SEQ ID NO: 404, CDR-L2 as set forth in SEQ ID NO: 405, and CDR-L3 as set forth in SEQ ID NO: 406; (42) CDR-H1 as set forth in SEQ ID NO:411, CDR-H2 as set forth in SEQ ID NO:412, CDR-H3 as set forth in SEQ ID NO:413, CDR-L1 as set forth in SEQ ID NO:414, CDR-L2 as set forth in SEQ ID NO:415, and CDR-L3 as set forth in SEQ ID NO:416; (43) CDR-H1 as set forth in SEQ ID NO: 421, CDR-H2 as set forth in SEQ ID NO: 422, CDR-H3 as set forth in SEQ ID NO: 423, CDR-L1 as set forth in SEQ ID NO: 424, CDR-L2 as set forth in SEQ ID NO: 425, and CDR-L3 as set forth in SEQ ID NO: 426; (44) CDR-H1 as set forth in SEQ ID NO: 431, CDR-H2 as set forth in SEQ ID NO: 432, CDR-H3 as set forth in SEQ ID NO: 433, CDR-L1 as set forth in SEQ ID NO: 434, CDR-L2 as set forth in SEQ ID NO: 435, and CDR-L3 as set forth in SEQ ID NO: 436; (45) CDR-H1 as set forth in SEQ ID NO: 441, CDR-H2 as set forth in SEQ ID NO: 442, CDR-H3 as set forth in SEQ ID NO: 443, CDR-L1 as set forth in SEQ ID NO: 444, CDR-L2 as set forth in SEQ ID NO: 445, and CDR-L3 as set forth in SEQ ID NO: 446; (46) CDR-H1 as set forth in SEQ ID NO:451, CDR-H2 as set forth in SEQ ID NO:452, CDR-H3 as set forth in SEQ ID NO:453, CDR-L1 as set forth in SEQ ID NO:454, CDR-L2 as set forth in SEQ ID NO:455, and CDR-L3 as set forth in SEQ ID NO:456; (47) CDR-H1 as set forth in SEQ ID NO: 461, CDR-H2 as set forth in SEQ ID NO: 462, CDR-H3 as set forth in SEQ ID NO: 463, CDR-L1 as set forth in SEQ ID NO: 464, CDR-L2 as set forth in SEQ ID NO: 465, and CDR-L3 as set forth in SEQ ID NO: 466; (48) CDR-H1 as set forth in SEQ ID NO:471, CDR-H2 as set forth in SEQ ID NO:472, CDR-H3 as set forth in SEQ ID NO:473, CDR-L1 as set forth in SEQ ID NO:474, CDR-L2 as set forth in SEQ ID NO:475, and CDR-L3 as set forth in SEQ ID NO:476; (49) CDR-H1 as set forth in SEQ ID NO:481, CDR-H2 as set forth in SEQ ID NO:482, CDR-H3 as set forth in SEQ ID NO:483, CDR-L1 as set forth in SEQ ID NO:484, CDR-L2 as set forth in SEQ ID NO:485, and CDR-L3 as set forth in SEQ ID NO:486; (50) CDR-H1 as set forth in SEQ ID NO:491, CDR-H2 as set forth in SEQ ID NO:492, CDR-H3 as set forth in SEQ ID NO:493, CDR-L1 as set forth in SEQ ID NO:494, CDR-L2 as set forth in SEQ ID NO:495, and CDR-L3 as set forth in SEQ ID NO:496; (51) CDR-H1 as set forth in SEQ ID NO:501, CDR-H2 as set forth in SEQ ID NO:502, CDR-H3 as set forth in SEQ ID NO:503, CDR-L1 as set forth in SEQ ID NO:504, CDR-L2 as set forth in SEQ ID NO:505, and CDR-L3 as set forth in SEQ ID NO:506; (52) CDR-H1 as set forth in SEQ ID NO:511, CDR-H2 as set forth in SEQ ID NO:512, CDR-H3 as set forth in SEQ ID NO:513, CDR-L1 as set forth in SEQ ID NO:514, CDR-L2 as set forth in SEQ ID NO:515, and CDR-L3 as set forth in SEQ ID NO:516; and (53) CDR-H1 as set forth in SEQ ID NO:521, CDR-H2 as set forth in SEQ ID NO:522, CDR-H3 as set forth in SEQ ID NO:523, CDR-L1 as set forth in SEQ ID NO:524, CDR-L2 as set forth in SEQ ID NO:525, and CDR-L3 as set forth in SEQ ID NO:
526. The antibody construct of any one of claims 1 to 13, comprising a VH region comprising CDR-H1, CDR-H2 and CDR-H3, and a VL region comprising CDR-L1, CDR-L2 and CDR-L3, selected from:
15. The antibody construct of any one of claims 1 to 14, wherein the first domain that binds to BCMA comprises a VH region having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NOs: 7, 17, 27, 37, 47, 57, 67, 77, 87, 97, 107, 117, 127, 137, 147, 157, 167, 177, 187, 197, 207, 217, 227, 237, 247, 257, 267, 277, 287, 307, 317, 327, 337, 347, 357, 367, 377, 387, 397, 407, 417, 427, 437, 447, 457, 467, 477, 487, 497, 507, 517 and 527.
16. The antibody construct of any one of claims 1 to 15, wherein the first domain that binds to BCMA comprises a VL region having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NOs: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98, 108, 118, 128, 138, 148, 158, 168, 178, 188, 198, 208, 218, 228, 238, 248, 258, 268, 278, 288, 298, 308, 318, 328, 338, 348, 358, 368, 378, 388, 398, 408, 418, 428, 438, 448, 458, 468, 478, 488, 498, 508, 518 and 528.
17. The first domain that binds to BCMA is (1) a VH region as set forth in SEQ ID NO:7 and a VL region as set forth in SEQ ID NO:8; (2) a VH region as set forth in SEQ ID NO:17 and a VL region as set forth in SEQ ID NO:18; (3) a VH region as set forth in SEQ ID NO:27 and a VL region as set forth in SEQ ID NO:28; (4) a VH region as set forth in SEQ ID NO:37 and a VL region as set forth in SEQ ID NO:38; (5) a VH region as set forth in SEQ ID NO:47 and a VL region as set forth in SEQ ID NO:48; (6) a VH region as set forth in SEQ ID NO:57 and a VL region as set forth in SEQ ID NO:58; (7) a VH region as set forth in SEQ ID NO:67 and a VL region as set forth in SEQ ID NO:68; (8) a VH region as set forth in SEQ ID NO: 77 and a VL region as set forth in SEQ ID NO: 78; (9) a VH region as set forth in SEQ ID NO: 87 and a VL region as set forth in SEQ ID NO: 88; (10) a VH region as set forth in SEQ ID NO:97 and a VL region as set forth in SEQ ID NO:98; (11) A VH region as set forth in SEQ ID NO: 107 and a VL region as set forth in SEQ ID NO: 108; (12) a VH region as set forth in SEQ ID NO: 117 and a VL region as set forth in SEQ ID NO: 118; (13) A VH region as set forth in SEQ ID NO: 127 and a VL region as set forth in SEQ ID NO: 128; (14) A VH region as set forth in SEQ ID NO: 137 and a VL region as set forth in SEQ ID NO: 138; (15) A VH region as set forth in SEQ ID NO: 147 and a VL region as set forth in SEQ ID NO: 148; (16) A VH region as set forth in SEQ ID NO: 157 and a VL region as set forth in SEQ ID NO: 158; (17) A VH region as set forth in SEQ ID NO: 167 and a VL region as set forth in SEQ ID NO: 168; (18) A VH region as set forth in SEQ ID NO: 177 and a VL region as set forth in SEQ ID NO: 178; (19) A VH region as set forth in SEQ ID NO: 187 and a VL region as set forth in SEQ ID NO: 188; (20) a VH region as set forth in SEQ ID NO: 197 and a VL region as set forth in SEQ ID NO: 198; (21) A VH region as set forth in SEQ ID NO: 207 and a VL region as set forth in SEQ ID NO: 208; (22) A VH region as set forth in SEQ ID NO: 217 and a VL region as set forth in SEQ ID NO: 218; (23) A VH region as set forth in SEQ ID NO: 227 and a VL region as set forth in SEQ ID NO: 228; (24) A VH region as set forth in SEQ ID NO: 237 and a VL region as set forth in SEQ ID NO: 238; (25) A VH region as set forth in SEQ ID NO: 247 and a VL region as set forth in SEQ ID NO: 248; (26) A VH region as set forth in SEQ ID NO:257 and a VL region as set forth in SEQ ID NO:258; (27) A VH region as set forth in SEQ ID NO: 267 and a VL region as set forth in SEQ ID NO: 268; (28) A VH region as set forth in SEQ ID NO:277 and a VL region as set forth in SEQ ID NO:278; (29) A VH region as set forth in SEQ ID NO:287 and a VL region as set forth in SEQ ID NO:288; (30) a VH region as set forth in SEQ ID NO:297 and a VL region as set forth in SEQ ID NO:298; (31) A VH region as set forth in SEQ ID NO: 307 and a VL region as set forth in SEQ ID NO: 308; (32) the VH region as set forth in SEQ ID NO: 317 and the VL region as set forth in SEQ ID NO: 318; (33) A VH region as set forth in SEQ ID NO: 327 and a VL region as set forth in SEQ ID NO: 328; (34) A VH region as set forth in SEQ ID NO: 337 and a VL region as set forth in SEQ ID NO: 338; (35) A VH region as set forth in SEQ ID NO: 347 and a VL region as set forth in SEQ ID NO: 348; (36) A VH region as set forth in SEQ ID NO: 357 and a VL region as set forth in SEQ ID NO: 358; (37) The VH region as set forth in SEQ ID NO: 367 and the VL region as set forth in SEQ ID NO: 368; (38) A VH region as set forth in SEQ ID NO: 377 and a VL region as set forth in SEQ ID NO: 378; (39) The VH region as set forth in SEQ ID NO: 387 and the VL region as set forth in SEQ ID NO: 388; (40) A VH region as set forth in SEQ ID NO:397 and a VL region as set forth in SEQ ID NO:398; (41) A VH region as set forth in SEQ ID NO:407 and a VL region as set forth in SEQ ID NO:408; (42) the VH region as set forth in SEQ ID NO:417 and the VL region as set forth in SEQ ID NO:418; (43) A VH region as set forth in SEQ ID NO: 427 and a VL region as set forth in SEQ ID NO: 428; (44) The VH region as set forth in SEQ ID NO:437 and the VL region as set forth in SEQ ID NO:438; (45) A VH region as set forth in SEQ ID NO:447 and a VL region as set forth in SEQ ID NO:448; (46) A VH region as set forth in SEQ ID NO:457 and a VL region as set forth in SEQ ID NO:458; (47) The VH region as set forth in SEQ ID NO:467 and the VL region as set forth in SEQ ID NO:468; (48) A VH region as set forth in SEQ ID NO:477 and a VL region as set forth in SEQ ID NO:478; (49) A VH region as set forth in SEQ ID NO:487 and a VL region as set forth in SEQ ID NO:488; (50) a VH region as set forth in SEQ ID NO:497 and a VL region as set forth in SEQ ID NO:498; (51) A VH region as set forth in SEQ ID NO:507 and a VL region as set forth in SEQ ID NO:508; (52) The VH region as set forth in SEQ ID NO:517 and the VL region as set forth in SEQ ID NO:518; and (53) The VH region as set forth in SEQ ID NO: 527 and the VL region as set forth in SEQ ID NO:
528. The antibody construct of any one of claims 1 to 16, comprising a VH region and a VL region selected from the group consisting of:
18. 18. The antibody construct of any one of claims 1 to 17, wherein the first domain that binds to BCMA comprises or consists of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 9, 19, 29, 39, 49, 59, 69, 79, 89, 109, 129, 139, 149, 159, 169, 179, 189, 199, 209, 219, 229, 239, 249, 259, 269, 279, 289, 299, 309, 319, 329, 339, 349, 359, 369, 379, 389, 399, 409, 419, 429, 439, 449, 459, 469, 479, 489, 499, 519 and 529.
19. The second domain that binds to CD3 is (a) CDR-L1 as set forth in SEQ ID NO:542, CDR-L2 as set forth in SEQ ID NO:543, and CDR-L3 as set forth in SEQ ID NO:544; (b) CDR-L1 as set forth in SEQ ID NO:599, CDR-L2 as set forth in SEQ ID NO:600, and CDR-L3 as set forth in SEQ ID NO:601; and (c) CDR-L1 as set forth in SEQ ID NO:621, CDR-L2 as set forth in SEQ ID NO:622, and CDR-L3 as set forth in SEQ ID NO:
623. The antibody construct of any one of claims 1 to 18, comprising a VL region comprising CDR-L1, CDR-L2 and CDR-L3 selected from the group consisting of:
20. The second domain that binds to CD3 is (a) CDR-H1 as set forth in SEQ ID NO:534, CDR-H2 as set forth in SEQ ID NO:535, and CDR-H3 as set forth in SEQ ID NO:536; (b) CDR-H1 as set forth in SEQ ID NO:545, CDR-H2 as set forth in SEQ ID NO:546, and CDR-H3 as set forth in SEQ ID NO:547; (c) CDR-H1 as set forth in SEQ ID NO:557, CDR-H2 as set forth in SEQ ID NO:558, and CDR-H3 as set forth in SEQ ID NO:559; (d) CDR-H1 as set forth in SEQ ID NO:568, CDR-H2 as set forth in SEQ ID NO:569, and CDR-H3 as set forth in SEQ ID NO:570; (e) CDR-H1 as set forth in SEQ ID NO:579, CDR-H2 as set forth in SEQ ID NO:580, and CDR-H3 as set forth in SEQ ID NO:581; (f) CDR-H1 as set forth in SEQ ID NO:591, CDR-H2 as set forth in SEQ ID NO:592, and CDR-H3 as set forth in SEQ ID NO:593; (g) CDR-H1 as set forth in SEQ ID NO:602, CDR-H2 as set forth in SEQ ID NO:603, and CDR-H3 as set forth in SEQ ID NO:604; (h) CDR-H1 as set forth in SEQ ID NO:613, CDR-H2 as set forth in SEQ ID NO:614, and CDR-H3 as set forth in SEQ ID NO:615; (i) CDR-H1 as set forth in SEQ ID NO:624, CDR-H2 as set forth in SEQ ID NO:625, and CDR-H3 as set forth in SEQ ID NO:626; and (j) CDR-H1 as set forth in SEQ ID NO: 636, CDR-H2 as set forth in SEQ ID NO: 637, and CDR-H3 as set forth in SEQ ID NO:
638. The antibody construct of any one of claims 1 to 19, comprising a VH region comprising CDR-H1, CDR-H2 and CDR-H3 selected from the group consisting of:
21. The second domain that binds to CD3 is (a) CDR-L1 as set forth in SEQ ID NO:531, CDR-L2 as set forth in SEQ ID NO:532, CDR-L3 as set forth in SEQ ID NO:533, CDR-H1 as set forth in SEQ ID NO:534, CDR-H2 as set forth in SEQ ID NO:535, and CDR-H3 as set forth in SEQ ID NO:536; (b) CDR-L1 as set forth in SEQ ID NO:542, CDR-L2 as set forth in SEQ ID NO:543, CDR-L3 as set forth in SEQ ID NO:544, CDR-H1 as set forth in SEQ ID NO:545, CDR-H2 as set forth in SEQ ID NO:546, and CDR-H3 as set forth in SEQ ID NO:547; (c) CDR-L1 as set forth in SEQ ID NO:554, CDR-L2 as set forth in SEQ ID NO:555, CDR-L3 as set forth in SEQ ID NO:556, CDR-H1 as set forth in SEQ ID NO:557, CDR-H2 as set forth in SEQ ID NO:558, and CDR-H3 as set forth in SEQ ID NO:559; (d) CDR-L1 as set forth in SEQ ID NO:565, CDR-L2 as set forth in SEQ ID NO:566, CDR-L3 as set forth in SEQ ID NO:567, CDR-H1 as set forth in SEQ ID NO:568, CDR-H2 as set forth in SEQ ID NO:569, and CDR-H3 as set forth in SEQ ID NO:570; (e) CDR-L1 as set forth in SEQ ID NO:576, CDR-L2 as set forth in SEQ ID NO:577, CDR-L3 as set forth in SEQ ID NO:578, CDR-H1 as set forth in SEQ ID NO:579, CDR-H2 as set forth in SEQ ID NO:580, and CDR-H3 as set forth in SEQ ID NO:581; (f) CDR-L1 as set forth in SEQ ID NO:588, CDR-L2 as set forth in SEQ ID NO:589, CDR-L3 as set forth in SEQ ID NO:590, CDR-H1 as set forth in SEQ ID NO:591, CDR-H2 as set forth in SEQ ID NO:592, and CDR-H3 as set forth in SEQ ID NO:593; (g) CDR-L1 as set forth in SEQ ID NO:599, CDR-L2 as set forth in SEQ ID NO:600, CDR-L3 as set forth in SEQ ID NO:601, CDR-H1 as set forth in SEQ ID NO:602, CDR-H2 as set forth in SEQ ID NO:603, and CDR-H3 as set forth in SEQ ID NO:604; (h) CDR-L1 as set forth in SEQ ID NO:610, CDR-L2 as set forth in SEQ ID NO:611, CDR-L3 as set forth in SEQ ID NO:612, CDR-H1 as set forth in SEQ ID NO:613, CDR-H2 as set forth in SEQ ID NO:614, and CDR-H3 as set forth in SEQ ID NO:615; (i) CDR-L1 as set forth in SEQ ID NO:621, CDR-L2 as set forth in SEQ ID NO:622, CDR-L3 as set forth in SEQ ID NO:623, CDR-H1 as set forth in SEQ ID NO:624, CDR-H2 as set forth in SEQ ID NO:625, and CDR-H3 as set forth in SEQ ID NO:626; and (j) CDR-L1 as set forth in SEQ ID NO: 633, CDR-L2 as set forth in SEQ ID NO: 634, CDR-L3 as set forth in SEQ ID NO: 635, CDR-H1 as set forth in SEQ ID NO: 636, CDR-H2 as set forth in SEQ ID NO: 637, and CDR-H3 as set forth in SEQ ID NO:
638. The antibody construct of any one of claims 1 to 20, comprising a VL region comprising CDR-L1, CDR-L2 and CDR-L3 selected from the group consisting of: and a VH region comprising CDR-H1, CDR-H2 and CDR-H3.
22. 22. The antibody construct of any one of claims 1 to 21, wherein the second domain that binds to CD3 comprises a VL region having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO:550, SEQ ID NO:551, SEQ ID NO:584, SEQ ID NO:585, SEQ ID NO:629 and SEQ ID NO:
630.
23. 23. The antibody construct of any one of claims 1 to 22, wherein the second domain that binds to CD3 comprises a VH region having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NO:537, SEQ ID NO:538, SEQ ID NO:548, SEQ ID NO:549, SEQ ID NO:560, SEQ ID NO:561, SEQ ID NO:571, SEQ ID NO:572, SEQ ID NO:582, SEQ ID NO:583, SEQ ID NO:594, SEQ ID NO:595, SEQ ID NO:605, SEQ ID NO:606, SEQ ID NO:616, SEQ ID NO:617, SEQ ID NO:627, SEQ ID NO:628, SEQ ID NO:639, SEQ ID NO:640 and SEQ ID NO:
644.
24. The second domain that binds to CD3 is (a) a VL region as set forth in SEQ ID NO: 539 or 521 and a VH region as set forth in SEQ ID NO: 537 or 538; (b) a VL region as set forth in SEQ ID NO: 550 or 521 and a VH region as set forth in SEQ ID NO: 548 or 549; (c) a VL region as set forth in SEQ ID NO: 562 or 521 and a VH region as set forth in SEQ ID NO: 560 or 561; (d) a VL region as set forth in SEQ ID NO: 573 or 521 and a VH region as set forth in SEQ ID NO: 571 or 572; (e) a VL region as set forth in SEQ ID NO: 584 or 585 and a VH region as set forth in SEQ ID NO: 582 or 583; (f) a VL region as set forth in SEQ ID NO: 596 or 521 and a VH region as set forth in SEQ ID NO: 594 or 595; (g) a VL region as set forth in SEQ ID NO: 607 or 585 and a VH region as set forth in SEQ ID NO: 605 or 606; (h) a VL region as set forth in SEQ ID NO: 618 or 521 and a VH region as set forth in SEQ ID NO: 616 or 617; (i) a VL region as set forth in SEQ ID NO: 629 or 630 and a VH region as set forth in SEQ ID NO: 627 or 628; (j) a VL region as set forth in SEQ ID NO: 641 or 630 and a VH region as set forth in SEQ ID NO: 639 or 640; and (k) a VL region as set forth in SEQ ID NO: 645 and a VH region as set forth in SEQ ID NO:
644. The antibody construct of any one of claims 1 to 23, comprising a VL region and a VH region selected from the group consisting of:
25. 25. The antibody construct of any one of claims 1 to 24, wherein the second domain that binds to CD3 comprises or consists of a polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NOs: 540, 541, 552, 553, 563, 564, 574, 575, 586, 587, 597, 598, 608, 609, 619, 620, 631, 632, 642, 643 and 646.
26. 26. The antibody construct of any one of claims 1 to 25, comprising a polypeptide having an amino acid sequence selected from the group consisting of those set forth in SEQ ID NOs: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530 and 661.
Citation Information
Patent Citations
CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
WO1999054440A1
Multispecific deimmunized CD3-binders
WO2005040220A1
Cross-species-specific CD3-epsilon binding domain
WO2008119567A2
